

S1 File - Wever et al. 2015 - Determinants of the efficacy of cardiac ischemic preconditioning: a systematic review and meta-analysis of animal studies

Text A - Detailed Methods

This systematic review is based on published results of animal experiments studying the effects of local or remote IPC on MI, which we identified using a systematic, computerized search in MEDLINE (via PubMed) and EMBASE. The inclusion criteria and method of analysis were pre-specified and documented in an *a priori* protocol (see <http://www.dcn.ed.ac.uk/camarades//>). This review is reported according to the PRISMA guidelines.

1.1 Amendments to the systematic review protocol

We extracted data on three additional study quality indicators, to obtain a comprehensive overview of study quality, and to allow for better comparison with systematic reviews in other fields of research. The additional items were: reporting of a conflict of interest statement (Y/N), reporting of ethical approval of the experiment (Y/N) and reporting of regulation of body temperature within a physiological range during surgery (Y/N). We did not perform meta-analysis on these items.

We omitted the planned subgroup analysis of total risk of bias score due to the poor reporting of many of the risk of bias items, since we expect this would severely hamper the analysis and would likely produce unreliable results.

1.2 Literature search strategy, inclusion and exclusion criteria

The full search strategies for PubMed and EMBASE are included in the supplemental material, and involved the search components "animal"^{1,2}, "heart", "ischemia reperfusion injury" and "preconditioning". We searched the databases for published articles up to January 2nd 2014. No language or date restrictions were applied. If necessary, papers in languages other than English were translated by scientists (native speakers for that particular language) within the Radboud university medical center or the University of Edinburgh.

We included studies in the systematic review if they fulfilled all of the following criteria: 1) the study assessed the effect of IPC on myocardial infarction and reported the mean and variance of the infarct size as a percentage of the area at risk (IS/AAR%), as well as the number of animals that these figures were based on; 2) the study was performed in animals *in vivo*; 3) the study was an original full paper which presented unique data. We excluded studies if 1) experiments were performed only in genetically modified animals; 2) animals underwent any co-intervention other than sham IPC or administration of vehicle.

We used Early Review Organizing Software (EROS; Institute of Clinical Effectiveness and Health Policy, Buenos Aires, Argentina) to randomly allocate each reference to two independent reviewers, who screened it for inclusion on the basis of title and abstract. In case of doubt, the whole publication was evaluated. Two independent reviewers subsequently assessed full-text copies of all publications eligible for inclusion and included them if they met our prespecified inclusion criteria. Disagreements were solved by discussion.

1.3 Study characteristics and data extraction

In each publication, we identified all independent comparisons of the infarct size in IPC-treated animals *versus* controls. We extracted data on study design, including the animals used (species, strain, sex, age, weight, and the presence of comorbidities or other conditions), the myocardial infarction model (pre-operative opioid use, anesthetic agent used during surgery, class of anesthetic agent used, site of coronary occlusion, duration of index ischemia and timing of the outcome measure) and the IPC intervention (site of IPC, remote organ, duration of ischemic stimulus, duration of intermittent reperfusion periods, the number of cycles, and interval between IPC and myocardial index ischemia; see supplemental figure SF1). We also recorded bibliographic details such as author, journal, language and year of publication.

We extracted data on infarct size if raw data or group averages, standard deviation (SD) or standard error (SE) and number of animals per group (n) were reported, or could be recalculated. If two or more identical comparisons existed (e.g. two separate experiments, with the same control and experimental groups), they were analyzed separately. In case of missing outcome measure data, we attempted to contact authors for additional information. If the data could not be obtained, we used a conservative estimate if possible. In case the group size was reported as a range (e.g. 6-9) in combination with an SD, we used the lowest number of animals in our meta-analysis. In case the SE was reported, we used the highest number of animals to recalculate the most conservative estimate of the SD. If no conservative estimate could be made we excluded the comparison from the analysis. If data were presented only graphically, we measured them using digital image analysis software (ImageJ; <http://rsbweb.nih.gov/ij/>). If multiple experimental groups were compared to the same control group, we corrected the group size of the control group for the number of comparisons made (n/number of comparisons).

1.4 Data handling exceptions

For two comparisons (both from³) for which the number of IPC cycles was reported to be 12 or more, we used 12 as the number of cycles in our analysis.

For five comparisons (one each from⁴⁻⁸), the duration of the ischemic period of the IPC stimulus differed between cycles. We therefore used the average duration of an ischemic period (total ischemic time/# cycles) in our analysis. The same approach was used for four comparisons in which the duration of the intermittent reperfusion periods differed between cycles (one each from^{7, 9-11})

For studies investigating "repeated IPC", i.e. applying an interval of one or several days between IPC stimuli, we used the duration of the intermittent reperfusion periods within one IPC stimulus as the intermittent reperfusion duration in our analysis (e.g. comparisons from^{3, 10, 12-20}). N.B. in such cases, the number of IPC cycles used is the total of all IPC cycles in the entire protocol.

One study⁸ states that the variance of their data are reported as SD, but are in the SE range. In our meta-analysis, entering these data as SD resulted in an enormous deviation of the study data in terms of variance and weight. We attempted to clarify this issue by contacting the authors, but received no response. We therefore treated the data conservatively and assumed that they were in fact reported as SE.

1.5 Assessment of methodological quality

We used the SYRCLE Risk of Bias tool²¹ to assess the risk of bias in the included studies. Two independent reviewers assessed each publication and disagreements were solved by discussion. Concerning the number of excluded animals, we assumed that there had been no exclusion if the number of animals per group mentioned in the materials and methods section was identical to the number stated in the results section or figure legends. In addition, we extracted data on reporting of any measure of randomization and any measure of blinding, in order to distinguish between reporting of measures to report bias and actual risk of bias. We assessed reporting of a sample size calculation an additional study quality indicator.

1.6 Data synthesis and statistical analyses

Data were analyzed using STATA SE, version 11.2 (StataCorp, College Station, TX, USA). All data were extracted in the same unit of analysis (IS/AAR%). For each independent comparison, we calculated an effect size as a raw difference in means (MD; the mean of the experimental group minus the mean of the control group) of IS/AAR% and corresponding 95% confidence interval (CI). To account for anticipated heterogeneity, we pooled effect sizes using random effect meta-analysis, which takes into account the precision of individual studies and the variation between studies and weights each study accordingly. Heterogeneity was quantified using I^2 and T^2 statistics (see²² for meta-analysis details).

We performed pre-specified subgroup analyses, using meta-regression, to explore sources of heterogeneity and assess the impact methodological and study quality indicators on the observed efficacy of IPC. Covariates assessed were: species, sex, comorbidity, opioid use pre-IPC, site of IPC, number of IPC cycles, duration of one ischemic cycle of IPC, total duration of IPC ischemia and duration of the delay between IPC and IR. For total duration of IPC ischemia, comparisons were stratified using increments (with increasing orders of magnitude) of $\log_{10}(0.4)$ minutes. For IPC to IR delay, comparisons were stratified using increments of $\log_{10}(0.8)$ minutes. The percentage of between-study variance explained by variables of interest was assessed using the T^2 and adjusted R^2 statistic.

We adjusted our significance level using the Holm-Bonferroni method²³ ($(1-(1-\alpha)^{1/m})$) to account for multiple comparisons.

We assessed for potential publication bias by visually inspection for asymmetry in funnel plots, performing Duval and Tweedie's trim and fill analysis²⁴ and Egger's regression analysis²⁵ for small study effects.

1.7 Sensitivity analyses

To assess the robustness of our findings, sensitivity analysis was performed for the cut-off points for the subgroups of total IPC ischemia and IPC to IR delay. For total IPC ischemia, the increment between categories was changed from $\log_{10}(0.4)$ minutes to $\log_{10}(0.3)$ or $\log_{10}(0.5)$ minutes. For IPC to IR delay, the increment between categories was changed from $\log_{10}(0.8)$ minutes to $\log_{10}(0.7)$ or $\log_{10}(0.9)$ minutes.

Thirteen publications (²⁶⁻³⁸) reported data from a myocardial infarction model in which a coronary-to-carotid artery shunt was used for cardiac reperfusion. We decided to consider this procedure part of the infarction model, rather than a co-intervention, but investigated the effect of our decision by excluding these studies in a sensitivity analysis.

Post-hoc, we tested the robustness of our findings using the MD by re-running our analysis using the standardized difference in means (SMD).

References

1. de Vries RB, Hooijmans CR, Tillema A, Leenaars M, Ritskes-Hoitinga M. Updated version of the embase search filter for animal studies. *Laboratory animals*. 2014;48:88
2. Hooijmans CR, Tillema A, Leenaars M, Ritskes-Hoitinga M. Enhancing search efficiency by means of a search filter for finding all studies on animal experimentation in pubmed. *Laboratory animals*. 2010;44:170-175
3. Cohen MV, Yang XM, Downey JM. Conscious rabbits become tolerant to multiple episodes of ischemic preconditioning. *Circulation research*. 1994;74:998-1004
4. Galagudza MM, Syrenskii AV, Vlasov TD, Morozova LI, Egorova EI, Polumiskov VI. Effects of individual and combined administration of ethylmethylhydroxypyridine succinate and ischemic preconditioning on ischemic-reperfusive myocardial injury in rats. [russian]. *Eksperimental'naia i klinicheskaia farmakologija*. 2009;72:22-26
5. Iliodromitis K, Farmakis D, Andreadou I, Zoga A, Bibli SI, Manolaki T, Dagres N, Iliodromitis EK, Anastasiou-Nana M, Kremastinos DT. Various models of cardiac conditioning in single or sequential periods of ischemia: Comparative effects on infarct size and intracellular signaling. *Int J Cardiol*. 2013;168:1336-1341
6. Liaudet L, Yang Z, Al-Affar EB, Szabo C. Myocardial ischemic preconditioning in rodents is dependent on poly (adp-ribose) synthetase. *Mol Med*. 2001;7:406-417
7. Liem DA, te Lintel Hekkert M, Manintveld OC, Boomsma F, Verdouw PD, Duncker DJ. Myocardium tolerant to an adenosine-dependent ischemic preconditioning stimulus can still be protected by stimuli that employ alternative signaling pathways. *American journal of physiology. Heart and circulatory physiology*. 2005;288:14

8. Shen B, Li J, Gao L, Zhang J, Yang B. Role of cc-chemokine receptor 5 on myocardial ischemia-reperfusion injury in rats. *Mol Cell Biochem*. 2013;378:137-144
9. Li Y, Kloner RA. Cardioprotective effects of ischemic preconditioning can be recaptured after they are lost. *J Am Coll Cardiol*. 1994;23:470-474
10. Sack S, Mohri M, Arras M, Schwarz ER, Schaper W. Ischaemic preconditioning--time course of renewal in the pig. *Cardiovascular research*. 1993;27:551-555
11. Vogt AM, Ando H, Arras M, Elsasser A. Lack of adenosine causes myocardial refractoriness. *J Am Coll Cardiol*. 1998;31:1134-1141
12. Li SJ, Wu YN, Kang Y, Yin YQ, Gao WZ, Liu YX, Lou JS. Effects of limb atraumatic ischemic preconditioning on apoptosis induced by myocardial ischemia-reperfusion injury in rats. [chinese]. *Chinese Pharmacological Bulletin*. 2009;25:100-104
13. Li SJ, Wu YN, Kang Y, Yin YQ, Gao WZ, Liu YX, Lou JS. Noninvasive limb ischemic preconditioning protects against myocardial i/r injury in rats. *J Surg Res*. 2010;164:162-168
14. Li SJ, Wu YN, Kang Y, Yin YQ, Gao WZ, Liu YX, Lou JS. Influence of limb atraumatic ischemic preconditioning on fibrinolysis factors in myocardial ischemia/reperfusion injury in rats. [chinese]. *Chinese Pharmacological Bulletin*. 2008;24:1344-1347
15. Mullenheim J, Schlack W, Frassdorf J, Heinen A, Preckel B, Thamer V. Additive protective effects of late and early ischaemic preconditioning are mediated by the opening of katp channels in vivo. *Pflugers Arch*. 2001;442:178-187
16. Mullenheim J, Ebel D, Bauer M, Otto F, Heinen A, Frassdorf J, Preckel B, Schlack W. Sevoflurane confers additional cardioprotection after ischemic late preconditioning in rabbits. *Anesthesiology*. 2003;99:624-631
17. Wu YN, Zhu XH, Yuan HJ, Yu H, Li SJ, Kang Y, Jiao JJ, Gao WZ, Liu YX, Lou JS. Noninvasive limb ischemic preconditioning increased antioxidative ability of myocardium after ischemia-reperfusion injury in rats. [chinese]. *Chinese Pharmacological Bulletin*. 2008;24:1049-1052
18. Wu YN, Yu H, Zhu XH, Yuan HJ, Kang Y, Jiao JJ, Gao WZ, Liu YX, Lou JS. Noninvasive delayed limb ischemic preconditioning attenuates myocardial ischemia-reperfusion injury in rats by a mitochondrial k(atp) channel-dependent mechanism. *Physiol Res*. 2011;60:271-279
19. Zhu XH, Li YM, Yuan HJ, Luo Q, Wu YN, Kang Y, Jiao JJ, Gao WZ, Liu YX, Lou JS. Noninvasive limb ischemic preconditioning increased antioxidative ability of myocardium after ischemia-reperfusion injury in diabetic rats. [chinese]. *Chinese Pharmacological Bulletin*. 2009;25:239-243
20. Zhu XH, Yuan HJ, Wu YN, Kang Y, Jiao JJ, Gao WZ, Liu YX, Lou JS, Xia Z. Non-invasive limb ischemic pre-conditioning reduces oxidative stress and attenuates myocardium ischemia-reperfusion injury in diabetic rats. *Free Radic Res*. 2011;45:201-210
21. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. Syrcle's risk of bias tool for animal studies. *BMC medical research methodology*. 2014;14:43
22. Vesterinen HM, Sena ES, Egan KJ, Hirst TC, Churolov L, Currie GL, Antonic A, Howells DW, Macleod MR. Meta-analysis of data from animal studies: A practical guide. *Journal of neuroscience methods*. 2014;221:92-102
23. Holm S. A simple sequentially rejective multiple test procedure. *Scand J Stat*. 1979;6:65-70
24. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics*. 2000;56:455-463
25. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Bmj*. 1997;315:629-634
26. Hatori N, Segawa D, Hinokiyama K, Kimura T, Iizuka Y, Ochi M, Tanaka S. Effects of ischemic preconditioning and synchronized coronary venous retroperfusion in an off-pump coronary artery bypass grafting model. *Artif Organs*. 2001;25:47-52
27. Hinokiyama K, Hatori N, Ochi M, Maehara T, Tanaka S. Myocardial protective effect of lidocaine during experimental off-pump coronary artery bypass grafting. *Ann Thorac Cardiovasc Surg*. 2003;9:36-42

28. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, et al. Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5'-nucleotidase activity and attenuation of adenosine release. *Circulation*. 1994;89:1237-1246
29. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, Kamada T. Alpha1-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5'-nucleotidase activity. *Journal of Clinical Investigation*. 1994;93:2197-2205
30. Kitakaze M, Minamino T, Node K, Komamura K, Shinozaki Y, Chujo M, Mori H, Inoue M, Hori M, Kamada T. Role of activation of ectosolic 5'-nucleotidase in the cardioprotection mediated by opening of k_c channels. *The American journal of physiology*. 1996;270:H1744-1756
31. Kitakaze M, Node K, Asanuma H, Takashima S, Sakata Y, Asakura M, Sanada S, Shinozaki Y, Mori H, Kuzuya T, Hori M. Protein tyrosine kinase is not involved in the infarct size-limiting effect of ischemic preconditioning in canine hearts. *Circulation research*. 2000;87:303-308
32. Kitakaze M, Node K, Minamino T, Komamura K, Funaya H, Shinozaki Y, Chujo M, Mori H, Inoue M, Hori M, Kamada T. Role of activation of protein kinase c in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5'-nucleotidase. *Circulation*. 1996;93:781-791
33. Minamino T, Kitakaze M, Morioka T, Node K, Komamura K, Takeda H, Inoue M, Hori M, Kamada T. Cardioprotection due to preconditioning correlates with increased ecto-5'-nucleotidase activity. *The American journal of physiology*. 1996;270:H238-244
34. Node K, Kitakaze M, Minamino T, Tada M, Inoue M, Hori M, Kamada T. Activation of ecto-5'-nucleotidase by protein kinase c and its role in ischaemic tolerance in the canine heart. *British journal of pharmacology*. 1997;120:273-281
35. Sanada S, Asanuma H, Tsukamoto O, Minamino T, Node K, Takashima S, Fukushima T, Ogai A, Shinozaki Y, Fujita M, Hirata A, Okuda H, Shimokawa H, Tomoike H, Hori M, Kitakaze M. Protein kinase a as another mediator of ischemic preconditioning independent of protein kinase c. *Circulation*. 2004;110:51-57
36. Sanada S, Kitakaze M, Asanuma H, Harada K, Ogita H, Node K, Takashima S, Sakata Y, Asakura M, Shinozaki Y, Mori H, Kuzuya T, Hori M. Role of mitochondrial and sarcolemmal k(atp) channels in ischemic preconditioning of the canine heart. *American journal of physiology. Heart and circulatory physiology*. 2001;280:H256-263
37. Sanada S, Kitakaze M, Papst PJ, Hatanaka K, Asanuma H, Aki T, Shinozaki Y, Ogita H, Node K, Takashima S, Asakura M, Yamada J, Fukushima T, Ogai A, Kuzuya T, Mori H, Terada N, Yoshida K, Hori M. Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart. *Circulation research*. 2001;88:175-180
38. Shintani Y, Node K, Asanuma H, Sanada S, Takashima S, Asano Y, Liao Y, Fujita M, Hirata A, Shinozaki Y, Fukushima T, Nagamachi Y, Okuda H, Kim J, Tomoike H, Hori M, Kitakaze M. Opening of ca2+-activated k₊ channels is involved in ischemic preconditioning in canine hearts. *Journal of molecular and cellular cardiology*. 2004;37:1213-1218

Wever et al. 2015 - Determinants of the efficacy of cardiac ischemic preconditioning: a systematic review and meta-analysis of animal studies

Text B - Full search strategies

Pubmed	
Heart	heart[MH] OR myocardium[MH] OR heart[TIAB] OR hearts[TIAB] OR cardiac[TIAB] OR myocardial[TIAB] OR myocardium[TIAB] OR myocardia[TIAB] OR myocard[TIAB] OR cardioprotection[TIAB] OR cardioprotective[TIAB] OR coronary[TIAB]
Ischemia-Reperfusion Injury	ischemia[MH] OR "warm ischemia"[MH] OR "cold ischemia"[MH] OR "reperfusion injury"[MH] OR "myocardial ischemia"[MH] OR "coronary occlusion"[MH] OR "heart injuries"[MH] OR "cardiovascular diseases"[MH] OR transplantation[MH] OR "heart transplantation"[MH] OR "primary graft dysfunction"[MH] OR "graft survival"[MH] OR "graft rejection" [MH] OR transplants[MH] OR ((ischemia[TIAB] OR ischaemia[TIAB] OR ischemic[TIAB] OR ischaemic[TIAB]) AND ("reperfusion"[tiab] OR reoxygenation[tiab] OR re-oxygenation[tiab])) OR "reperfusion injury"[TIAB] OR "reperfusion injuries"[TIAB] OR "I/R"[TIAB] OR "IRI"[TIAB] OR occlusion[TIAB] OR transplantation[TIAB] OR transplantations[TIAB] OR transplant[TIAB] OR transplants[TIAB] OR graft[TIAB] OR grafts[TIAB]
Preconditioning	"ischemic preconditioning"[MH] OR "IPC"[TIAB] OR "RIPC"[TIAB] OR "brief ischemia"[TIAB] OR "brief ischaemia"[TIAB] OR preconditioning[TIAB] OR "pre conditioning"[TIAB] OR "pre-conditioning"[TIAB] OR "transient ischaemia"[TIAB] OR "transient ischemia"[TIAB] OR "intermittent ischaemia"[TIAB] OR "intermittent ischemia"[TIAB] OR "remote conditioning"[TIAB]
Animals	("animal experimentation"[MeSH Terms] OR "models, animal"[MeSH Terms] OR "invertebrates"[MeSH Terms] OR "Animals"[Mesh:noexp] OR "animal population groups"[MeSH Terms] OR "chordata"[MeSH Terms:noexp] OR "chordata, nonvertebrate"[MeSH Terms] OR "vertebrates"[MeSH Terms:noexp] OR "amphibians"[MeSH Terms] OR "birds"[MeSH Terms] OR "fishes"[MeSH Terms] OR "reptiles"[MeSH Terms] OR "mammals"[MeSH Terms:noexp] OR "primates"[MeSH Terms:noexp] OR "artiodactyla"[MeSH Terms] OR "carnivora"[MeSH Terms] OR "cetacea"[MeSH Terms] OR "chiroptera"[MeSH Terms] OR "elephants"[MeSH Terms] OR "hyraxes"[MeSH Terms] OR "insectivora"[MeSH Terms] OR "lagomorpha"[MeSH Terms] OR "marsupialia"[MeSH Terms] OR "monotremata"[MeSH Terms] OR "perissodactyla"[MeSH Terms] OR "rodentia"[MeSH Terms] OR "scandentia"[MeSH Terms] OR "sirenia"[MeSH Terms] OR "xenarthra"[MeSH Terms] OR "haplorhini"[MeSH Terms:noexp] OR "strepsirrhini"[MeSH Terms] OR "platyrhini"[MeSH Terms] OR "tarsii"[MeSH Terms] OR "catarrhini"[MeSH Terms:noexp] OR "cercopithecidae"[MeSH Terms] OR "hylobatidae"[MeSH Terms] OR "hominidae"[MeSH Terms:noexp] OR "gorilla gorilla"[MeSH Terms] OR "pan paniscus"[MeSH Terms] OR "pan troglodytes"[MeSH Terms] OR "pongo pygmaeus"[MeSH Terms]) OR ((animals[tiab] OR animal[tiab] OR mice[Tiab] OR mus[Tiab] OR mouse[Tiab] OR murine[Tiab] OR woodmouse[tiab] OR rats[Tiab] OR rat[Tiab] OR murinae[Tiab] OR muridae[Tiab] OR cottonrat[tiab] OR cottonrats[tiab] OR hamster[tiab] OR hamsters[tiab] OR cricetinae[tiab] OR rodentia[Tiab] OR rodent[Tiab] OR rodents[Tiab] OR pigs[Tiab] OR pig[tiab] OR swine[tiab] OR swines[tiab] OR piglets[tiab] OR piglet[tiab] OR boar[tiab] OR boars[tiab] OR "sus scrofa"[tiab] OR ferrets[tiab] OR ferret[tiab] OR polecat[tiab] OR polecats[tiab] OR "mustela putorius"[tiab] OR "guinea pigs"[Tiab] OR "guinea


pig”[Tiab] OR cavia[Tiab] OR callithrix[Tiab] OR marmoset[Tiab] OR marmosets[Tiab] OR cebuella[Tiab] OR hapale[Tiab] OR octodon[Tiab] OR chinchilla[Tiab] OR chinchillas[Tiab] OR gerbillinae[Tiab] OR gerbil[Tiab] OR gerbils[Tiab] OR jird[Tiab] OR jirds[Tiab] OR merione[Tiab] OR meriones[Tiab] OR rabbits[Tiab] OR rabbit[Tiab] OR hares[Tiab] OR hare[Tiab] OR diptera[Tiab] OR flies[Tiab] OR fly[Tiab] OR dipteral[Tiab] OR drosophila[Tiab] OR drosophilidae[Tiab] OR cats[Tiab] OR cat[Tiab] OR carus[Tiab] OR felis[Tiab] OR nematoda[Tiab] OR nematode[Tiab] OR nematodes[Tiab] OR sipunculida[Tiab] OR dogs[Tiab] OR dog[Tiab] OR canine[Tiab] OR canines[Tiab] OR canis[Tiab] OR sheep[Tiab] OR sheeps[Tiab] OR mouflon[Tiab] OR mouflons[Tiab] OR ovis[Tiab] OR goats[Tiab] OR goat[Tiab] OR capra[Tiab] OR capras[Tiab] OR rupicapra[Tiab] OR rupicapras[Tiab] OR chamois[Tiab] OR hapolrhini[Tiab] OR monkey[Tiab] OR monkeys[Tiab] OR anthropoidea[Tiab] OR anthropoids[Tiab] OR saguinus[Tiab] OR tamarin[Tiab] OR tamarins[Tiab] OR leontopithecus[Tiab] OR hominidae[Tiab] OR ape[Tiab] OR apes[Tiab] OR “pan paniscus”[Tiab] OR bonobo[Tiab] OR bonobos[Tiab] OR “pan troglodytes”[Tiab] OR gibbon[Tiab] OR gibbons[Tiab] OR siamang[Tiab] OR siamangs[Tiab] OR nomascus[Tiab] OR symphalangus[Tiab] OR chimpanzee[Tiab] OR chimpanzees[Tiab] OR prosimian[Tiab] OR prosimians[Tiab] OR “bush baby”[Tiab] OR bush babies[Tiab] OR galagos[Tiab] OR galago[Tiab] OR pongidae[Tiab] OR gorilla[Tiab] OR gorillas[Tiab] OR “pongo pygmaeus”[Tiab] OR orangutan[Tiab] OR orangutans[Tiab] OR lemur[Tiab] OR lemurs[Tiab] OR lemuridae[Tiab] OR horse[Tiab] OR horses[Tiab] OR equus[Tiab] OR cow[Tiab] OR calf[Tiab] OR bull[Tiab] OR chicken[Tiab] OR chickens[Tiab] OR gallus[Tiab] OR quail[Tiab] OR bird[Tiab] OR birds[Tiab] OR quails[Tiab] OR poultry[Tiab] OR poutries[Tiab] OR fowl[Tiab] OR fowls[Tiab] OR reptile[Tiab] OR reptilia[Tiab] OR reptiles[Tiab] OR snakes[Tiab] OR snake[Tiab] OR lizard[Tiab] OR lizards[Tiab] OR alligator[Tiab] OR alligators[Tiab] OR crocodile[Tiab] OR crocodiles[Tiab] OR turtle[Tiab] OR turtles[Tiab] OR amphibian[Tiab] OR amphibians[Tiab] OR amphibia[Tiab] OR frog[Tiab] OR frogs[Tiab] OR bombina[Tiab] OR salientia[Tiab] OR toad[Tiab] OR toads[Tiab] OR “epidalea calamita”[Tiab] OR salamander[Tiab] OR salamanders[Tiab] OR eel[Tiab] OR eels[Tiab] OR fish[Tiab] OR fishes[Tiab] OR pisces[Tiab] OR catfish[Tiab] OR catfishes[Tiab] OR siluriformes[Tiab] OR arius[Tiab] OR heteropneustes[Tiab] OR sweatfish[Tiab] OR perch[Tiab] OR perches[Tiab] OR percidae[Tiab] OR perca[Tiab] OR trout[Tiab] OR trouts[Tiab] OR char[Tiab] OR chars[Tiab] OR salvelinus[Tiab] OR minnow[Tiab] OR cyprinidae[Tiab] OR carps[Tiab] OR carp[Tiab] OR zebrafish[Tiab] OR zebrafishes[Tiab] OR goldfish[Tiab] OR goldfishes[Tiab] OR guppy[Tiab] OR guppies[Tiab] OR chub[Tiab] OR chubs[Tiab] OR tinca[Tiab] OR barbels[Tiab] OR barbus[Tiab] OR pimephales[Tiab] OR promelas[Tiab] OR “poecilia reticulata”[Tiab] OR mullet[Tiab] OR mullets[Tiab] OR eel[Tiab] OR eels[Tiab] OR seahorse[Tiab] OR seahorses[Tiab] OR mugil curema[Tiab] OR atlantic cod[Tiab] OR shark[Tiab] OR sharks[Tiab] OR catshark[Tiab] OR anguilla[Tiab] OR salmonid[Tiab] OR salmonids[Tiab] OR whitefish[Tiab] OR whitefishes[Tiab] OR salmon[Tiab] OR salmons[Tiab] OR sole[Tiab] OR solea[Tiab] OR lamprey[Tiab] OR lampreys[Tiab] OR pumpkinseed[Tiab] OR sunfish[Tiab] OR sunfishes[Tiab] OR tilapia[Tiab] OR tilapias[Tiab] OR turbot[Tiab] OR turbots[Tiab] OR flatfish[Tiab] OR flatfishes[Tiab] OR sciuridae[Tiab] OR squirrel[Tiab] OR squirrels[Tiab] OR chipmunk[Tiab] OR chipmunks[Tiab] OR suslik[Tiab] OR susliks[Tiab] OR vole[Tiab] OR voles[Tiab] OR lemming[Tiab] OR lemmings[Tiab] OR muskrat[Tiab] OR muskrats[Tiab] OR lemmus[Tiab] OR otter[Tiab] OR otters[Tiab] OR marten[Tiab] OR martens[Tiab] OR martes[Tiab] OR weasel[Tiab] OR badger[Tiab] OR badgers[Tiab] OR ermine[Tiab] OR mink[Tiab] OR minks[Tiab] OR sable[Tiab] OR

	sables[Tiab] OR gulo[Tiab] OR guloso[Tiab] OR wolverine[Tiab] OR wolverines[Tiab] OR mustela[Tiab] OR llama[Tiab] OR llamas[Tiab] OR alpaca[Tiab] OR alpacas[Tiab] OR camelid[Tiab] OR camelids[Tiab] OR guanaco[Tiab] OR guanacos[Tiab] OR chiroptera[Tiab] OR chiropteras[Tiab] OR bat[Tiab] OR bats[Tiab] OR fox[Tiab] OR foxes[Tiab] OR iguana[Tiab] OR iguanas[Tiab] OR xenopus laevis[Tiab] OR parakeet[Tiab] OR parakeets[Tiab] OR parrot[Tiab] OR parrots[Tiab] OR donkey[Tiab] OR donkeys[Tiab] OR mule[Tiab] OR mules[Tiab] OR zebra[Tiab] OR zebras[Tiab] OR shrew[Tiab] OR shrews[Tiab] OR bison[Tiab] OR bisons[Tiab] OR buffalo[Tiab] OR buffaloes[Tiab] OR deer[Tiab] OR deers[Tiab] OR bear[Tiab] OR bears[Tiab] OR panda[Tiab] OR pandas[Tiab] OR "wild hog"[Tiab] OR "wild boar"[Tiab] OR fitchew[Tiab] OR fitch[Tiab] OR beaver[Tiab] OR beavers[Tiab] OR jerboa[Tiab] OR jerboas[Tiab] OR capybara[Tiab] OR capybaras[Tiab]) NOT medline[sb])
--	---


EMBASE	
Heart	exp heart/ or (heart or hearts or cardiac or myocardial or myocardium or myocardia or myocard or cardioprotection or cardioprotective or coronary).ti,ab.
Ischemia-Reperfusion Injury	exp reperfusion injury/ or exp cold ischemia/ or exp primary graft dysfunction/ or exp transplantation/ or (((ischemia or ischaemia or ischemia or ischaemia) and (reperfusion or reoxygenation or re-oxygenation)) or reperfusion injury or reperfusion injuries or I/r or IRI or occlusion or transplantation or transplantations or transplant or transplants or graft or grafts).ti,ab.
Preconditioning	exp ischemic preconditioning/ or (IPC or RIPC or brief ischemia or brief ischaemia or preconditioning or pre conditioning or pre-conditioning or transient ischaemia or transient ischemia or intermittent ischaemia or intermittent ischemia or remote conditioning).ti,ab.
Animals	exp animal experiment/ or exp animal model/ or exp experimental animal/ or exp transgenic animal/ or exp male animal/ or exp female animal/ or exp juvenile animal/ OR animal/ OR chordata/ OR vertebrate/ OR tetrapod/ OR exp fish/ OR amniote/ OR exp amphibia/ OR mammal/ OR exp reptile/ OR exp sauropsid/ OR therian/ OR exp monotreme/ OR placental mammals/ OR exp marsupial/ OR Euarchontoglires/ OR exp Afrotheria/ OR exp Boreoeutheria/ OR exp Laurasiatheria/ OR exp Xenarthra/ OR primate/ OR exp Dermoptera/ OR exp Glires/ OR exp Scandentia/ OR Haplorthini/ OR exp prosimian/ OR simian/ OR exp tarsiiform/ OR Catarrhini/ OR exp Platyrrhini/ OR ape/ OR exp Cercopithecidae/ OR hominid/ OR exp hylobatidae/ OR exp chimpanzee/ OR exp gorilla/ OR exp orang utan/ OR (animal OR animals OR pisces OR fish OR fishes OR catfish OR catfishes OR sweatfish OR silurus OR arius OR heteropneustes OR clarias OR gariepinus OR fathead minnow OR fathead minnows OR pimephales OR promelas OR cichlidae OR trout OR trouts OR char OR chars OR salvelinus OR salmo OR oncorhynchus OR guppy OR guppies OR millionfish OR poecilia OR goldfish OR goldfishes OR carassius OR auratus OR mullet OR mullets OR mugil OR curema OR shark OR sharks OR cod OR cods OR gadus OR morhua OR carp OR carps OR cyprinus OR carpio OR killifish OR eel OR eels OR anguilla OR zander OR sander OR lucioperca OR stizostedion OR turbot OR turbots OR psetta OR flatfish OR flatfishes OR plaice OR pleuronectes OR platessa OR tilapia OR tilapias OR oreochromis OR sarotherodon OR common sole OR dover sole OR solea OR zebrafish OR zebrafishes OR danio OR rerio OR seabass OR dicentrarchus OR labrax OR morone OR lamprey OR lampreys OR petromyzon OR pumpkinseed OR

pumpkinseeds OR lepomis OR gibbosus OR herring OR clupea OR harengus OR amphibia OR amphibian OR amphibians OR anura OR salientia OR frog OR frogs OR rana OR toad OR toads OR bufo OR xenopus OR laevis OR bombina OR epidalea OR calamita OR salamander OR salamanders OR newt OR newts OR triturus OR reptilia OR reptile OR reptiles OR bearded dragon OR pogona OR vitticeps OR iguana OR iguanas OR lizard OR lizards OR anguis fragilis OR turtle OR turtles OR snakes OR snake OR aves OR bird OR birds OR quail OR quails OR coturnix OR bobwhite OR colinus OR virginianus OR poultry OR poultries OR fowl OR fowls OR chicken OR chickens OR gallus OR zebra finch OR taeniopygia OR guttata OR canary OR canaries OR serinus OR canaria OR parakeet OR parakeets OR grasskeet OR parrot OR parrots OR psittacine OR psittacines OR shelduck OR tadorna OR goose OR geese OR branta OR leucopsis OR woodlark OR iullula OR flycatcher OR ficedula OR hypoleuca OR dove OR doves OR geopelia OR cuneata OR duck OR ducks OR greylag OR graylag OR anser OR harrier OR circus pygargus OR red knot OR great knot OR calidris OR canutus OR godwit OR limosa OR lapponica OR meleagris OR gallopavo OR jackdaw OR corvus OR monedula OR ruff OR philomachus OR pugnax OR lapwing OR peewit OR plover OR vanellus OR swan OR cygnus OR columbianus OR bewickii OR gull OR chroicocephalus OR ridibundus OR albifrons OR great tit OR parus OR aythya OR fuligula OR streptopelia OR risoria OR spoonbill OR platalea OR leucorodia OR blackbird OR turdus OR merula OR blue tit OR cyanistes OR pigeon OR pigeons OR columba OR pintail OR anas OR starling OR sturnus OR owl OR athene noctua OR pochard OR ferina OR cockatiel OR nymphicus OR hollandicus OR skylark OR alauda OR tern OR sterna OR teal OR crecca OR oystercatcher OR haematopus OR ostralegus OR shrew OR shrews OR sorex OR araneus OR crocidura OR russula OR european mole OR talpa OR chiroptera OR bat OR bats OR eptesicus OR serotinus OR myotis OR dasycneme OR daubentonii OR pipistrelle OR pipistrellus OR cat OR cats OR felis OR catus OR feline OR dog OR dogs OR canis OR canine OR canines OR otter OR otters OR lutra OR badger OR badgers OR meles OR fitchew OR fitch OR foumart or foulmart OR ferrets OR ferret OR polecat OR polecats OR mustela OR putorius OR weasel OR weasels OR fox OR foxes OR vulpes OR common seal OR phoca OR vitulina OR grey seal OR halichoerus OR horse OR horses OR equus OR equine OR equidae OR donkey OR donkeys OR mule OR mules OR pig OR pigs OR swine OR swines OR hog OR hogs OR boar OR boars OR porcine OR piglet OR piglets OR sus OR scrofa OR llama OR llamas OR lama OR glama OR deer OR deers OR cervus OR elaphus OR cow OR cows OR bos taurus OR bos indicus OR bovine OR bull OR bulls OR cattle OR bison OR bisons OR sheep OR sheeps OR ovis aries OR ovine OR lamb OR lambs OR mouflon OR mouflons OR goat OR goats OR capra OR caprine OR chamois OR rupicapra OR leporidae OR lagomorpha OR lagomorph OR rabbit OR rabbits OR oryctolagus OR cuniculus OR laprine OR hares OR lepus OR rodentia OR rodent OR rodents OR murinae OR mouse OR mice OR mus OR musculus OR murine OR woodmouse OR apodemus OR rat OR rats OR rattus OR norvegicus OR guinea pig OR guinea pigs OR cavia OR porcellus OR hamster OR hamsters OR mesocricetus OR cricetus OR cricetus OR gerbil OR gerbils OR jird OR jirds OR meriones OR unguiculatus OR jerboa OR jerboas OR jaculus OR chinchilla OR chinchillas OR beaver OR beavers OR castor fiber OR castor canadensis OR sciuridae OR squirrel OR squirrels OR sciurus OR chipmunk OR chipmunks OR marmot OR marmots OR marmota OR suslik OR susliks OR spermophilus OR cynomys OR cottonrat OR cottonrats OR sigmodon OR vole OR voles OR microtus OR myodes OR glareolus OR primate OR primates OR prosimian OR prosimians OR lemur OR lemurs OR lemuridae OR loris OR bush baby OR bush babies OR bushbaby OR bushbabies OR galago OR galagos OR anthropoidea OR


anthropoids OR simian OR simians OR monkey OR monkeys OR marmoset OR marmosets OR callithrix OR cebuella OR tamarin OR tamarins OR saguinus OR leontopithecus OR squirrel monkey OR squirrel monkeys OR saimiri OR night monkey OR night monkeys OR owl monkey OR owl monkeys OR douroucoulis OR aotus OR spider monkey OR spider monkeys OR atèles OR baboon OR baboons OR papio OR rhesus monkey OR macaque OR macaca OR mulatta OR cynomolgus OR fascicularis OR green monkey OR green monkeys OR chlorocebus OR vervet OR vervets OR pygerythrus OR hominoidea OR ape OR apes OR hylobatidae OR gibbon OR gibbons OR siamang OR siamangs OR nomascus OR symphalangus OR hominidae OR orangutan OR orangutans OR pongo OR chimpanzee OR chimpanzees OR pan troglodytes OR bonobo OR bonobos OR pan paniscus OR gorilla OR gorillas OR troglodytes).ti,ab.



Supplemental Figure A| Ischemia-reperfusion injury (IRI) and ischemic preconditioning (IPC) characteristics for a typical control and experimental group.
 Control animals undergo a waiting period, followed by 60 minutes of coronary occlusion (ischemic period) and 120 minutes of reperfusion. In the experimental group, the applied IPC protocol consists of 3 cycles of 5 minutes of ischemia, interspersed by 5 minutes of reperfusion. The total duration of IPC ischemia is 15 minutes. The delay to myocardial IRI in this protocol is 60 minutes.



Supplemental Figure B| Individual effect estimates of all 785 included comparisons. Data are presented as raw difference in means (MD) in infarct size as a percentage of the area at risk (IS/AAR%). Comparisons are sorted by MD from low to high. The vertical error bars represent the 95% confidence intervals for the individual estimates. Horizontal white line and grey bar represent the pooled effect estimate and its 95% confidence interval.



Supplemental Figure C| Sensitivity analysis total duration IPC ischemia (A-C) and IPC to IRI delay (D-F). Data are presented as raw difference in means (MD) in infarct size as a percentage of the area at risk (IS/AAR%). Horizontal white line and grey bar represent the pooled effect estimate and its 95% confidence interval. The number of comparisons contributing data is indicated in each bar. Panels B and D represent the original subgroups, other panels represent alternative subgroups based on slightly smaller (A and E) or larger (C and F) log increments.

Supplemental table A - study and comparison characteristics - page 1 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Alcindor2004 ¹	dog	NR	m/f	none	local	NA	4	5	20	5
Alizadeh2011 ²	rat	NR	m	none	local	NA	1	5	5	5
Alkhulaifi1993_ip0.5 ³	rat	NR	m	none	local	NA	1	5	5	0.5
Alkhulaifi1993_ip1 ³	rat	NR	m	none	local	NA	1	5	5	1
Amour2009 ⁴	rabbit	NR	m	none	local	NA	1	5	5	15
Andreadou2004 ⁵	rabbit	NR	m	none	local	NA	2	5	10	10
Andreadou2006 ⁶	rabbit	NR	m	none	local	NA	2	5	10	10
Andreadou2011_1cy ⁷	rabbit	NR	m	none	local	NA	1	5	5	10
Andreadou2011_4cy ⁷	rabbit	NR	m	none	local	NA	4	4	16	10
Aouam2005_1cy ⁸	rabbit	NR	m	none	local	NA	1	5	5	10
Aouam2005_6cy ⁸	rabbit	NR	m	none	local	NA	6	4	24	4
Argaud2004 ⁹	rabbit	yes	m	none	local	NA	1	5	5	5
Argaud2005a ¹⁰	rabbit	yes	m	none	local	NA	1	5	5	5
Argaud2005b ¹¹	rabbit	NR	m	none	local	NA	1	5	5	5
Argaud2005c ¹²	rabbit	NR	m	none	local	NA	1	5	5	5
Argaud2008 ¹³	rabbit	NR	m	none	local	NA	1	5	5	5
Auchampach1992 ¹⁴	dog	NR	m/f	none	local	NA	1	5	5	10
Auchampach1993 ¹⁵	dog	NR	m/f	none	local	NA	1	5	5	10
Auchampach2004 ¹⁶	dog	NR	m/f	none	local	NA	4	5	20	10
Aye1999_1cy ¹⁷	rat	NR	m	none	local	NA	1	3	3	10
Aye1999_3cy ¹⁷	rat	NR	m	none	local	NA	3	3	9	5
Baines1997_1cy ¹⁸	rabbit	NR	m/f	none	local	NA	1	5	5	10
Baines1997_4cy ¹⁸	rabbit	NR	m/f	none	local	NA	4	5	20	10
Baines1999 ¹⁹	rabbit	NR	m/f	none	local	NA	1	5	5	10
Barbosa1996_01.25ip ²⁰	rat	NR	f	none	local	NA	1	1	1	5
Barbosa1996_02.5ip ²⁰	rat	NR	f	none	local	NA	1	3	3	5
Barbosa1996_05ip ²⁰	rat	NR	f	none	local	NA	1	5	5	5
Barbosa1996_10ip ²⁰	rat	NR	f	none	local	NA	1	10	10	5
Barbosa1996_2cy ²⁰	rat	NR	f	none	local	NA	2	5	10	5
Barbosa1996_2cy10ip ²⁰	rat	NR	f	none	local	NA	2	10	20	5
Barbosa1996_4cy ²⁰	rat	NR	f	none	local	NA	4	5	20	5

Supplemental table A - study and comparison characteristics - page 2 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Basalay2012_exp1 ²¹	rat	NR	m	none	remote	hind limb	1	15	15	10
Basalay2012_exp2 ²¹	rat	NR	m	none	remote	hind limb	1	15	15	10
Basalay2012_exp3 ²¹	rat	NR	m	none	remote	hind limb	1	15	15	10
Baumert2007 ²²	pig	NR	NR	none	local	NA	4	5	20	5
Baxter1994 ²³	rabbit	yes	m	none	local	NA	4	5	20	1440
Baxter1995 ²⁴	rabbit	yes	m	none	local	NA	4	5	20	1440
Baxter1997_1cy ²⁵	rabbit	yes	m	none	local	NA	1	5	5	2880
Baxter1997_2cy ²⁵	rabbit	yes	m	none	local	NA	2	5	10	2880
Baxter1997_4cy ²⁵	rabbit	yes	m	none	local	NA	4	5	20	2880
Baxter1997_ip24h ²⁵	rabbit	yes	m	none	local	NA	4	5	20	1440
Baxter1997_ip48h ²⁵	rabbit	yes	m	none	local	NA	4	5	20	2880
Baxter1997_ip72h ²⁵	rabbit	yes	m	none	local	NA	4	5	20	4320
Baxter1997_ip96h ²⁵	rabbit	yes	m	none	local	NA	4	5	20	5760
Belosjorow1999 ²⁶	rabbit	NR	NR	none	local	NA	1	5	5	10
Belosjorow2003 ²⁷	rabbit	NR	NR	none	local	NA	1	5	5	10
Bencsik2010 ²⁸	rat	NR	NR	none	local	NA	5	4	20	1440
Bernardo1999 ²⁹	rabbit	NR	m	none	local	NA	4	5	20	1440
Bibli2013 ³⁰	rabbit	NR	m	none	local	NA	2	5	10	10
Blokhin2008a ³¹	rat	NR	m	none	local	NA	1	5	5	5
Blokhin2008b_20is ³²	rat	NR	m	none	local	NA	3	5	15	5
Blokhin2008b_30is ³²	rat	NR	m	none	local	NA	3	5	15	5
Blokhin2008b_40is ³²	rat	NR	m	none	local	NA	3	5	15	5
Blokhin2008b_50is ³²	rat	NR	m	none	local	NA	3	5	15	5
Blokhin2008b_60is ³²	rat	NR	m	none	local	NA	3	5	15	5
Boengler2007_old ³³	mouse	NR	m/f	senescence	local	NA	1	10	10	10
Boengler2007_youth ³³	mouse	NR	m/f	none	local	NA	1	10	10	10
Brandenburger2012 ³⁴	rat	NR	NR	none	remote	hind limb	4	5	20	5
Bukhari1995 ³⁵	sheep	NR	m/f	none	local	NA	3	5	15	5
Burckhardt1995_ip2h ³⁶	rabbit	NR	NR	none	local	NA	1	5	5	120
Burckhardt1995_ip4h ³⁶	rabbit	NR	NR	none	local	NA	1	5	5	240
Burns1996_adult ³⁷	sheep	NR	m/f	none	local	NA	3	5	15	5

Supplemental table A - study and comparison characteristics - page 3 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Burns1996_old ³⁷	sheep	NR	m/f	senescence	local	NA	3	5	15	5
Cai2008 ³⁸	mouse	NR	m	none	local	NA	1	10	10	5
Cai2013 ³⁹	mouse	NR	m	none	remote	hind limb	3	5	15	1440
Canyon2005 ⁴⁰	rat	NR	m	none	local	NA	3	3	9	3
Cason1997 ⁴¹	rabbit	NR	NR	none	local	NA	1	5	5	15
Chazov2001 ⁴²	rat	NR	m	none	local	NA	3	5	15	5
Chen1997 ⁴³	rabbit	NR	m	none	local	NA	4	5	20	10
Chen2005 ⁴⁴	rat	NR	NR	none	remote	hind limb	4	5	20	5
Chen2008 ⁴⁵	rat	NR	m	none	local	NA	2	3	6	5
Cheng2009 ⁴⁶	rat	NR	m	none	local	NA	3	5	15	5
Cheng2010a ⁴⁷	rat	NR	m	none	local	NA	4	5	20	5
Cheng2010b ⁴⁸	rat	NR	m	none	local	NA	4	5	20	5
Chiari2002 ⁴⁹	rabbit	yes	m/f	brain death	local	NA	2	5	10	10
Chien1996 ⁵⁰	rabbit	NR	m	none	local	NA	1	5	5	10
Chien1999 ⁵¹	rabbit	NR	m	none	local	NA	1	5	5	10
Cohen1991 ⁵²	rabbit	NR	NR	none	local	NA	1	5	5	10
Cohen1994_1cy ⁵³	rabbit	none	NR	none	local	NA	1	5	5	10
Cohen1994_rep ⁵³	rabbit	none	NR	none	local	NA	12	5	60	10
Cohen1994_rep+1cy ⁵³	rabbit	none	NR	none	local	NA	12	5	60	10
Cohen1999 ⁵⁴	rabbit	yes	m/f	none	local	NA	1	5	5	10
Cohen2000 ⁵⁵	rabbit	yes	m/f	none	local	NA	1	5	5	10
Colantonio2004 ⁵⁶	dog	NR	NR	none	local	NA	1	10	10	10
Dai2003 ⁵⁷	rat	NR	f	none	local	NA	3	3	9	5
Dai2009_healthy ⁵⁸	rat	NR	f	none	local	NA	3	3	9	5
Dai2009_hyperten ⁵⁸	rat	NR	f	hypertension	local	NA	3	3	9	5
Dairaku2002 ⁵⁹	rat	NR	m	none	local	NA	3	3	9	3
Daleau2001_120is ⁶⁰	rabbit	NR	m	none	local	NA	2	5	10	10
Daleau2001_30is ⁶⁰	rabbit	NR	m	none	local	NA	2	5	10	10
Das2006 ⁶¹	rabbit	NR	m	none	local	NA	1	5	5	10
Das2007 ⁶²	rabbit	NR	m	none	local	NA	1	5	5	10
Das2012 ⁶³	rabbit	NR	m	none	local	NA	1	5	5	10

Supplemental table A - study and comparison characteristics - page 4 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Dawn2002 ⁶⁴	rabbit	NR	m	none	local	NA	6	4	24	1440
Dawn2004a ⁶⁵	mouse	NR	NR	none	local	NA	6	4	24	1440
Dawn2004b ⁶⁶	mouse	NR	NR	none	local	NA	6	4	24	1440
Demiryurek2005a ⁶⁷	rat	NR	m	none	local	NA	1	5	5	5
Demiryurek2005b ⁶⁸	rat	NR	m	none	local	NA	1	5	5	5
DePaulis2013 ⁶⁹	rat	NR	m	none	local	NA	3	3	9	5
Depre2010_ip24h ⁷⁰	pig	NR	NR	none	local	NA	2	10	20	1440
Depre2010_ip60 ⁷⁰	pig	NR	NR	none	local	NA	6	10	60	60
Deuchar2007 ⁷¹	rat	NR	m	none	local	NA	3	3	9	5
DeZeeuw2001_10ip ⁷²	pig	NR	m/f	none	remote	brain	1	10	10	20
DeZeeuw2001_30ip ⁷²	pig	NR	m/f	none	remote	brain	1	30	30	30
Ding2000 ⁷³	rabbit	NR	m	none	local	NA	2	5	10	10
Ding2001 ⁷⁴	rabbit	NR	m	none	remote	RAO	1	10	10	10
Dong2004 ⁷⁵	rat	NR	m	none	remote	hind limb	1	10	10	10
Ebel2003_diabetic ⁷⁶	rabbit	NR	m	diabetes	local	NA	1	5	5	1440
Ebel2003_healthy1 ⁷⁶	rabbit	NR	m	none	local	NA	1	5	5	1440
Ebel2003_healthy2 ⁷⁶	rabbit	NR	m	none	local	NA	1	5	5	1440
Ebel2003_hypergly ⁷⁶	rabbit	NR	m	hyperglycaemia	local	NA	1	5	5	1440
Ebel2009_diabetic ⁷⁷	rat	NR	m	diabetes	local	NA	3	3	9	5
Ebel2009_healthy ⁷⁷	rat	NR	m	none	local	NA	3	3	9	5
Eckle2006_1cy ⁷⁸	mouse	NR	m/f	none	local	NA	1	5	5	5
Eckle2006_2cy ⁷⁸	mouse	NR	m/f	none	local	NA	2	5	10	5
Eckle2006_3cy ⁷⁸	mouse	NR	m/f	none	local	NA	3	5	15	5
Eckle2006_4cy ⁷⁸	mouse	NR	m/f	none	local	NA	4	5	20	5
Eckle2012 ⁷⁹	mouse	NR	m	none	local	NA	4	5	20	5
Erikson1996 ⁸⁰	dog	NR	NR	none	local	NA	4	5	20	5
Fang2008 ⁸¹	rat	NR	m	none	local	NA	3	5	15	5
Farhat2001_braindead ⁸²	rabbit	NR	NR	brain death	local	NA	1	5	5	5
Farhat2001_healthy ⁸²	rabbit	NR	NR	none	local	NA	1	5	5	5
Fisher2002_ip15m ⁸³	mouse	NR	m	none	local	NA	3	5	15	15
Fisher2002_ip24h ⁸³	mouse	NR	m	none	local	NA	3	5	15	1440

Supplemental table A - study and comparison characteristics - page 5 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Flack3rd1991 ⁸⁴	pig	NR	m/f	none	local	NA	4	5	20	5
Flaherty2008 ⁸⁵	mouse	NR	m	none	local	NA	6	4	24	4
Flynn2005_1cy ⁸⁶	rabbit	NR	m	none	local	NA	1	5	5	10
Flynn2005_2cy ⁸⁶	rabbit	NR	m	none	local	NA	1	5	5	10
Fryer1998 ⁸⁷	rat	NR	m	none	local	NA	1	5	5	5
Fryer1999_1cy ⁸⁸	rat	NR	m	none	local	NA	1	5	5	5
Fryer1999_3cy ⁸⁸	rat	NR	m	none	local	NA	3	5	15	5
Fryer2000 ⁸⁹	rat	NR	m	none	local	NA	1	5	5	5
Fryer2001a ⁹⁰	rat	NR	m	none	local	NA	1	5	5	5
Fryer2001b ⁹¹	rat	NR	m	none	local	NA	1	5	5	5
Fryer2001c ⁹²	rat	NR	m	none	local	NA	1	5	5	5
Fryer2002 ⁹³	rat	NR	m	none	local	NA	1	5	5	5
Fukuma2000 ⁹⁴	rabbit	NR	m	none	local	NA	1	5	5	5
Galagudza2007a_diabetic ⁹⁵	rat	NR	m	diabetes	local	NA	1	5	5	5
Galagudza2007a_healthy ⁹⁵	rat	NR	m	none	local	NA	1	5	5	5
Galagudza2007b_1cy ⁹⁶	rat	NR	m	none	local	NA	1	5	5	5
Galagudza2007b_3cy ⁹⁶	rat	NR	m	none	local	NA	3	5	15	5
Galagudza2007b_RIPC ⁹⁶	rat	NR	m	none	remote	MAO	1	5	5	15
Galagudza2009 ⁹⁷	rat	NR	m	none	local	NA	3	4	12	5
Gao2000 ⁹⁸	mouse	NR	m/f	none	local	NA	3	5	15	10
Gao2003_ip10 ⁹⁹	rat	NR	m	none	local	NA	3	5	15	10
Gao2003_ip24h ⁹⁹	rat	NR	m	none	local	NA	3	5	15	1440
Gao2012_IPC ¹⁰⁰	rat	NR	m	none	local	NA	3	5	15	5
Gao2012_RIPC ¹⁰⁰	rat	NR	m	none	remote	hind limb	3	5	15	5
Ge2011_exp1 ¹⁰¹	mouse	NR	NR	hyperglycaemia	local	NA	4	5	20	5
Ge2011_exp2 ¹⁰¹	mouse	NR	NR	hyperglycaemia	local	NA	4	5	20	5
Gerczuk2012 ¹⁰²	rat	NR	m	none	local	NA	3	3	9	5
Gho1996_IPC ¹⁰³	rat	NR	m	none	local	NA	1	15	15	10
Gho1996_MA0 ¹⁰³	rat	NR	m	none	remote	MAO	1	15	15	10
Gho1996_RAO ¹⁰³	rat	NR	m	none	remote	RAO	1	15	15	10
Gomez2011 ¹⁰⁴	mouse	yes	m	none	local	NA	1	5	5	5

Supplemental table A - study and comparison characteristics - page 6 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Gomoll1996_02ip ¹⁰⁵	ferret	NR	m	none	local	NA	1	2	2	10
Gomoll1996_05ip ¹⁰⁵	ferret	NR	m	none	local	NA	1	5	5	10
Gomoll1996_10ip ¹⁰⁵	ferret	NR	m	none	local	NA	1	10	10	10
Gomoll1996_75is ¹⁰⁵	ferret	NR	m	none	local	NA	1	5	5	10
Gomoll1996_90is ¹⁰⁵	ferret	NR	m	none	local	NA	1	5	5	10
Goto1993 ¹⁰⁶	rabbit	NR	m	none	local	NA	2	2	4	5
Gourine2005 ¹⁰⁷	rat	NR	m	none	local	NA	3	5	15	5
Gozal2005 ¹⁰⁸	rabbit	NR	NR	none	local	NA	1	5	5	10
Griol-Charhbili2005 ¹⁰⁹	mouse	NR	m	none	local	NA	3	3	9	5
Gross1992 ¹¹⁰	dog	NR	m/f	none	local	NA	1	5	5	10
Gross2009 ¹¹¹	dog	NR	m/f	none	local	NA	1	5	5	10
Grover1992 ¹¹²	dog	NR	m/f	none	local	NA	1	5	5	10
Grover1996 ¹¹³	dog	NR	m/f	none	local	NA	1	5	5	10
Grund1997_1cy ¹¹⁴	pig	NR	m/f	none	local	NA	1	10	10	30
Grund1997_2cy ¹¹⁴	pig	NR	m/f	none	local	NA	2	10	20	30
Gu2008 ¹¹⁵	dog	NR	m/f	hyperglycaemia	local	NA	4	5	20	5
Gumina1999_1cy ¹¹⁶	dog	NR	m/f		local	NA	1	5	5	10
Gumina1999_4cy ¹¹⁶	dog	NR	m/f	none	local	NA	4	5	20	5
Gumina1999_60is ¹¹⁶	dog	NR	m/f	none	local	NA	1	5	5	10
Gumina2001 ¹¹⁷	dog	NR	m/f	none	local	NA	1	5	5	10
Gumina2005_1cy ¹¹⁸	dog	NR	m/f	none	local	NA	1	10	10	10
Gumina2005_1cyip2h ¹¹⁸	dog	NR	m/f	none	local	NA	1	10	10	120
Gumina2005_2cy ¹¹⁸	dog	NR	m/f	none	local	NA	2	10	20	10
Guo1998_early ¹¹⁹	mouse	NR	m	none	local	NA	6	4	24	10
Guo1998_late24hR ¹¹⁹	mouse	NR	m	none	local	NA	6	4	24	1440
Guo1998_late4R ¹¹⁹	mouse	NR	m	none	local	NA	6	4	24	1440
Guo1999_ip10 ¹²⁰	mouse	NR	m	none	local	NA	6	4	24	10
Guo1999_ip24h ¹²⁰	mouse	NR	m	none	local	NA	6	4	24	1440
Guo2001_1cy ¹²¹	mouse	NR	m	none	local	NA	1	4	4	10
Guo2001_6cy ¹²¹	mouse	NR	m	none	local	NA	6	4	24	4
Guo2007 ¹²²	rat	NR	NR	none	local	NA	2	5	10	5

Supplemental table A - study and comparison characteristics - page 7 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Guo2012_exp1 ¹²³	mouse	NR	m	none	local	NA	6	4	24	1440
Guo2012_exp2 ¹²³	mouse	NR	m	none	local	NA	6	4	24	1440
Guo2012_exp3 ¹²³	mouse	NR	m	none	local	NA	6	4	24	1440
Gysembergh1998 ¹²⁴	rabbit	yes	NR	none	local	NA	1	5	5	5
Haessler1994_iso ¹²⁵	rabbit	NR	NR	none	local	NA	1	5	5	10
Haessler1994_kxy ¹²⁵	rabbit	NR	NR	none	local	NA	1	5	5	10
Haessler1994_pen ¹²⁵	rabbit	NR	NR	none	local	NA	1	5	5	10
Haessler1997 ¹²⁶	rabbit	NR	NR	none	local	NA	1	5	5	10
Hale1992_exp1 ¹²⁷	rabbit	NR	m	none	local	NA	2	5	10	5
Hale1992_exp2 ¹²⁷	rabbit	NR	m	none	local	NA	2	5	10	5
Hale1999_1cy ¹²⁸	rabbit	NR	NR	none	local	NA	1	5	5	5
Hale1999_2cy ¹²⁸	rabbit	NR	NR	none	local	NA	2	7	14	5
Halkos2004 ¹²⁹	dog	yes	NR	none	local	NA	1	5	5	10
Hampton2003 ¹³⁰	mouse	NR	NR	none	local	NA	3	5	15	1440
Haruna1998 ¹³¹	rabbit	NR	f	none	local	NA	1	5	5	10
Hatori2001 ¹³²	pig	NR	m/f	none	local	NA	1	5	5	15
Houseinloy2012 ¹³³	pig	yes	NR	none	remote	hind limb	4	5	20	5
He2009 ¹³⁴	rabbit	NR	f	none	local	NA	3	5	15	5
Heinen2011_IPC ¹³⁵	rat	NR	m	none	local	NA	4	5	20	5
Heinen2011_IPC+RIPC ¹³⁵	rat	NR	m	none	local+remote	hind limb	4	5	20	5
Heinen2011_RIPC ¹³⁵	rat	NR	m	none	remote	hind limb	4	5	20	5
HemetsbergerH2008 ¹³⁶	pig	NR	NR	none	local	NA	2	5	10	5
HemetsbergerR2008 ¹³⁷	pig	NR	NR	none	local	NA	2	5	10	5
Hiasa2001 ¹³⁸	rat	NR	m	none	local	NA	4	5	20	10
Hibert2013 ¹³⁹	rat	NR	m	none	remote	hind limb	1	10	10	10
Hide1996 ¹⁴⁰	rabbit	yes	m	none	local	NA	1	5	5	15
Hinokiyama2003 ¹⁴¹	pig	NR	m/f	none	local	NA	1	5	5	15
Hiroi2010_1ip ¹⁴²	rat	NR	m	none	local	NA	4	1	4	1440
Hiroi2010_3ip ¹⁴²	rat	NR	m	none	local	NA	4	3	12	1440
Hoshida1994 ¹⁴³	dog	NR	m/f	none	local	NA	4	5	20	5
Htun1998 ¹⁴⁴	pig	yes	m	none	local	NA	2	10	20	30

Supplemental table A - study and comparison characteristics - page 8 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Hu2002_adult ¹⁴⁵	rat	NR	m	none	remote	MAO	6	4	24	1440
Hu2002_old ¹⁴⁵	rat	NR	m	senescence	remote	MAO	6	4	24	1440
Huang1999 ¹⁴⁶	pig	NR	NR	none	local	NA	2	10	20	10
Huang2004 ¹⁴⁷	rabbit	NR	NR	none	local	NA	2	10	20	10
Huang2011 ¹⁴⁸	rabbit	NR	NR	none	local	NA	2	10	20	10
Huang2013 ¹⁴⁹	rat	NR	NR	none	local	NA	2	10	20	10
Iliodromitis1994_1cy10 ¹⁵⁰	rabbit	NR	m/f	none	local	NA	1	5	5	10
Iliodromitis1994_1cy60 ¹⁵⁰	rabbit	NR	m/f	none	local	NA	1	5	5	60
Iliodromitis1994_2cy ¹⁵⁰	rabbit	NR	m/f	none	local	NA	2	5	10	60
Iliodromitis1994_3cy ¹⁵⁰	rabbit	NR	m/f	none	local	NA	3	5	15	10
Iliodromitis1996a_1ip ¹⁵¹	rabbit	NR	NR	none	local	NA	1	1	1	10
Iliodromitis1996a_5ip ¹⁵¹	rabbit	NR	NR	none	local	NA	1	5	5	10
Iliodromitis1996b_2cy45 ¹⁵²	rabbit	NR	NR	none	local	NA	2	5	10	10
Iliodromitis1996b_2cy60 ¹⁵²	rabbit	NR	NR	none	local	NA	2	5	10	10
Iliodromitis1996b_2cy75 ¹⁵²	rabbit	NR	NR	none	local	NA	2	5	10	10
Iliodromitis1996b_ip60 ¹⁵²	rabbit	NR	NR	none	local	NA	1	5	5	60
Iliodromitis1996b_ip65 ¹⁵²	rabbit	NR	NR	none	local	NA	1	5	5	65
Iliodromitis1996b_ip70 ¹⁵²	rabbit	NR	NR	none	local	NA	1	5	5	70
Iliodromitis1996b_ip75 ¹⁵²	rabbit	NR	NR	none	local	NA	1	5	5	75
Iliodromitis1996b_ip80 ¹⁵²	rabbit	NR	NR	none	local	NA	1	5	5	80
Iliodromitis1997_1cy ¹⁵³	rabbit	NR	NR	none	local	NA	1	5	5	10
Iliodromitis1997_2cy ¹⁵³	rabbit	NR	NR	none	local	NA	2	5	10	10
Iliodromitis1997_4cy ¹⁵³	rabbit	NR	NR	none	local	NA	4	5	20	10
Iliodromitis1997_6cy ¹⁵³	rabbit	NR	NR	none	local	NA	6	5	30	10
Iliodromitis1997_8cy ¹⁵³	rabbit	NR	NR	none	local	NA	8	5	40	10
Iliodromitis2002a_1cy ¹⁵⁴	rabbit	NR	m	none	local	NA	1	5	5	10
Iliodromitis2002a_3cy ¹⁵⁴	rabbit	NR	m	none	local	NA	3	5	15	10
Iliodromitis2002b ¹⁵⁵	rabbit	NR	m	none	local	NA	1	5	5	10
Iliodromitis2003_3cy ¹⁵⁶	rabbit	NR	m	none	local	NA	3	5	15	10
Iliodromitis2003_3cy90 ¹⁵⁶	rabbit	NR	m	none	local	NA	3	5	15	90
Iliodromitis2003_8cy ¹⁵⁶	rabbit	NR	m	none	local	NA	8	5	40	10

Supplemental table A - study and comparison characteristics - page 9 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Iliodromitis2004 ¹⁵⁷	rabbit	NR	m	none	local	NA	3	5	15	10
Iliodromitis2006a ¹⁵⁸	rabbit	NR	m	none	local	NA	2	5	10	10
Iliodromitis2006b_exp1 ¹⁵⁹	rabbit	NR	m	hypercholesterolemia	local	NA	2	5	10	10
Iliodromitis2006b_exp2 ¹⁵⁹	rabbit	NR	m	hypercholesterolemia	local	NA	2	5	10	10
Iliodromitis2008_3cy ¹⁶⁰	rabbit	NR	m	none	local	NA	3	5	15	10
Iliodromitis2008_8cy ¹⁶⁰	rabbit	NR	m	none	local	NA	8	5	40	10
Iliodromitis2013_20ip ¹⁶¹	rabbit	NR	m	none	local	NA	1	20	20	12
Iliodromitis2013_5ip+20ip ¹⁶¹	rabbit	NR	m	none	local	NA	3	10	30	12
Iliodromitis2013_5ip20is ¹⁶¹	rabbit	NR	m	none	local	NA	2	5	10	10
Iliodromitis2013_5ip40is ¹⁶¹	rabbit	NR	m	none	local	NA	2	5	10	10
Imagawa1997 ¹⁶²	rabbit	yes	m	none	local	NA	4	5	20	2880
Imagawa1998 ¹⁶³	rabbit	yes	m	none	local	NA	1	5	5	10
Imagawa1999 ¹⁶⁴	rabbit	yes	m	none	local	NA	4	5	20	2880
Ismaeil1999 ¹⁶⁵	rabbit	NR	NR	none	local	NA	1	5	5	15
Iwamoto1991 ¹⁶⁶	rabbit	NR	m	none	local	NA	4	5	20	5
Jaberansari2001_2cy ¹⁶⁷	pig	NR	m/f	none	local	NA	2	5	10	1440
Jaberansari2001_4cy ¹⁶⁷	pig	NR	m/f	none	local	NA	4	5	20	1440
Jancso2004_2cy ¹⁶⁸	pig	NR	m/f	none	local	NA	2	2	4	1440
Jancso2004_4cy ¹⁶⁸	pig	NR	m/f	none	local	NA	4	5	20	1440
Jansco2005 ¹⁶⁹	rabbit	NR	NR	none	local	NA	4	5	20	1440
Ji2013_diabetic ¹⁷⁰	rat	NR	m	diabetes	local	NA	2	5	10	5
Ji2013_healthy ¹⁷⁰	rat	NR	m	none	local	NA	2	5	10	5
Jiao2002 ¹⁷¹	rat	NR	m	none	local	NA	2	5	10	10
Jung2000_healthy ¹⁷²	rabbit	NR	m	none	local	NA	2	5	10	10
Jung2000_hyperchol ¹⁷²	rabbit	NR	m	hypercholesterolemia	local	NA	2	5	10	10
Junhua1997 ¹⁷³	rabbit	NR	NR	none	local	NA	4	5	20	1440
Kalakech2013_mouse ¹⁷⁴	mouse	NR	m	none	remote	hind limb	4	5	20	5
Kalakech2013_rat ¹⁷⁴	rat	NR	m	none	remote	hind limb	4	5	20	5
Kapadia1997 ¹⁷⁵	pig	NR	NR	none	local	NA	2	10	20	15
Kara 2004 ¹⁷⁶	rat	NR	m	none	local	NA	1	5	5	5
Kara2006 ¹⁷⁷	rat	NR	m	none	local	NA	1	5	5	5

Supplemental table A - study and comparison characteristics - page 10 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Kariya1997 ¹⁷⁸	rabbit	NR	m	none	local	NA	1	5	5	5
Katakam2007_lean ¹⁷⁹	rat	NR	m	none	local	NA	1	5	5	5
Katakam2007_obese ¹⁷⁹	rat	NR	m	obese	local	NA	1	5	5	5
Kersten1997 ¹⁸⁰	dog	NR	NR	none	local	NA	4	5	20	5
Kersten1998 ¹⁸¹	dog	NR	NR	hyperglycaemia	local	NA	4	5	20	5
Kersten2000_diabetic ¹⁸²	dog	NR	NR	diabetes	local	NA	4	5	20	5
Kersten2000_healthy ¹⁸²	dog	NR	NR	none	local	NA	4	5	20	5
Kingma1999 ¹⁸³	rabbit	NR	m	none	local	NA	2	5	10	10
Kingma2011 ¹⁸⁴	dog	yes	m/f	none	remote	RAO	4	5	20	5
Kingma2013 ¹⁸⁵	dog	yes	m/f	none	local	NA	4	5	20	5
Kirsch2000_braindead ¹⁸⁶	rabbit	NR	NR	brain death	local	NA	1	3	3	3
Kirsch2000_healthy ¹⁸⁶	rabbit	NR	NR	none	local	NA	1	3	3	3
Kis2003 ¹⁸⁷	rabbit	yes	m	none	local	NA	4	5	20	1440
Kitakaze1994a ¹⁸⁸	dog	NR	NR	none	local	NA	4	5	20	5
Kitakaze1994b_anesth ¹⁸⁹	dog	NR	NR	none	local	NA	4	5	20	5
Kitakaze1994b_conscious ¹⁸⁹	dog	NR	NR	none	local	NA	4	5	20	5
Kitakaze1996a ¹⁹⁰	dog	NR	NR	none	local	NA	4	5	20	5
Kitakaze1996b ¹⁹¹	dog	NR	NR	none	local	NA	4	5	20	5
Kitakaze2000 ¹⁹²	dog	NR	NR	none	local	NA	4	5	20	5
Kocoglu2008 ¹⁹³	rat	NR	m	none	local	NA	1	5	5	5
Kohler2007 ¹⁹⁴	mouse	NR	NR	none	local	NA	4	5	20	5
Kojima1995 ¹⁹⁵	rat	NR	m	none	local	NA	1	5	5	10
Kolettis2013 ¹⁹⁶	rat	NR	m	none	local	NA	2	5	10	10
Koneru2007 ¹⁹⁷	rat	NR	m	none	local	NA	4	4	16	4
Koning1994a_ip120 ¹⁹⁸	pig	NR	NR	none	local	NA	1	10	10	120
Koning1994a_ip15 ¹⁹⁸	pig	NR	NR	none	local	NA	1	10	10	15
Koning1994a_ip180 ¹⁹⁸	pig	NR	NR	none	local	NA	1	10	10	180
Koning1994a_ip240 ¹⁹⁸	pig	NR	NR	none	local	NA	1	10	10	240
Koning1994a_ip60 ¹⁹⁸	pig	NR	NR	none	local	NA	1	10	10	60
Koning1994b_ip15 ¹⁹⁹	pig	NR	NR	none	local	NA	1	10	10	15
Koning1994b_ip60 ¹⁹⁹	pig	NR	NR	none	local	NA	1	10	10	60

Supplemental table A - study and comparison characteristics - page 11 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Kositprapa2001 ²⁰⁰	rabbit	NR	m	none	local	NA	4	5	20	1440
Kouchi1998 ²⁰¹	rabbit	NR	f	none	local	NA	1	5	5	10
Kremastinos2000_healthy ²⁰²	rabbit	NR	m	none	local	NA	1	5	5	10
Kremastinos2000_hyperchol ²⁰²	rabbit	NR	m	hypercholesterolemia	local	NA	1	5	5	10
Kristensen2004 ²⁰³	pig	NR	NR	none	local	NA	2	10	20	30
Kudej2006_ip10 ²⁰⁴	pig	yes	NR	none	local	NA	2	10	20	10
Kudej2006_ip24h ²⁰⁴	pig	yes	NR	none	local	NA	2	10	20	1440
Kunuthur2012_exp1 ²⁰⁵	mouse	NR	m	none	local	NA	1	5	5	5
Kunuthur2012_exp2 ²⁰⁵	mouse	NR	m	none	local	NA	1	5	5	5
Kuzmin2000 ²⁰⁶	rat	NR	m	none	local	NA	3	5	15	5
Kuzume2004_1cy ²⁰⁷	rabbit	NR	NR	none	local	NA	1	5	5	10
Kuzume2004_2cy ²⁰⁷	rabbit	NR	NR	none	local	NA	2	5	10	10
Kuzuya1993_ip03h ²⁰⁸	dog	NR	m/f	none	local	NA	4	5	20	1440
Kuzuya1993_ip05 ²⁰⁸	dog	NR	m/f	none	local	NA	4	5	20	5
Kuzuya1993_ip12h ²⁰⁸	dog	NR	m/f	none	local	NA	4	5	20	180
Kuzuya1993_ip24h ²⁰⁸	dog	NR	m/f	none	local	NA	4	5	20	720
Landim2013_healthy ²⁰⁹	rat	NR	m	none	local	NA	3	3	9	3
Landim2013_hyperchol ²⁰⁹	rat	NR	m	hypercholesterolemia	local	NA	3	3	9	3
Lang2006_IPC ²¹⁰	rat	NR	m	none	local	NA	3	5	15	5
Lang2006_RIPC ²¹⁰	rat	NR	m	none	remote	RAO	1	10	10	20
Lange2006 ²¹¹	rabbit	NR	m	none	local	NA	1	5	5	30
Lankford2006 ²¹²	mouse	NR	m	none	local	NA	3	5	15	10
Larsen2007 ²¹³	pig	NR	f	none	local	NA	2	5	10	5
Lasley1995 ²¹⁴	rabbit	NR	m/f	none	local	NA	1	5	5	10
Lazou2006 ²¹⁵	rabbit	NR	m	none	local	NA	1	5	5	10
Lee2000 ²¹⁶	dog	NR	NR	none	local	NA	1	5	5	10
Lee2004_bif1cy ²¹⁷	rabbit	NR	NR	none	local	NA	1	5	5	10
Lee2004_bif3cy ²¹⁷	rabbit	NR	NR	none	local	NA	3	5	15	10
Lee2004_bif5cy ²¹⁷	rabbit	NR	NR	none	local	NA	5	5	25	10
Lee2004_bif7cy ²¹⁷	rabbit	NR	NR	none	local	NA	7	5	35	10
Lee2004_trif1cy ²¹⁷	rabbit	NR	NR	none	local	NA	1	5	5	10

Supplemental table A - study and comparison characteristics - page 12 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Lee2004_trif3cy ²¹⁷	rabbit	NR	NR	none	local	NA	3	5	15	10
Lee2004_trif5cy ²¹⁷	rabbit	NR	NR	none	local	NA	5	5	25	10
Li_G1990_01cy ²¹⁸	dog	NR	m	none	local	NA	1	5	5	10
Li_G1990_06cy ²¹⁸	dog	NR	m	none	local	NA	6	5	30	10
Li_G1990_12cy ²¹⁸	dog	NR	m	none	local	NA	12	5	60	10
Li_Q2003 ²¹⁹	mouse	NR	m	none	local	NA	6	4	24	1440
Li_R2009 ²²⁰	rat	NR	m	none	local	NA	3	5	15	5
Li_S2008_IPC ²²¹	rat	NR	NR	none	local	NA	3	5	15	5
Li_S2008_RIPC ²²¹	rat	NR	NR	none	remote	hind limb	9	5	45	1440
Li_S2009_IPC ²²²	rat	NR	NR	none	local	NA	3	5	15	5
Li_S2009_RIPC ²²²	rat	NR	NR	none	remote	hind limb	9	5	45	1440
Li_S2010_IPC ²²³	rat	NR	m	none	local	NA	3	5	15	5
Li_S2010_RIPC ²²³	rat	NR	m	none	remote	hind limb	9	5	45	1440
Li_W2003 ²²⁴	rabbit	NR	m	none	local	NA	4	5	20	1440
Li_X2012a ²²⁵	pig	NR	NR	none	local	NA	3	5	15	5
Li_X2012b ²²⁶	pig	NR	m/f	none	local	NA	3	5	15	5
Li_Y1992a_ip05 ²²⁷	rat	NR	f	none	local	NA	3	3	9	5
Li_Y1992a_ip1h ²²⁷	rat	NR	f	none	local	NA	3	3	9	60
Li_Y1992a_ip2h ²²⁷	rat	NR	f	none	local	NA	3	3	9	120
Li_Y1992a_ip3h ²²⁷	rat	NR	f	none	local	NA	3	3	9	180
Li_Y1992b ²²⁸	rat	NR	f	none	local	NA	3	5	15	5
Li_Y1993a ²²⁹	rat	NR	f	none	local	NA	3	3	9	5
Li_Y1993b ²³⁰	rat	NR	f	none	local	NA	3	3	9	5
Li_Y1994_ip05 ²³¹	rat	NR	f	none	local	NA	3	3	9	5
Li_Y1994_ip1h ²³¹	rat	NR	f	none	local	NA	3	3	9	60
Li_Y1994_ip60ip ²³¹	rat	NR	f	none	local	NA	6	3	18	5
Li_Y1995 ²³²	rat	NR	f	none	local	NA	3	3	9	5
Li_Y2011 ²³³	mouse	NR	m	none	local	NA	3	5	15	1440
Liao2013_convent ²³⁴	mouse	NR	m	none	local	NA	3	5	15	5
Liao2013_lungrec ²³⁴	mouse	NR	m	none	local	NA	3	5	15	5
Liaudet2001_mouse ²³⁵	mouse	NR	NR	none	local	NA	4	5	20	10

Supplemental table A - study and comparison characteristics - page 13 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Liaudet2001_rat ²³⁵	rat	NR	m	none	local	NA	4	5	20	5
Lie2010 ²³⁶	pig	NR	f	none	local	NA	2	10	20	30
Liem2001_1cy ²³⁷	rat	NR	m	none	local	NA	1	15	15	10
Liem2001_3cy ²³⁷	rat	NR	m	none	local	NA	3	3	9	3
Liem2005_01cyip70 ²³⁸	rat	NR	m	none	local	NA	1	15	15	70
Liem2005_04cyip70 ²³⁸	rat	NR	m	none	local	NA	4	15	60	70
Liem2005_2cy ²³⁸	rat	NR	m	none	local	NA	2	15	30	10
Liem2005_3cy ²³⁸	rat	NR	m	none	local	NA	3	3	9	5
Liem2005_6cy ²³⁸	rat	NR	m	none	local	NA	6	15	90	10
Liem2005_7cy ²³⁸	rat	NR	m	none	local	NA	7	10	70	5
Liem2005_ip010 ²³⁸	rat	NR	m	none	local	NA	1	15	15	10
Liem2005_ip090 ²³⁸	rat	NR	m	none	local	NA	1	15	15	90
Liem2005_ip175 ²³⁸	rat	NR	m	none	local	NA	1	15	15	175
Liem2005_IPC+RIPC ²³⁸	rat	NR	m	none	local+remote	MAO	6	15	90	10
Liem2005_RIPC ²³⁸	rat	NR	m	none	remote	MAO	2	15	30	10
Lim2007_30is ²³⁹	mouse	NR	m/f	none	local	NA	1	5	5	5
Lim2007_45is ²³⁹	mouse	NR	m/f	none	local	NA	1	5	5	5
Lim2010 ²⁴⁰	mouse	NR	m	none	remote	hind limb	3	5	15	5
Liu1993a ²⁴¹	rat	NR	m	diabetes	local	NA	3	5	15	5
Liu1993b ²⁴²	rat	NR	m	none	local	NA	3	5	15	5
Liu1994 ²⁴³	rabbit	NR	m/f	none	local	NA	1	5	5	10
Liu2005 ²⁴⁴	rat	NR	m	none	local	NA	3	5	15	1440
Liu2008 ²⁴⁵	rat	NR	m	none	local	NA	5	4	20	4
LiuG1992a ²⁴⁶	rabbit	NR	m/f	none	local	NA	1	5	5	10
LiuG1992b ²⁴⁷	rabbit	NR	m	none	local	NA	1	5	5	10
LiuY1992_1cy ²⁴⁸	rat	NR	m	none	local	NA	1	5	5	10
LiuY1992_3cy ²⁴⁸	rat	NR	m	none	local	NA	3	5	15	5
Loke1998 ²⁴⁹	dog	NR	m/f	none	local	NA	3	5	15	10
Lott1996 ²⁵⁰	rat	NR	m	none	local	NA	2	5	10	5
Lotz2011 ²⁵¹	rabbit	NR	m	none	remote	RAO	3	10	30	10
Lou2003 ²⁵²	rat	none	m	none	local	NA	3	5	15	5

Supplemental table A - study and comparison characteristics - page 14 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Lu2009 ²⁵³	mouse	NR	NR	none	local	NA	3	5	15	5
Lu2011 ²⁵⁴	rat	NR	m	none	local	NA	3	5	15	5
Lu2012_1cy ²⁵⁵	rat	NR	m	none	remote	hind limb	1	5	5	5
Lu2012_3cy ²⁵⁵	rat	NR	m	none	remote	hind limb	3	5	15	5
Luo2004 ²⁵⁶	rat	NR	m	none	local	NA	4	3	12	1440
Manintveld2005 ²⁵⁷	rat	NR	m	none	local	NA	1	15	15	10
Manintveld2011_1cy ²⁵⁸	rat	NR	NR	none	local	NA	1	15	15	10
Manintveld2011_3cy ²⁵⁸	rat	NR	NR	none	local	NA	3	3	9	5
Marber1993 ²⁵⁹	rabbit	yes	NR	none	local	NA	4	5	20	1440
Martin1997 ²⁶⁰	pig	NR	m/f	none	local	NA	1	10	10	10
Matsuda1993 ²⁶¹	dog	NR	m/f	none	local	NA	4	5	20	5
Matsumura2000 ²⁶²	rat	NR	m	none	local	NA	1	3	3	10
McVey1999a ²⁶³	rat	NR	m	none	local	NA	3	3	9	5
McVey1999b ²⁶⁴	dog	NR	NR	none	local	NA	1	5	5	10
Mei1998 ²⁶⁵	dog	NR	NR	none	local	NA	1	5	5	10
Miki1996 ²⁶⁶	rabbit	NR	m	none	local	NA	1	2	2	5
Miki1998a ²⁶⁷	rabbit	NR	m/f	none	local	NA	1	5	5	10
Miki1998b ²⁶⁸	rabbit	NR	m	none	local	NA	1	5	5	5
Miki1999_hist ²⁶⁹	rabbit	none	m/f	none	local	NA	4	5	20	1440
Miki1999_TTC ²⁶⁹	rabbit	none	m/f	none	local	NA	4	5	20	1440
Miller1999_2cy ²⁷⁰	mouse	NR	NR	none	local	NA	3	5	15	5
Miller1999_3cy ²⁷⁰	mouse	NR	NR	none	local	NA	2	5	10	5
Minamino1996_ip005 ²⁷¹	dog	NR	m/f	none	local	NA	4	5	20	5
Minamino1996_ip030 ²⁷¹	dog	NR	m/f	none	local	NA	4	5	20	30
Minamino1996_ip060 ²⁷¹	dog	NR	m/f	none	local	NA	4	5	20	60
Minamino1996_ip120 ²⁷¹	dog	NR	m/f	none	local	NA	4	5	20	120
Miura1991_1cy ²⁷²	rabbit	NR	m	none	local	NA	1	5	5	5
Miura1991_2cy ²⁷²	rabbit	NR	m	none	local	NA	2	5	10	5
Miura1991_2ip ²⁷²	rabbit	NR	m	none	local	NA	2	2	4	5
Miura1992 ²⁷³	rabbit	NR	m	none	local	NA	1	2	2	5
Miura1998_1cy ²⁷⁴	rabbit	NR	m	none	local	NA	1	5	5	5

Supplemental table A - study and comparison characteristics - page 15 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Miura1998_2cy ²⁷⁴	rabbit	NR	m	none	local	NA	2	5	10	5
Mizumura1995 ²⁷⁵	dog	NR	m/f	none	local	NA	1	5	5	10
Mizumura1996_2.5ip ²⁷⁶	dog	NR	m/f	none	local	NA	1	3	3	10
Mizumura1996_5ip ²⁷⁶	dog	NR	m/f	none	local	NA	1	5	5	10
Mizumura1997_2.5ip ²⁷⁷	dog	NR	m/f	none	local	NA	1	3	3	10
Mizumura1997_5ip ²⁷⁷	dog	NR	m/f	none	local	NA	1	5	5	10
Morgan1999 ²⁷⁸	rabbit	NR	NR	none	local	NA	3	5	15	120
Mortensen2006 ²⁷⁹	pig	none	NR	none	local	NA	2	10	20	30
Mullenheim2001a ²⁸⁰	rabbit	NR	m	none	local	NA	1	5	5	10
Mullenheim2001b ²⁸¹	rabbit	NR	m	none	local	NA	1	5	5	1440
Mullenheim2001c_ip10 ²⁸²	rabbit	NR	m	none	local	NA	1	5	5	10
Mullenheim2001c_ip24h ²⁸²	rabbit	NR	m	none	local	NA	1	5	5	1440
Mullenheim2001c_ip24hip ²⁸²	rabbit	NR	m	none	local	NA	2	5	10	10
Mullenheim2003_ip24h ²⁸³	rabbit	none	m	none	local	NA	1	5	5	1440
Mullenheim2003_ip24hip ²⁸³	rabbit	none	m	none	local	NA	2	5	10	10
Munch-Ellingsen1997 ²⁸⁴	rabbit	NR	m/f	none	local	NA	1	5	5	10
Munch-Ellingsen1998 ²⁸⁵	rabbit	NR	m/f	none	local	NA	1	5	5	10
Murry1986_3his ²⁸⁶	dog	NR	m/f	none	local	NA	4	5	20	5
Murry1986_40is ²⁸⁶	dog	NR	m/f	none	local	NA	4	5	20	5
Murry1991_ip120 ²⁸⁷	dog	NR	m/f	none	local	NA	1	15	15	120
Murry1991_ip5 ²⁸⁷	dog	NR	m/f	none	local	NA	1	15	15	5
Nadtochiy2009 ²⁸⁸	mouse	NR	m	none	local	NA	3	5	15	5
Nakae2000_2.5ip ²⁸⁹	rabbit	NR	m	none	local	NA	1	3	3	20
Nakae2000_5ip ²⁸⁹	rabbit	NR	m	none	local	NA	1	5	5	20
Nakano1997_3ip ²⁹⁰	rabbit	NR	m	none	local	NA	1	3	3	5
Nakano1997_5ip ²⁹⁰	rabbit	NR	m	none	local	NA	1	5	5	5
Naumenko2010 ²⁹¹	rat	NR	m	none	local	NA	3	3	9	3
Nawada1997 ²⁹²	rabbit	NR	f	none	local	NA	1	5	5	10
Neckar2002_2cy ²⁹³	rat	NR	m	none	local	NA	2	5	10	5
Neckar2002_5cy ²⁹³	rat	NR	m	none	local	NA	5	5	25	5
Nieszner2002_diabetic ²⁹⁴	rabbit	NR	m	diabetes	local	NA	3	2	6	2

Supplemental table A - study and comparison characteristics - page 16 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Nieszner2002_healthy ²⁹⁴	rabbit	NR	m	none	local	NA	3	2	6	2
Nishihara2006 ²⁹⁵	rat	NR	m	none	local	NA	1	5	5	5
Nithipatikom2006a ²⁹⁶	dog	NR	m/f	none	local	NA	1	5	5	10
Nithipatikom2006b ²⁹⁷	dog	NR	m/f	none	local	NA	1	5	5	10
Node1997 ²⁹⁸	dog	NR	m/f	none	local	NA	4	5	20	5
Nozawa1999 ²⁹⁹	rabbit	NR	NR	none	local	NA	1	2	2	5
Nozawa2003_ip20 ³⁰⁰	rat	NR	m	none	local	NA	2	5	10	20
Nozawa2003_ip5 ³⁰⁰	rat	NR	m	none	local	NA	2	5	10	5
Okamura1999 ³⁰¹	rat	NR	m	none	local	NA	3	3	9	3
Okubo2000 ³⁰²	rabbit	NR	m	none	local	NA	4	5	20	1440
Okubo2004a ³⁰³	rabbit	NR	m	none	local	NA	4	5	20	10
Okubo2004b_ip10 ³⁰⁴	rabbit	NR	m	none	local	NA	4	5	20	10
Okubo2004b_ip24h ³⁰⁴	rabbit	NR	m	none	local	NA	4	5	20	1440
Ovize1992_60is ³⁰⁵	dog	yes	m/f	none	local	NA	4	3	12	5
Ovize1992_90is ³⁰⁵	dog	yes	m/f	none	local	NA	4	3	12	5
Ovize1995_05ip ³⁰⁶	pig	NR	m/f	none	local	NA	1	5	5	10
Ovize1995_10ip ³⁰⁶	pig	NR	m/f	none	local	NA	1	10	10	10
Pagel2007 ³⁰⁷	rabbit	NR	m	none	local	NA	3	5	15	5
Patel2001 ³⁰⁸	rat	NR	m	none	local	NA	1	5	5	5
Patel2002_1cy ³⁰⁹	rat	NR	m	none	local	NA	1	15	15	5
Patel2002_3cy ³⁰⁹	rat	NR	m	none	local	NA	3	5	15	5
Patel2005 ³¹⁰	rat	NR	m	none	local	NA	3	5	15	1440
Peart2003 ³¹¹	dog	NR	NR	none	local	NA	1	5	5	10
Pell1998 ³¹²	rabbit	yes	m	none	remote	RAO	1	10	10	10
Perricone2013 ³¹³	mouse	NR	m	none	local	NA	3	5	15	5
Petrishev2006_IPC ³¹⁴	rat	NR	NR	none	local	NA	4	3	12	6
Petrishev2006_RIPC ³¹⁴	rat	NR	NR	none	remote	MAO	1	20	20	15
Ping1999 ³¹⁵	rabbit	NR	NR	none	local	NA	6	4	24	1440
Ping2002 ³¹⁶	mouse	NR	NR	none	local	NA	6	4	24	1440
Piot1997 ³¹⁷	rat	NR	f	none	local	NA	5	5	25	5
Poulsen2014 ³¹⁸	pig	NR	f	none	local	NA	2	10	20	30

Supplemental table A - study and comparison characteristics - page 17 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Przyklenk1993 ³¹⁹	dog	yes	NR	none	remote	LCX	4	5	20	5
Przyklenk1995 ³²⁰	dog	NR	NR	none	local	NA	4	5	20	5
Przyklenk1996 ³²¹	dog	NR	NR	none	local	NA	4	5	20	5
Przyklenk1997 ³²²	dog	NR	NR	none	local	NA	1	10	10	30
Przyklenk2001_adult ³²³	rabbit	NR	NR	none	local	NA	1	5	5	10
Przyklenk2001_middle ³²³	rabbit	NR	NR	middle-age	local	NA	1	5	5	10
Przyklenk2001_old ³²³	rabbit	NR	NR	senescence	local	NA	1	5	5	10
Przyklenk2003_adult ³²⁴	rabbit	NR	m/f	none	local	NA	1	5	5	10
Przyklenk2003_old ³²⁴	rabbit	NR	m/f	senescence	local	NA	1	5	5	10
Qian1996 ³²⁵	rat	NR	NR	none	local	NA	1	5	5	5
Qian1999_1cy ³²⁶	rat	NR	m	none	local	NA	1	5	5	10
Qian1999_1cy24h ³²⁶	rat	NR	m	none	local	NA	1	5	5	1440
Qian1999_2cy24h ³²⁶	rat	NR	m	none	local	NA	2	5	10	1440
Qian1999_3cy ³²⁶	rat	NR	m	none	local	NA	3	5	15	10
Qian1999_3cy24h ³²⁶	rat	NR	m	none	local	NA	3	5	15	1440
Qian1999_3cy48h ³²⁶	rat	NR	m	none	local	NA	3	5	15	2880
Qiu1997a ³²⁷	rabbit	NR	m	none	local	NA	6	4	24	1440
Qiu1997b_25cy ³²⁸	pig	NR	m/f	none	local	NA	25	2	50	1440
Qiu1997b_ip24h ³²⁸	pig	NR	m/f	none	local	NA	10	2	20	1440
Qiu1997b_ip25 ³²⁸	pig	NR	m/f	none	local	NA	10	2	20	25
Rajesh2003_ip10 ³²⁹	rat	NR	m	cardiac hypertrophy	local	NA	4	3	12	10
Rajesh2003_ip24h ³²⁹	rat	NR	m	cardiac hypertrophy	local	NA	4	3	12	1440
Rajesh2003_ip5h ³²⁹	rat	NR	m	cardiac hypertrophy	local	NA	4	3	12	300
Rajesh2004_healthy ³³⁰	rat	NR	m	none	local	NA	4	3	12	10
Rajesh2004_hypertr ³³⁰	rat	NR	m	cardiac hypertrophy	local	NA	4	3	12	10
Raphael2005 ³³¹	rabbit	NR	NR	none	local	NA	1	5	5	10
Redel2009_3cy ³³²	mouse	NR	m	none	local	NA	3	5	15	40
Redel2009_6cy ³³²	mouse	NR	m	none	local	NA	6	5	30	40
Reffelmann2003 ³³³	rabbit	NR	m	none	local	NA	1	5	5	10
Ren2004 ³³⁴	mouse	NR	m/f	none	local	NA	6	4	24	1440
Richard1993 ³³⁵	rat	NR	m	none	local	NA	3	5	15	5

Supplemental table A - study and comparison characteristics - page 18 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Richard1994 ³³⁶	rat	NR	m	none	local	NA	3	5	15	5
Rioufol1997 ³³⁷	pig	NR	NR	none	local	NA	1	10	10	10
Rivo2006 ³³⁸	rabbit	NR	NR	none	local	NA	1	5	5	10
Roesner2007 ³³⁹	pig	yes	m	none	local	NA	1	10	10	15
Roesner2010 ³⁴⁰	pig	yes	m	none	local	NA	1	10	10	15
Rohmann1994 ³⁴¹	pig	NR	m/f	none	local	NA	1	10	10	15
Sack1993_ip30 ³⁴²	pig	NR	m	none	local	NA	2	10	20	30
Sack1993_ip4dip ³⁴²	pig	NR	m	none	local	NA	4	10	40	30
Sack1993_ip60 ³⁴²	pig	NR	m	none	local	NA	2	10	20	60
Sack1993_ip60ip ³⁴²	pig	NR	m	none	local	NA	4	10	40	30
Sanada2001a_exp1 ³⁴³	dog	NR	NR	none	local	NA	4	5	20	5
Sanada2001a_exp2 ³⁴³	dog	NR	NR	none	local	NA	4	5	20	5
Sanada2001b ³⁴⁴	dog	NR	NR	none	local	NA	4	5	20	5
Sanada2004 ³⁴⁵	dog	NR	NR	none	local	NA	1	5	5	25
Sandhu1997_3cy ³⁴⁶	rabbit	NR	m/f	none	local	NA	3	5	15	10
Sandhu1997_lstab ³⁴⁶	rabbit	NR	m/f	none	local	NA	1	5	5	10
Sandhu1997_sstab ³⁴⁶	rabbit	NR	m/f	none	local	NA	1	5	5	10
Sanz1995 ³⁴⁷	pig	NR	NR	none	local	NA	2	5	10	5
Sarkar2012 ³⁴⁸	mouse	NR	NR	none	local	NA	2	5	10	5
Sasamori2006 ³⁴⁹	dog	NR	m/f	none	local	NA	4	5	20	5
Sato2007_45is ³⁵⁰	rat	NR	m	none	local	NA	12	2	24	1440
Sato2007_60is ³⁵⁰	rat	NR	m	none	local	NA	12	2	24	1440
Sbarouni2006_healthy ³⁵¹	rabbit	NR	f	none	local	NA	2	5	10	10
Sbarouni2006_ovx ³⁵¹	rabbit	NR	f	ovariectomy	local	NA	2	5	10	10
Schmidt2014 ³⁵²	pig	NR	m/f	none	remote	hind limb	4	5	20	5
Schoemaker2000_IPC ³⁵³	rat	NR	m	none	local	NA	1	15	15	10
Schoemaker2000_RIPC ³⁵³	rat	NR	m	none	remote	MAO	1	15	15	10
Schott1990 ³⁵⁴	pig	NR	m	none	local	NA	1	10	10	30
Schultz1995 ³⁵⁵	rat	NR	m	none	local	NA	3	5	15	5
Schultz1996 ³⁵⁶	rat	NR	m	none	local	NA	3	5	15	5
Schultz1997a ³⁵⁷	rat	NR	NR	none	local	NA	1	5	5	10

Supplemental table A - study and comparison characteristics - page 19 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Schultz1997b ³⁵⁸	rat	NR	m	none	local	NA	3	5	15	5
Schultz1997c ³⁵⁹	rat	NR	m	none	local	NA	3	5	15	5
Schultz1997d ³⁶⁰	rat	NR	m	none	local	NA	3	5	15	5
Schultz1998a_1cy ³⁶¹	rat	NR	m	none	local	NA	1	5	5	20
Schultz1998a_3cy ³⁶¹	rat	NR	m	none	local	NA	3	5	15	5
Schultz1998b_exp1 ³⁶²	rat	NR	m	none	local	NA	3	5	15	5
Schultz1998b_exp2 ³⁶²	rat	NR	m	none	local	NA	3	5	15	5
Schultz1998c ³⁶³	rat	NR	m	none	local	NA	3	5	15	5
Schulz1994 ³⁶⁴	pig	NR	m/f	none	local	NA	1	10	10	15
Schwartz1997 ³⁶⁵	dog	none	m/f	none	local	NA	1	5	5	10
Schwartz2001_2cy ³⁶⁶	dog	NR	m/f	none	local	NA	2	10	20	10
Schwartz2001_ip10 ³⁶⁶	dog	NR	m/f	none	local	NA	1	10	10	10
Schwartz2001_ip2h ³⁶⁶	dog	NR	m/f	none	local	NA	1	10	10	120
Schwartz2001_ip3h ³⁶⁶	dog	NR	m/f	none	local	NA	1	10	10	180
Schwartz2001_ip5h ³⁶⁶	dog	NR	m/f	none	local	NA	1	10	10	300
Schwartz2002 ³⁶⁷	pig	NR	m/f	none	local	NA	2	5	10	10
Schwarz1997 ³⁶⁸	pig	NR	m	none	local	NA	2	10	20	30
Schwarz1998_ip24h ³⁶⁹	pig	NR	m	none	local	NA	2	10	20	1440
Schwarz1998_ip30 ³⁶⁹	pig	NR	m	none	local	NA	2	10	20	30
Schwarz1998_ip5h ³⁶⁹	pig	NR	m	none	local	NA	2	10	20	300
Schwarz1998_ip60 ³⁶⁹	pig	NR	m	none	local	NA	2	10	20	60
Schwarz1998_ip90 ³⁶⁹	pig	NR	m	none	local	NA	2	10	20	90
Sebbag1996 ³⁷⁰	dog	yes	m/f	none	local	NA	4	5	20	5
Shahid2008 ³⁷¹	rat	NR	m	none	remote	hind limb	1	15	15	10
Shattock1996 ³⁷²	pig	NR	m	none	local	NA	2	8	16	8
Shekarforoush2011 ³⁷³	rat	NR	m	none	local	NA	1	5	5	NR
Sheldrick1999 ³⁷⁴	rabbit	NR	m	none	local	NA	1	5	5	10
Shen2008 ³⁷⁵	pig	NR	f	none	local	NA	2	10	20	1440
Shen2013 ³⁷⁶	rat	NR	m	none	local	NA	3	7	21	10
Shinmura2000 ³⁷⁷	rabbit	NR	m	none	local	NA	6	4	24	1440
Shinmura2002 ³⁷⁸	rabbit	NR	m	none	local	NA	6	4	24	1440

Supplemental table A - study and comparison characteristics - page 20 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Shintani2004 ³⁷⁹	dog	NR	NR	none	local	NA	4	5	20	5
Singh2000 ³⁸⁰	rat	NR	m/f	none	local	NA	4	5	20	1440
Singh2004 ³⁸¹	rat	NR	m/f	none	remote	RAO	4	5	20	10
Sivarajah2005 ³⁸²	rat	NR	m	none	local	NA	2	5	10	5
Sivarajah2006 ³⁸³	rat	NR	m	none	local	NA	2	5	10	5
Smits1998 ³⁸⁴	pig	NR	m/f	none	local	NA	2	5	10	10
Smul2011 ³⁸⁵	rabbit	NR	m	none	local	NA	1	5	5	30
Speechly-Dick1994a ³⁸⁶	rat	NR	m	none	local	NA	1	5	5	10
Speechly-Dick1994b_healthy ³⁸⁷	rat	NR	m	none	local	NA	1	5	5	10
Speechly-Dick1994b_hypert ³⁸⁷	rat	NR	m	hypertension	local	NA	1	5	5	10
Strohm2000 ³⁸⁸	pig	NR	m	none	local	NA	2	10	20	10
Su2006 ³⁸⁹	rat	NR	m	none	local	NA	2	5	10	5
Suzuki1998_2ip ³⁹⁰	rabbit	NR	m	none	local	NA	1	2	2	5
Suzuki1998_3ip ³⁹⁰	rabbit	NR	m	none	local	NA	1	3	3	5
Takano1998a ³⁹¹	rabbit	NR	m	none	local	NA	6	4	24	1440
Takano1998b ³⁹²	rabbit	NR	m	none	local	NA	6	4	24	1440
Takano2000a ³⁹³	rabbit	NR	m	none	local	NA	6	4	24	1440
Takano2000b ³⁹⁴	rabbit	NR	m	none	local	NA	6	4	24	1440
Takaoka1999_IPC ³⁹⁵	rabbit	NR	m	none	local	NA	1	5	5	20
Takaoka1999_RIPC ³⁹⁵	rabbit	NR	m	none	remote	RAO	1	10	10	20
Takasaki1998 ³⁹⁶	rat	NR	m	none	local	NA	3	5	15	5
Talukder2010_f30is ³⁹⁷	mouse	NR	f	none	local	NA	3	5	15	5
Talukder2010_f60is ³⁹⁷	mouse	NR	f	none	local	NA	3	5	15	5
Talukder2010_m30is ³⁹⁷	mouse	NR	m	none	local	NA	3	5	15	5
Talukder2010_m60is ³⁹⁷	mouse	NR	m	none	local	NA	3	5	15	5
Tanaka1994a_4cy24h ³⁹⁸	rabbit	NR	m	none	local	NA	4	5	20	1440
Tanaka1994a_4cy48h ³⁹⁸	rabbit	NR	m	none	local	NA	4	5	20	2880
Tanaka1994a_ip24h ³⁹⁸	rabbit	NR	m	none	local	NA	1	5	5	1440
Tanaka1994a_ip2h ³⁹⁸	rabbit	NR	m	none	local	NA	1	5	5	120
Tanaka1994a_ip5 ³⁹⁸	rabbit	NR	m	none	local	NA	1	5	5	5
Tanaka1994b ³⁹⁹	rabbit	NR	m	none	local	NA	1	5	5	5

Supplemental table A - study and comparison characteristics - page 21 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Tang2004 ⁴⁰⁰	rabbit	NR	m	none	local	NA	6	4	24	1440
Tang2005_exp1 ⁴⁰¹	rabbit	NR	m	none	local	NA	6	4	24	1440
Tang2005_exp2 ⁴⁰¹	rabbit	NR	m	none	local	NA	6	4	24	1440
Tang2005_hyperchol ⁴⁰¹	rabbit	NR	m	hypercholesterolemia	local	NA	6	4	24	1440
Tang2006_ip2_30is ⁴⁰²	rat	NR	m	none	local	NA	12	2	24	2
Tang2006_ip2_45is ⁴⁰²	rat	NR	m	none	local	NA	12	2	24	2
Tang2006_ip2_60is ⁴⁰²	rat	NR	m	none	local	NA	12	2	24	2
Tang2006_ip24h_30is ⁴⁰²	rat	NR	m	none	local	NA	12	2	24	1440
Tang2006_ip24h_45is ⁴⁰²	rat	NR	m	none	local	NA	12	2	24	1440
Tang2006_ip24h_60is ⁴⁰²	rat	NR	m	none	local	NA	12	2	24	1440
Tanhehco2000 ⁴⁰³	rabbit	NR	m	none	local	NA	2	5	10	10
Tanno2000_1cy ⁴⁰⁴	rat	NR	m	none	local	NA	1	5	5	5
Tanno2000_2cyexp1 ⁴⁰⁴	rat	NR	m	none	local	NA	2	5	10	5
Tanno2000_2cyexp2 ⁴⁰⁴	rat	NR	m	none	local	NA	2	5	10	5
Tanno2000_2cyexp3 ⁴⁰⁴	rat	NR	m	none	local	NA	2	5	10	5
Tanno2000_2cyexp4 ⁴⁰⁴	rat	NR	m	none	local	NA	2	5	10	5
Thornton1990 ⁴⁰⁵	rabbit	NR	m/f	none	local	NA	2	5	10	10
Thornton1992 ⁴⁰⁶	rabbit	NR	m/f	none	local	NA	2	5	10	10
Thornton1993a ⁴⁰⁷	rabbit	NR	m/f	none	local	NA	1	5	5	10
Thornton1993b ⁴⁰⁸	rabbit	NR	m/f	none	local	NA	1	5	5	10
Thornton1993c ⁴⁰⁹	rabbit	NR	m/f	none	local	NA	2	5	10	10
Tissier2001 ⁴¹⁰	rabbit	NR	m	none	local	NA	6	4	24	1440
Tissier2002_3drep ⁴¹¹	rabbit	NR	m	none	local	NA	6	4	24	1440
Tissier2002_3drep_hist ⁴¹¹	rabbit	NR	m	none	local	NA	6	4	24	1440
Tissier2002_3hrep ⁴¹¹	rabbit	NR	m	none	local	NA	6	4	24	1440
Toller1999 ⁴¹²	dog	NR	m/f	none	local	NA	1	2	2	60
Toombs1993a ⁴¹³	rabbit	NR	m/f	none	local	NA	1	5	5	10
Toufektsian2003 ⁴¹⁴	rat	NR	m	none	local	NA	1	5	5	5
Toyoda2000_30is ⁴¹⁵	sheep	NR	m/f	none	local	NA	1	5	5	5
Toyoda2000_45is ⁴¹⁵	sheep	NR	m/f	none	local	NA	1	5	5	5
Toyoda2000_60is ⁴¹⁵	sheep	NR	m/f	none	local	NA	1	5	5	5

Supplemental table A - study and comparison characteristics - page 22 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Tranter2010 ⁴¹⁶	mouse	NR	m/f	none	local	NA	6	4	24	1440
Tsovolas2008 ⁴¹⁷	rabbit	NR	m	none	local	NA	2	5	10	10
Tsuchida1992 ⁴¹⁸	rabbit	NR	m	none	local	NA	1	5	5	5
Tsuchida1994a ⁴¹⁹	rabbit	NR	m/f	none	local	NA	1	5	5	10
Tsuchida1994b ⁴²⁰	rabbit	NR	m/f	none	local	NA	1	5	5	120
Tsuchida1998_20is ⁴²¹	rat	NR	m	none	local	NA	2	5	10	5
Tsuchida1998_30is ⁴²¹	rat	NR	m	none	local	NA	2	5	10	5
Tsuchida1998_40is ⁴²¹	rat	NR	m	none	local	NA	2	5	10	5
Turan2008 ⁴²²	rat	NR	m	none	local	NA	1	5	5	10
Ueda1999_healthy ⁴²³	rabbit	NR	NR	none	local	NA	1	5	5	10
Ueda1999_hyperchol ⁴²³	rabbit	NR	NR	hypercholesterolemia	local	NA	1	5	5	10
Uematsu1998 ⁴²⁴	sheep	NR	m/f	none	local	NA	1	5	5	5
Valtchanova2004_ip24h ⁴²⁵	rat	NR	m	none	local	NA	3	5	15	1440
Valtchanova2004_ip5 ⁴²⁵	rat	NR	m	none	local	NA	3	5	15	5
Valtchanova-Matchouganska2003 ⁴²⁶	rat	NR	m	none	local	NA	3	5	15	5
VandenDoe1998_030is ⁴²⁷	rat	NR	m	none	local	NA	1	15	15	10
VandenDoe1998_045is ⁴²⁷	rat	NR	m	none	local	NA	1	15	15	10
VandenDoe1998_060is ⁴²⁷	rat	NR	m	none	local	NA	1	15	15	10
VandenDoe1998_120is ⁴²⁷	rat	NR	m	none	local	NA	1	15	15	10
VanderHeide1994 ⁴²⁸	dog	yes	m/f	none	local	NA	4	5	20	5
VanWinkle1994b ⁴²⁹	pig	yes	NR	none	local	NA	2	10	20	10
VanWylen1994 ⁴³⁰	dog	yes	m/f	none	local	NA	2	5	10	10
Vetterlein2006 ⁴³¹	rat	NR	m	none	local	NA	3	5	15	10
Vincent2012 ⁴³²	mouse	NR	m	none	local	NA	3	1	3	10
Virag2013 ⁴³³	mouse	NR	f	none	local	NA	3	5	15	5
Vladic2011_mouse ⁴³⁴	mouse	NR	m	hyperglycaemia	local	NA	4	5	20	5
Vladic2011_rbhealthy ⁴³⁴	rabbit	NR	m	hyperglycaemia	local	NA	1	5	5	15
Vladic2011_rbhypergly ⁴³⁴	rabbit	NR	m	hyperglycaemia	local	NA	1	5	5	15
Vogt1998_ip30 ⁴³⁵	pig	NR	m	none	local	NA	2	10	20	30
Vogt1998_ip60 ⁴³⁵	pig	NR	m	none	local	NA	2	10	20	60
Vogt1998_ip60ip ⁴³⁵	pig	NR	m	none	local	NA	4	10	40	30

Supplemental table A - study and comparison characteristics - page 23 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Vogt2001_1cy ⁴³⁶	pig	NR	m	none	local	NA	1	10	10	30
Vogt2001_2cy ⁴³⁶	pig	NR	m	none	local	NA	2	10	20	30
Wall1994 ⁴³⁷	rabbit	NR	m/f	none	local	NA	1	5	5	10
Walsh1994 ⁴³⁸	rabbit	NR	NR	none	local	NA	1	5	5	10
Wang2001 ⁴³⁹	rat	NR	m	none	remote	MAO	1	30	30	1440
Wang2002 ⁴⁴⁰	rat	NR	m	none	remote	MAO	1	25	25	15
Wang2009 ⁴⁴¹	rat	NR	m	none	remote	hind limb	3	5	15	5
Wang2004 ⁴⁴²	sheep	NR	m	none	local	NA	3	5	15	10
WangY2004_ip24h ⁴⁴³	rabbit	NR	m	none	local	NA	6	4	24	1440
WangY2004_ip72h ⁴⁴³	rabbit	NR	m	none	local	NA	6	4	24	4320
Watanabe2006 ⁴⁴⁴	rat	NR	m	coronary stenosis	local	NA	2	5	10	5
Weber2005 ⁴⁴⁵	rat	NR	m	none	local	NA	3	5	15	5
Weber2008 ⁴⁴⁶	rat	NR	m	none	local	NA	1	5	5	1440
Weinbrenner2002_IPC ⁴⁴⁷	rat	NR	m	none	local	NA	3	5	15	5
Weinbrenner2002_RIPC05 ⁴⁴⁷	rat	NR	m	none	remote	IAO	1	5	5	10
Weinbrenner2002_RIPC10 ⁴⁴⁷	rat	NR	m	none	remote	IAO	1	10	10	10
Weinbrenner2002_RIPC15 ⁴⁴⁷	rat	NR	m	none	remote	IAO	1	15	15	10
Weinbrenner2004_1cy ⁴⁴⁸	rat	NR	m	none	local	NA	1	5	5	5
Weinbrenner2004_3cy ⁴⁴⁸	rat	NR	m	none	local	NA	3	5	15	5
Weinbrenner2004_RIPC ⁴⁴⁸	rat	NR	m	none	remote	IAO	1	15	15	10
Wolfe1993_ip30 ⁴⁴⁹	rat	NR	m	none	local	NA	4	5	20	30
Wolfe1993_ip360 ⁴⁴⁹	rat	NR	m	none	local	NA	4	5	20	360
Wolfe1993_ip5 ⁴⁴⁹	rat	NR	m	none	local	NA	4	5	20	5
Wolfe1993_ip60 ⁴⁴⁹	rat	NR	m	none	local	NA	4	5	20	60
Wolfrum2002 ⁴⁵⁰	rat	NR	m	none	remote	MAO	1	15	15	15
Wolfrum2005 ⁴⁵¹	rat	NR	m	none	remote	MAO	1	15	15	15
Wong2010 ⁴⁵²	rat	NR	m	none	local	NA	3	5	15	5
Wong2012_IPC1 ⁴⁵³	rat	NR	m	none	local	NA	3	5	15	5
Wong2012_IPC2 ⁴⁵³	rat	NR	m	none	local	NA	3	5	15	5
Wong2012_RIPC1 ⁴⁵³	rat	NR	m	none	remote	hind limb	3	5	15	5
Wong2012_RIPC2 ⁴⁵³	rat	NR	m	none	remote	hind limb	3	5	15	5

Supplemental table A - study and comparison characteristics - page 24 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Wu2001 ⁴⁵⁴	rabbit	NR	m	none	local	NA	1	5	5	5
Wu2008a ⁴⁵⁵	rat	NR	m	diabetes	local	NA	3	5	15	5
Wu2008b_IPC ⁴⁵⁶	rat	NR	m	none	local	NA	3	5	15	5
Wu2008b_RIPC ⁴⁵⁶	rat	NR	m	none	remote	hind limb	9	5	45	1440
Wu2009 ⁴⁵⁷	rat	NR	m	diabetes	local	NA	3	5	15	5
Wu2011_IPC ⁴⁵⁸	rat	NR	m	none	local	NA	3	5	15	5
Wu2011_RIPC ⁴⁵⁸	rat	NR	m	none	remote	hind limb	9	5	45	1440
Wu2013 ⁴⁵⁹	rabbit	NR	NR	none	local	NA	2	10	20	10
Xiang2011_early ⁴⁶⁰	mouse	NR	m	none	local	NA	3	4	12	4
Xiang2011_late24hR ⁴⁶⁰	mouse	NR	m	none	local	NA	3	4	12	1440
Xiang2011_late40R ⁴⁶⁰	mouse	NR	m	none	local	NA	3	4	12	1440
Xiao2001_ip24h ⁴⁶¹	rat	NR	m	none	local	NA	6	4	24	1440
Xiao2001_ip48h ⁴⁶¹	rat	NR	m	none	local	NA	6	4	24	2880
Xiao2001_ip72h ⁴⁶¹	rat	NR	m	none	local	NA	6	4	24	4320
Xiong2011 ⁴⁶²	rat	NR	m	none	local	NA	3	5	15	5
Xu2001 ⁴⁶³	rabbit	NR	m/f	none	local	NA	3	5	15	20
Xu2002 ⁴⁶⁴	rabbit	NR	m/f	none	local	NA	1	5	5	10
Xu2006 ⁴⁶⁵	rabbit	NR	m/f	none	local	NA	1	5	5	10
Xu2010 ⁴⁶⁶	rat	NR	m	none	local	NA	3	5	15	1440
Xu2013 ⁴⁶⁷	rabbit	NR	m/f	none	local	NA	1	5	5	10
Xuan2007 ⁴⁶⁸	mouse	NR	NR	none	local	NA	6	4	24	4
Yada2006 ⁴⁶⁹	dog	yes	m/f	none	local	NA	4	5	20	5
Yamada2002_2ip ⁴⁷⁰	rabbit	NR	m	none	local	NA	1	2	2	10
Yamada2002_5ip ⁴⁷⁰	rabbit	NR	m	none	local	NA	1	5	5	10
Yamasaki1997_05ip ⁴⁷¹	rabbit	NR	m	none	local	NA	1	5	5	5
Yamasaki1997_10ip ⁴⁷¹	rabbit	NR	m	none	local	NA	1	10	10	5
Yamasaki1997_15ip ⁴⁷¹	rabbit	NR	m	none	local	NA	1	15	15	5
Yamasaki2000_45is ⁴⁷²	rabbit	NR	m	none	local	NA	1	5	5	5
Yamasaki2000_50is ⁴⁷²	rabbit	NR	m	none	local	NA	1	5	5	5
Yamasaki2000_ip005 ⁴⁷²	rabbit	NR	m	none	local	NA	1	5	5	5
Yamasaki2000_ip040 ⁴⁷²	rabbit	NR	m	none	local	NA	1	5	5	40

Supplemental table A - study and comparison characteristics - page 25 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
Yamasaki2000_ip120 ⁴⁷²	rabbit	NR	m	none	local	NA	1	5	5	120
Yamashita1998_ip10 ⁴⁷³	rat	NR	m	none	local	NA	4	3	12	10
Yamashita1998_ip24h ⁴⁷³	rat	NR	m	none	local	NA	4	3	12	1440
Yamashita1998_ip3h ⁴⁷³	rat	NR	m	none	local	NA	4	3	12	180
Yamashita2000 ⁴⁷⁴	rat	NR	m	none	local	NA	4	3	12	1440
Yang1993_1cy ⁴⁷⁵	rabbit	NR	m/f	none	local	NA	1	5	5	120
Yang1993_2cy ⁴⁷⁵	rabbit	NR	m/f	none	local	NA	2	5	10	10
Yang1996 ⁴⁷⁶	rabbit	none	NR	none	local	NA	4	5	20	1440
Yang2006 ⁴⁷⁷	pig	NR	NR	none	local	NA	3	10	30	5
Yang2010 ⁴⁷⁸	macaque	NR	m	none	local	NA	2	10	20	10
Yang2011 ⁴⁷⁹	rat	NR	m	none	local	NA	4	3	12	5
YangX2013 ⁴⁸⁰	rat	NR	m	none	local	NA	3	5	15	5
YangZ2013 ⁴⁸¹	mouse	NR	NR	none	local	NA	2	5	10	5
Yao1993a ⁴⁸²	dog	NR	m/f	none	local	NA	1	10	10	10
Yao1993b ⁴⁸³	dog	NR	m/f	none	local	NA	1	10	10	10
Yao1994a_ip10 ⁴⁸⁴	dog	NR	m/f	none	local	NA	1	10	10	10
Yao1994a_ip60 ⁴⁸⁴	dog	NR	m/f	none	local	NA	1	10	10	60
Yao1994b_10ip ⁴⁸⁵	dog	NR	m/f	none	local	NA	1	10	10	10
Yao1994b_3ip ⁴⁸⁵	dog	NR	m/f	none	local	NA	1	3	3	10
Yao1997 ⁴⁸⁶	dog	NR	m/f	none	local	NA	1	10	10	60
Yellow1992 ⁴⁸⁷	rat	NR	m	none	local	NA	1	5	5	10
Yorozuya2004_1cy ⁴⁸⁸	rabbit	NR	m	none	local	NA	1	5	5	5
Yorozuya2004_4cy ⁴⁸⁸	rabbit	NR	m	none	local	NA	4	5	20	5
Ytrehus1994 ⁴⁸⁹	rabbit	NR	m/f	none	local	NA	1	5	5	10
Yu2007 ⁴⁹⁰	rat	NR	m	none	local	NA	3	5	15	1440
Yu2010 ⁴⁹¹	rat	NR	NR	none	local	NA	12	5	60	NR
Yu2011 ⁴⁹²	rat	NR	m	none	local	NA	2	5	10	5
Zacharowski2007 ⁴⁹³	rat	none	m	none	local	NA	3	2	6	10
Zhang2004 ⁴⁹⁴	rat	NR	m	none	local	NA	3	5	15	5
Zhang2010 ⁴⁹⁵	rat	NR	f	none	local	NA	2	5	10	5
ZhangS2006 ⁴⁹⁶	rat	NR	m	none	local	NA	3	5	15	5

Supplemental table A - study and comparison characteristics - page 26 of 26

comparison	species	opioids pre-IPC	sex (m/f)	condition / comorbidity	site of IPC	remote organ	IPC # ischemic cycli	IPC ischemic cycle (min)	IPC total ischemia (min)	IPC to IRI delay (min)
ZhangX2006 ⁴⁹⁷	rabbit	NR	m/f	none	local	NA	3	5	15	5
Zhao2003 ⁴⁹⁸	dog	yes	m/f	none	local	NA	1	5	5	10
Zhao2012_ip24h ⁴⁹⁹	rat	NR	m	none	local	NA	3	5	15	1440
Zhao2012_ip5 ⁴⁹⁹	rat	NR	m	none	local	NA	3	5	15	5
Zhu2007 ⁵⁰⁰	mouse	NR	m	none	local	NA	3	5	15	15
Zhu2009_IPC ⁵⁰¹	rat	NR	NR	diabetes	local	NA	3	5	15	5
Zhu2009_RIPC ⁵⁰¹	rat	NR	NR	diabetes	remote	hind limb	9	5	45	5
Zhu2011_IPC ⁵⁰²	rat	NR	m	diabetes	local	NA	3	5	15	5
Zhu2011_RIPC ⁵⁰²	rat	NR	m	diabetes	remote	hind limb	9	5	45	5
Zhu2013 ⁵⁰³	rat	NR	m	none	remote	hind limb	3	5	15	5

Meta-analysis includes data from 785 independent comparisons identified from 503 studies. Multiple comparisons from a single study are indicated by an underscore followed by a comparison code. IPC = ischemic preconditioning, m = male, f = female, IRI = ischemia-reperfusion injury, NR = not reported, NA = not applicable, IAO = infrarenal aorta occlusion, RAO = renal artery occlusion, MAO = mesenteric artery occlusion, LCX = left circumflex coronary artery occlusion.

Supplemental Table B - study quality and risk of bias - page 1 of 12

study	reporting - randomization	reporting - blinding	reporting - powercalculation	bias - random group allocation	bias - groups similar at baseline	bias - blinded group allocation	bias - random housing	bias - blind intervention	bias - random outcome assessment	bias - blind outcome assessment	bias - reporting of drop-outs	bias - other
Alcindor2004 ¹	Y	N	N	?	?	?	?	?	?	?	L	L
Alizadeh2011 ²	N	N	N	?	L	?	?	?	?	?	H	L
Alkhulaifi1993 ³	Y	N	N	?	?	?	?	?	?	?	?	L
Amour2009 ⁴	Y	N	N	?	L	?	?	?	?	?	H	H
Andreadou2004 ⁵	Y	N	N	?	?	?	?	?	?	?	L	L
Andreadou2006 ⁶	Y	N	N	?	?	?	?	?	?	?	L	L
Andreadou2011 ⁷	Y	N	N	?	?	?	?	?	?	?	?	L
Aouam2005 ⁸	Y	N	N	?	L	?	?	?	?	?	H	H
Argaud2004 ⁹	Y	N	N	?	L	?	?	?	?	?	?	L
Argaud2005a ¹⁰	Y	N	N	?	L	?	?	?	?	?	?	L
Argaud2005b ¹¹	Y	Y	N	?	L	?	?	?	?	?	L	L
Argaud2005c ¹²	N	N	N	?	L	?	?	?	?	?	L	L
Argaud2008 ¹³	N	N	N	?	?	?	?	?	?	?	?	L
Auchampach1992 ¹⁴	N	N	N	?	?	?	?	?	?	?	?	L
Auchampach1993 ¹⁵	Y	N	N	?	?	?	?	?	?	?	L	L
Auchampach2004 ¹⁶	Y	N	N	?	?	?	?	?	?	?	H	L
Aye1999 ¹⁷	N	N	N	?	L	?	?	?	?	?	?	L
Baines1997 ¹⁸	N	N	N	?	?	?	?	?	?	?	?	L
Baines1999 ¹⁹	N	N	N	?	?	?	?	?	?	?	?	L
Barbosa1996 ²⁰	Y	N	N	?	L	?	?	?	?	?	?	L
Basalay2012 ²¹	N	N	N	?	L	?	?	?	?	?	H	L
Baumert2007 ²²	Y	Y	Y	?	?	?	?	?	?	?	L	L
Baxter1994 ²³	Y	N	N	?	?	?	?	?	?	?	?	L
Baxter1995 ²⁴	N	N	N	?	?	?	?	?	?	?	?	L
Baxter1997 ²⁵	Y	Y	N	?	?	?	?	?	?	?	?	L
Belosjorow1999 ²⁶	N	N	N	?	?	?	?	?	?	?	L	L
Belosjorow2003 ²⁷	N	N	N	?	?	?	?	?	?	?	L	L
Bencsik2010 ²⁸	N	N	N	?	?	?	?	?	?	?	?	L
Bernardo1999 ²⁹	Y	N	N	?	H	?	?	?	?	?	?	L
Bibli2013 ³⁰	Y	N	N	?	L	?	?	?	?	?	L	L
Blokhin2008a ³¹	N	N	N	?	?	?	?	?	?	?	L	L
Blokhin2008b ³²	N	N	N	?	?	?	?	?	?	?	H	L
Boengler2007 ³³	N	N	N	?	H	?	?	?	?	?	H	L
Brandenburger2012 ³⁴	Y	N	N	?	?	?	?	?	?	?	?	L
Bukhari1995 ³⁵	Y	N	N	?	?	?	?	?	?	?	?	L
Burckhartt1995 ³⁶	Y	N	N	?	?	?	?	?	?	?	L	L
Burns1996 ³⁷	N	N	N	?	?	?	?	?	?	?	?	L
Cai2008 ³⁸	N	N	N	?	L	?	?	?	?	?	?	L
Cai2013 ³⁹	N	N	N	?	?	?	?	?	?	?	?	L
Canyon2005 ⁴⁰	Y	N	N	?	?	?	?	?	?	?	H	L
Cason1997 ⁴¹	Y	N	N	L	?	?	?	?	?	?	L	L
Chazov2001 ⁴²	N	N	N	?	?	?	?	?	?	?	?	L
Chen1997 ⁴³	N	N	N	?	?	?	?	?	?	?	?	L
Chen2005 ⁴⁴	Y	Y	N	?	?	?	?	?	?	?	L	L
Chen2008 ⁴⁵	Y	N	N	?	L	?	?	?	?	?	?	L

Supplemental Table B - study quality and risk of bias - page 2 of 12

study	reporting - randomization	reporting - blinding	reporting - power/calculation	bias - random group allocation	bias - groups similar at baseline	bias - blinded group allocation	bias - random housing	bias - blind intervention	bias - random outcome assessment	bias - reporting of drop-outs	bias - other
Cheng2009 ⁴⁶	Y	N	N	?	?	?	?	?	?	?	L
Cheng2010a ⁴⁷	N	N	N	?	?	?	?	?	?	?	L
Cheng2010b ⁴⁸	N	N	N	?	?	?	?	?	?	?	L
Chiari2002 ⁴⁹	N	N	N	?	?	?	?	?	?	?	L
Chien1996 ⁵⁰	Y	N	N	?	L	?	?	?	?	L	L
Chien1999 ⁵¹	Y	N	N	H	?	?	?	?	?	H	L
Cohen1991 ⁵²	Y	N	N	?	?	?	?	?	?	L	L
Cohen1994 ⁵³	Y	N	N	?	?	?	?	?	?	L	L
Cohen1999 ⁵⁴	Y	N	N	?	?	?	?	?	?	L	L
Cohen2000 ⁵⁵	Y	Y	N	?	?	?	?	?	?	L	L
Colantonio2004 ⁵⁶	Y	Y	N	?	?	?	?	?	?	?	L
Dai2003 ⁵⁷	Y	N	N	?	L	?	?	?	?	L	L
Dai2009 ⁵⁸	Y	N	N	?	L	?	?	?	?	L	L
Dairaku2002 ⁵⁹	N	N	N	?	?	?	?	?	?	?	L
Daleau2001 ⁶⁰	N	N	N	?	L	?	?	?	?	?	L
Das2006 ⁶¹	N	N	N	?	L	?	?	?	?	?	L
Das2007 ⁶²	N	N	N	?	L	?	?	?	?	?	L
Das2012 ⁶³	Y	Y	N	?	L	?	?	?	L	L	L
Dawn2002 ⁶⁴	N	N	N	?	?	?	?	?	?	L	L
Dawn2004a ⁶⁵	N	N	N	?	?	?	?	?	?	L	L
Dawn2004b ⁶⁶	N	N	N	?	?	?	?	?	?	H	L
Demiryurek2005a ⁶⁷	N	N	N	?	L	?	?	?	?	L	L
Demiryurek2005b ⁶⁸	N	N	N	?	L	?	?	?	?	?	L
DePaulis2013 ⁶⁹	Y	N	N	?	L	?	?	?	?	?	L
Depre2010 ⁷⁰	N	N	N	?	?	?	?	?	?	L	L
Deuchar2007 ⁷¹	N	N	N	?	?	?	?	?	?	?	L
DeZeeuw2001 ⁷²	N	N	N	?	?	?	?	?	?	L	L
Ding2000 ⁷³	N	N	N	?	?	?	?	?	?	L	L
Ding2001 ⁷⁴	N	N	N	?	L	?	?	?	?	?	L
Dong2004 ⁷⁵	N	N	N	?	?	?	?	?	?	?	L
Ebel2003 ⁷⁶	Y	N	N	?	L	?	?	?	?	?	L
Ebel2009 ⁷⁷	Y	N	N	?	L	?	?	?	?	?	L
Eckle2006 ⁷⁸	N	N	N	?	?	?	?	?	?	?	L
Eckle2012 ⁷⁹	N	N	N	?	?	?	?	?	?	?	L
Erikson1996 ⁸⁰	Y	N	N	?	H	?	?	?	?	L	L
Fang2008 ⁸¹	Y	Y	N	?	?	?	?	?	?	?	L
Farhat2001 ⁸²	Y	N	N	?	?	?	?	?	?	?	L
Fisher2002 ⁸³	N	N	N	?	?	?	?	?	?	?	L
Flack3rd1991 ⁸⁴	N	N	N	?	?	?	?	?	?	?	L
Flaherty2008 ⁸⁵	N	N	N	?	L	?	?	?	?	H	L
Flynn2005 ⁸⁶	Y	Y	N	?	?	?	?	?	?	?	L
Fryer1998 ⁸⁷	Y	N	N	?	L	?	?	?	?	?	L
Fryer1999 ⁸⁸	Y	N	N	?	L	?	?	?	?	?	L
Fryer2000 ⁸⁹	Y	N	N	?	?	?	?	?	?	?	L
Fryer2001a ⁹⁰	N	N	N	?	L	?	?	?	?	?	L

Supplemental Table B - study quality and risk of bias - page 3 of 12

study	reporting - randomization	reporting - blinding	reporting - power/calculation	bias - random group allocation	bias - groups similar at baseline	bias - blinded group allocation	bias - random housing	bias - blind intervention	bias - random outcome assessment	bias - reporting of drop-outs	bias - other
Fryer2001b ⁹¹	N	N	N	?	L	?	?	?	?	?	L
Fryer2001c ⁹²	N	N	N	?	L	?	?	?	?	?	L
Fryer2002 ⁹³	Y	N	N	?	L	?	?	?	?	?	L
Fukuma2000 ⁹⁴	N	N	N	?	L	?	?	?	?	?	L
Galagudza2007a ⁹⁵	N	N	N	?	L	?	?	?	?	L	L
Galagudza2007b ⁹⁶	N	N	N	?	?	?	?	?	?	L	L
Galagudza2009 ⁹⁷	N	N	N	?	?	?	?	?	?	L	L
Gao2000 ⁹⁸	N	Y	N	?	?	?	?	?	?	L	L
Gao2003 ⁹⁹	Y	N	N	?	?	?	?	?	?	?	L
Gao2012 ¹⁰⁰	Y	N	N	?	?	?	?	?	?	L	L
Ge2011 ¹⁰¹	Y	N	N	?	?	?	?	?	?	?	L
Gerczuk2012 ¹⁰²	Y	N	N	?	L	?	?	?	?	L	L
Gho1996 ¹⁰³	N	N	N	?	?	?	?	?	?	L	L
Gomez2011 ¹⁰⁴	Y	N	N	?	?	?	?	?	?	?	L
Gomoll1996 ¹⁰⁵	N	N	N	?	L	?	?	?	?	?	L
Goto1993 ¹⁰⁶	Y	N	N	?	L	?	?	?	?	L	L
Gourine2005 ¹⁰⁷	Y	N	N	?	L	?	?	?	?	L	L
Gozal2005 ¹⁰⁸	Y	N	N	L	?	?	?	?	?	?	L
Griol-Charhbili2005 ¹⁰⁹	N	Y	N	?	L	?	?	?	?	?	L
Gross1992 ¹¹⁰	Y	N	N	?	?	?	?	?	?	L	L
Gross2009 ¹¹¹	N	N	N	H	?	?	?	?	?	L	L
Grover1992 ¹¹²	N	N	N	?	?	?	?	?	?	?	L
Grover1996 ¹¹³	N	N	N	?	?	?	?	?	?	L	L
Grund1997 ¹¹⁴	Y	N	N	?	?	?	?	?	?	L	L
Gu2008 ¹¹⁵	Y	N	N	?	?	?	?	?	?	L	L
Gumina1999 ¹¹⁶	Y	N	N	?	?	?	?	?	?	L	L
Gumina2001 ¹¹⁷	Y	N	N	?	?	?	?	?	?	L	L
Gumina2005 ¹¹⁸	N	N	N	?	?	?	?	?	?	L	L
Guo1998 ¹¹⁹	N	N	N	?	L	?	?	?	?	?	L
Guo1999 ¹²⁰	N	N	N	?	?	?	?	?	?	?	L
Guo2001 ¹²¹	N	N	N	?	L	?	?	?	?	?	L
Guo2007 ¹²²	N	N	N	?	?	?	?	?	?	?	L
Guo2012 ¹²³	N	N	N	?	L	?	?	?	?	L	L
Gysembergh1998 ¹²⁴	N	N	N	?	?	?	?	?	?	?	L
Haessler1994 ¹²⁵	Y	N	N	?	?	?	?	?	?	L	L
Haessler1997 ¹²⁶	Y	N	N	?	?	?	?	?	?	L	L
Hale1992 ¹²⁷	Y	N	N	?	L	?	?	?	?	H	L
Hale1999 ¹²⁸	Y	N	N	?	L	?	?	?	?	H	H
Halkos2004 ¹²⁹	Y	N	N	?	?	?	?	?	?	?	L
Hampton2003 ¹³⁰	N	Y	N	?	?	?	?	?	?	L	L
Haruna1998 ¹³¹	Y	N	N	?	L	?	?	?	?	?	L
Hatori2001 ¹³²	Y	Y	N	L	?	?	?	?	?	L	L
Hausenloy2012 ¹³³	Y	N	N	?	?	?	?	?	?	?	L
He2009 ¹³⁴	Y	N	N	?	?	?	?	?	?	L	L
Heinen2011 ¹³⁵	Y	N	N	?	L	?	?	?	?	?	L

Supplemental Table B - study quality and risk of bias - page 4 of 12

Supplemental Table B - study quality and risk of bias - page 5 of 12

Supplemental Table B - study quality and risk of bias - page 6 of 12

study	reporting - randomization	reporting - blinding	reporting - power/calculation	bias - random group allocation	bias - groups similar at baseline	bias - blinded group allocation	bias - random housing	bias - blind intervention	bias - random outcome assessment	bias - blind outcome assessment	bias - reporting of drop-outs	bias - other
Li_X2012b ²²⁶	Y	Y	N	?	?	?	?	?	?	?	L	L
Li_Y1992a ²²⁷	Y	N	N	?	?	?	?	?	?	?	?	H
Li_Y1992b ²²⁸	Y	Y	N	?	?	?	?	H	?	?	?	H
Li_Y1993a ²²⁹	Y	Y	N	?	L	?	?	L	?	?	?	L
Li_Y1993b ²³⁰	Y	Y	N	?	L	?	?	L	?	?	?	L
Li_Y1994 ²³¹	Y	N	N	?	L	?	?	?	?	?	?	L
Li_Y1995 ²³²	Y	N	N	?	L	?	?	?	?	?	?	L
Li_Y2011 ²³³	N	N	N	?	?	?	?	?	?	?	?	L
Liao2013 ²³⁴	Y	N	N	L	?	?	?	?	?	H	?	L
Liaudet2001 ²³⁵	N	N	N	?	?	?	?	?	?	?	?	L
Lie2010 ²³⁶	Y	N	N	?	L	?	?	L	?	?	?	L
Liem2001 ²³⁷	N	N	N	?	L	?	?	?	?	?	?	L
Liem2005 ²³⁸	N	N	N	?	L	?	?	?	?	?	?	L
Lim2007 ²³⁹	N	N	N	?	?	?	?	?	?	?	?	L
Lim2010 ²⁴⁰	Y	N	N	?	L	?	?	?	?	?	?	L
Liu1993a ²⁴¹	Y	N	N	?	L	?	?	?	?	?	?	L
Liu1993b ²⁴²	Y	N	N	?	L	?	?	?	?	?	L	L
Liu1994 ²⁴³	N	N	N	?	?	?	?	?	?	?	?	L
Liu2005 ²⁴⁴	Y	N	N	?	?	?	?	?	?	?	?	L
Liu2008 ²⁴⁵	N	N	N	?	?	?	?	?	?	?	L	L
LiuG1992a ²⁴⁶	Y	N	N	?	?	?	?	?	?	?	?	H
LiuG1992b ²⁴⁷	Y	N	N	?	?	?	?	?	?	?	?	L
LiuY1992 ²⁴⁸	Y	N	N	?	?	?	?	?	?	?	?	L
Loke1998 ²⁴⁹	Y	N	N	?	?	?	?	?	?	?	?	L
Lott1996 ²⁵⁰	Y	N	N	?	L	?	?	?	?	?	?	L
Lotz2011 ²⁵¹	Y	N	N	?	L	?	?	?	?	?	?	H
Lou2003 ²⁵²	Y	N	N	?	L	?	?	?	?	?	?	L
Lu2009 ²⁵³	N	N	N	?	?	?	?	?	?	?	?	L
Lu2011 ²⁵⁴	Y	N	N	?	L	?	?	?	?	?	?	L
Lu2012 ²⁵⁵	Y	N	N	?	L	?	?	?	?	?	L	L
Luo2004 ²⁵⁶	Y	N	N	?	?	?	?	?	?	?	?	L
Manintveld2005 ²⁵⁷	N	N	N	?	L	?	?	?	?	?	?	L
Manintveld2011 ²⁵⁸	N	N	N	?	?	?	?	?	?	?	?	L
Marber1993 ²⁵⁹	N	N	N	H	?	?	?	?	?	?	H	H
Martin1997 ²⁶⁰	N	N	N	?	?	?	?	?	?	?	?	L
Matsuda1993 ²⁶¹	N	N	N	?	?	?	?	?	?	?	H	L
Matsumura2000 ²⁶²	N	N	N	?	L	?	?	?	?	?	L	L
McVey1999a ²⁶³	N	N	N	?	L	?	?	?	?	?	L	L
McVey1999b ²⁶⁴	N	N	N	?	?	?	?	?	?	?	?	L
Mei1998 ²⁶⁵	Y	N	N	?	?	?	?	?	?	?	L	L
Miki1996 ²⁶⁶	Y	N	N	?	L	?	?	?	?	?	L	L
Miki1998a ²⁶⁷	N	N	N	?	?	?	?	?	?	?	L	L
Miki1998b ²⁶⁸	N	N	N	?	L	?	?	?	?	?	L	L
Miki1999 ²⁶⁹	N	N	N	?	?	?	?	?	?	?	L	H
Miller1999 ²⁷⁰	Y	Y	N	?	?	?	?	?	?	L	?	L

Supplemental Table B - study quality and risk of bias - page 7 of 12

study	reporting - randomization	reporting - blinding	reporting - powercalculation	bias - random group allocation	bias - groups similar at baseline	bias - blinded group allocation	bias - random housing	bias - blind intervention	bias - random outcome assessment	bias - reporting of drop-outs	bias - other
Minamino1996 ²⁷¹	N	N	N	?	?	?	?	?	?	?	L
Miura1991 ²⁷²	Y	N	N	?	L	?	?	?	?	?	L
Miura1992 ²⁷³	N	N	N	?	L	?	?	?	?	?	L
Miura1998 ²⁷⁴	Y	N	N	H	L	?	?	?	?	L	L
Mizumura1995 ²⁷⁵	Y	N	N	?	?	?	?	?	?	?	L
Mizumura1996 ²⁷⁶	N	N	N	?	?	?	?	?	?	?	L
Mizumura1997 ²⁷⁷	Y	N	N	?	?	?	?	?	?	?	L
Morgan1999 ²⁷⁸	Y	N	N	?	?	?	?	?	?	?	L
Mortensen2006 ²⁷⁹	N	N	N	?	?	?	?	?	?	?	L
Mullenheim2001a ²⁸⁰	N	N	N	?	L	?	?	?	?	?	L
Mullenheim2001b ²⁸¹	Y	N	N	?	L	?	?	?	?	?	L
Mullenheim2001c ²⁸²	Y	N	N	?	L	?	?	?	?	?	L
Mullenheim2003 ²⁸³	N	N	N	?	?	?	?	?	?	?	L
Munch-Ellingsen1997 ²⁸⁴	N	N	N	?	?	?	?	?	?	L	L
Munch-Ellingsen1998 ²⁸⁵	N	N	N	?	?	?	?	?	?	L	L
Murry1986 ²⁸⁶	Y	N	N	?	?	?	?	?	?	L	L
Murry1991 ²⁸⁷	N	N	N	?	?	?	?	?	?	H	H
Nadtochiy2009 ²⁸⁸	N	N	N	?	L	?	?	?	?	?	L
Nakae2000 ²⁸⁹	N	N	N	?	L	?	?	?	?	L	L
Nakano1997 ²⁹⁰	N	N	N	?	L	?	?	?	?	?	L
Naumenko2010 ²⁹¹	Y	N	N	?	?	?	?	?	?	?	L
Nawada1997 ²⁹²	N	N	N	?	L	?	?	?	?	L	L
Neckar2002 ²⁹³	N	N	N	?	L	?	?	?	?	L	L
Nieszner2002 ²⁹⁴	N	N	N	?	?	?	?	?	?	?	L
Nishihara2006 ²⁹⁵	N	N	N	?	L	?	?	?	?	?	L
Nithipatikom2006a ²⁹⁶	N	N	N	H	?	?	?	?	?	?	L
Nithipatikom2006b ²⁹⁷	N	N	N	H	?	?	?	?	?	?	L
Node1997 ²⁹⁸	Y	N	N	?	?	?	?	?	?	L	L
Nozawa1999 ²⁹⁹	Y	Y	N	?	L	?	L	?	L	L	L
Nozawa2003 ³⁰⁰	N	N	N	?	L	?	?	?	?	?	L
Okamura1999 ³⁰¹	Y	N	N	?	L	?	?	?	?	?	L
Okubo2000 ³⁰²	Y	N	N	?	L	?	?	?	?	L	L
Okubo2004a ³⁰³	Y	N	N	?	L	?	?	?	?	H	L
Okubo2004b ³⁰⁴	N	N	N	?	L	?	?	?	?	?	L
Ovize1992 ³⁰⁵	Y	N	N	?	?	?	?	?	?	L	L
Ovize1995 ³⁰⁶	Y	N	N	?	?	?	?	?	?	L	L
Pagel2007 ³⁰⁷	Y	N	N	?	L	?	?	?	?	L	L
Patel2001 ³⁰⁸	Y	N	N	?	L	?	?	?	?	?	L
Patel2002 ³⁰⁹	Y	N	N	?	L	?	?	?	?	?	L
Patel2005 ³¹⁰	N	N	N	?	L	?	?	?	?	L	L
Peart2003 ³¹¹	Y	N	N	?	?	?	?	?	?	?	L
Pell1998 ³¹²	Y	Y	N	?	L	?	?	?	L	?	L
Perricone2013 ³¹³	N	Y	N	?	?	?	?	?	L	?	L
Petrishev2006 ³¹⁴	N	N	N	?	?	?	?	?	?	?	L
Ping1999 ³¹⁵	N	N	N	?	L	?	?	?	L	?	L

Supplemental Table B - study quality and risk of bias - page 8 of 12

study	reporting - randomization	reporting - blinding	reporting - power/calculation	bias - random group allocation	bias - groups similar at baseline	bias - blinded group allocation	bias - random housing	bias - blind intervention	bias - random outcome assessment	bias - reporting of drop-outs	bias - other
Ping2002 ³¹⁶	N	N	N	?	?	?	?	?	?	?	L
Piot1997 ³¹⁷	Y	N	N	?	?	?	?	?	?	?	L
Poulsen2014 ³¹⁸	N	N	N	?	?	?	?	?	?	?	L
Przyklenk1993 ³¹⁹	Y	Y	N	?	?	?	?	?	?	L	?
Przyklenk1995 ³²⁰	Y	N	N	?	?	?	?	?	?	L	L
Przyklenk1996 ³²¹	Y	Y	N	?	?	?	?	?	?	L	H
Przyklenk1997 ³²²	Y	N	N	?	?	?	?	?	?	L	L
Przyklenk2001 ³²³	Y	N	N	?	?	?	?	?	?	?	L
Przyklenk2003 ³²⁴	Y	Y	N	?	?	?	?	?	?	L	L
Qian1996 ³²⁵	Y	N	N	?	?	?	?	?	?	?	L
Qian1999 ³²⁶	N	N	N	?	L	?	?	?	?	?	L
Qiu1997a ³²⁷	N	N	N	?	L	?	?	?	?	L	L
Qiu1997b ³²⁸	N	N	Y	?	?	?	?	?	?	L	L
Rajesh2003 ³²⁹	Y	N	N	?	L	?	?	?	?	?	L
Rajesh2004 ³³⁰	N	N	N	?	L	?	?	?	?	?	L
Raphael2005 ³³¹	Y	N	N	?	?	?	?	?	?	L	L
Redel2009 ³³²	Y	Y	N	?	L	?	?	?	?	L	L
Reffelmann2003 ³³³	Y	N	N	?	L	?	?	?	?	?	H
Ren2004 ³³⁴	N	N	N	?	?	?	?	?	?	L	L
Richard1993 ³³⁵	N	N	N	?	L	?	?	?	?	?	H
Richard1994 ³³⁶	N	N	N	?	?	?	?	?	?	?	L
Rioufol1997 ³³⁷	Y	N	N	L	?	?	?	?	?	L	L
Rivo2006 ³³⁸	Y	N	N	?	?	?	?	?	?	L	L
Roesner2007 ³³⁹	Y	N	N	?	L	?	?	?	?	L	L
Roesner2010 ³⁴⁰	N	Y	N	?	L	?	?	?	?	L	L
Rohmann1994 ³⁴¹	N	N	N	?	?	?	?	?	?	L	L
Sack1993 ³⁴²	N	N	N	?	L	?	?	?	?	?	L
Sanada2001a ³⁴³	N	N	N	?	?	?	?	?	?	L	L
Sanada2001b ³⁴⁴	Y	Y	N	?	?	?	?	?	?	L	?
Sanada2004 ³⁴⁵	N	N	N	?	?	?	?	?	?	L	L
Sandhu1997 ³⁴⁶	N	N	N	?	?	?	?	?	?	?	L
Sanz1995 ³⁴⁷	Y	Y	N	?	?	?	?	?	?	L	L
Sarkar2012 ³⁴⁸	N	N	N	?	?	?	?	?	?	?	L
Sasamori2006 ³⁴⁹	Y	N	N	?	?	?	?	?	?	?	L
Sato2007 ³⁵⁰	N	N	N	?	L	?	?	?	?	L	L
Sbarouni2006 ³⁵¹	N	N	N	?	L	?	?	?	?	H	L
Schmidt2014 ³⁵²	Y	Y	N	?	?	?	?	?	?	L	L
Schoemaker2000 ³⁵³	N	N	N	?	L	?	?	?	?	?	L
Schott1990 ³⁵⁴	Y	N	N	?	L	?	?	?	?	L	L
Schultz1995 ³⁵⁵	Y	N	N	?	L	?	?	?	?	L	L
Schultz1996 ³⁵⁶	Y	N	N	?	L	?	?	?	?	L	L
Schultz1997a ³⁵⁷	Y	N	N	?	?	?	?	?	?	?	L
Schultz1997b ³⁵⁸	Y	N	N	?	L	?	?	?	?	L	L
Schultz1997c ³⁵⁹	Y	N	N	?	L	?	?	?	?	?	H
Schultz1997d ³⁶⁰	Y	N	N	?	L	?	?	?	?	?	H

Supplemental Table B - study quality and risk of bias - page 9 of 12

Supplemental Table B - study quality and risk of bias - page 10 of 12

study	reporting - randomization	reporting - blinding	reporting - power/calculation	bias - random group allocation	bias - groups similar at baseline	bias - blinded group allocation	bias - random housing	bias - blind intervention	bias - random outcome assessment	bias - reporting of drop-outs	bias - other
Thornton1992 ⁴⁰⁶	N	N	N	H	?	H	?	?	?	L	L
Thornton1993a ⁴⁰⁷	N	N	N	H	?	?	?	?	?	?	L
Thornton1993b ⁴⁰⁸	Y	N	N	?	?	?	?	?	?	?	L
Thornton1993c ⁴⁰⁹	N	N	N	?	?	?	?	?	?	L	L
Tissier2001 ⁴¹⁰	Y	N	N	?	L	?	?	?	?	L	L
Tissier2002 ⁴¹¹	Y	N	N	?	L	?	?	?	?	?	L
Toller1999 ⁴¹²	Y	N	N	?	?	?	?	?	?	L	L
Toombs1993a ⁴¹³	N	Y	N	?	?	?	?	?	?	?	L
Toufektsian2003 ⁴¹⁴	Y	N	N	?	L	?	?	?	?	?	L
Toyoda2000 ⁴¹⁵	Y	N	N	?	?	?	?	?	?	L	L
Tranter2010 ⁴¹⁶	N	N	Y	?	?	?	?	?	?	?	L
Tsovolas2008 ⁴¹⁷	Y	N	N	?	L	?	?	?	?	?	L
Tsuchida1992 ⁴¹⁸	N	N	N	?	L	?	?	?	?	L	L
Tsuchida1994a ⁴¹⁹	Y	N	N	?	?	?	?	?	?	L	L
Tsuchida1994b ⁴²⁰	Y	N	N	?	?	?	?	?	?	L	L
Tsuchida1998 ⁴²¹	Y	N	N	?	L	?	?	?	?	L	L
Turan2008 ⁴²²	N	N	N	?	?	?	?	?	?	?	L
Ueda1999 ⁴²³	Y	N	N	?	?	?	?	?	?	?	L
Uematsu1998 ⁴²⁴	Y	N	N	?	?	?	?	?	?	L	L
Valtchanova2004 ⁴²⁵	N	N	N	?	?	?	?	?	?	?	L
Valtchanova-Matchouganska2003 ⁴²⁶	Y	N	N	?	?	?	?	?	?	?	L
VandenDoele1998 ⁴²⁷	N	N	N	?	L	?	?	?	?	L	L
VanderHeide1994 ⁴²⁸	N	N	N	?	?	?	?	?	?	L	L
VanWinkle1994b ⁴²⁹	N	N	N	?	?	?	?	?	?	L	L
VanWylen1994 ⁴³⁰	N	N	N	?	?	?	?	?	?	L	L
Vetterlein2006 ⁴³¹	N	N	N	?	L	?	?	?	?	?	L
Vincent2012 ⁴³²	Y	N	N	?	?	?	?	?	?	?	L
Virag2013 ⁴³³	N	N	N	?	?	?	?	?	?	?	L
Vladic2011 ⁴³⁴	Y	N	N	?	L	?	?	?	?	?	L
Vogt1998 ⁴³⁵	N	N	N	?	L	?	?	?	?	L	L
Vogt2001 ⁴³⁶	N	Y	N	?	?	?	?	?	?	?	L
Wall1994 ⁴³⁷	Y	N	N	?	?	?	?	?	?	?	H
Walsh1994 ⁴³⁸	N	N	N	?	?	?	?	?	H	?	L
Wang2001 ⁴³⁹	Y	N	N	?	L	?	?	?	?	L	L
Wang2002 ⁴⁴⁰	Y	N	N	?	L	?	?	?	?	L	L
Wang2009 ⁴⁴¹	Y	N	N	?	?	?	?	?	?	?	L
WangS2004 ⁴⁴²	Y	N	N	?	L	?	?	?	?	L	L
WangY2004 ⁴⁴³	N	N	N	?	L	?	?	?	?	?	H
Watanabe2006 ⁴⁴⁴	N	N	N	?	L	?	?	?	?	L	L
Weber2005 ⁴⁴⁵	N	N	N	?	?	?	?	?	?	?	H
Weber2008 ⁴⁴⁶	Y	N	Y	L	?	?	?	?	?	?	L
Weinbrenner2002 ⁴⁴⁷	N	N	N	?	?	?	?	?	?	?	L
Weinbrenner2004 ⁴⁴⁸	N	N	N	?	H	?	?	?	?	?	L
Wolfe1993 ⁴⁴⁹	N	N	N	?	?	?	?	?	?	L	L
Wolfrum2002 ⁴⁵⁰	Y	N	N	?	L	?	?	?	?	?	L

Supplemental Table B - study quality and risk of bias - page 11 of 12

Supplemental Table B - study quality and risk of bias - page 12 of 12

study	reporting - randomization	reporting - blinding	reporting - powercalculation	bias - random group allocation	bias - groups similar at baseline	bias - blinded group allocation	bias - random housing	bias - blind intervention	bias - random outcome assessment	bias - blind outcome assessment	bias - reporting of drop-outs	bias - other
ZhangS2006 ⁴⁹⁶	N	N	N	?	?	?	?	?	?	?	?	L
ZhangX2006 ⁴⁹⁷	Y	N	N	?	?	?	?	?	?	?	L	L
Zhao2003 ⁴⁹⁸	Y	N	N	?	?	?	?	?	?	?	?	H
Zhao2012 ⁴⁹⁹	N	N	N	?	?	?	?	?	?	?	?	L
Zhu2007 ⁵⁰⁰	N	Y	N	?	?	?	?	?	?	L	?	L
Zhu2009 ⁵⁰¹	Y	N	N	?	L	?	?	?	?	?	?	L
Zhu2011 ⁵⁰²	Y	N	N	?	L	?	?	?	?	?	?	H
Zhu2013 ⁵⁰³	Y	Y	N	?	L	?	?	?	?	L	?	L

Meta-analysis includes data from 785 independent comparisons identified from 503 studies. Y = yes, N = not reported, ? = unclear risk of bias, L = low risk of bias, H = high risk of bias.

Wever et al. 2015 - Determinants of the efficacy of cardiac ischemic preconditioning: a systematic review and meta-analysis of animal studies

Supplemental table C - Meta-analysis study quality

	# pub	# comp (%)	MD [95%CI]
all ($T^2 = 164.4$, $I^2 = 94.7\%$)	503	785 (100)	24.6 [23.5, 25.6]
reported randomization			
P>0.11, adj. $R^2 = 0.42\%$			
not reported	258	420 (54)	25.3 [24.0, 26.7]
yes	245	365 (47)	23.7 [21.7, 25.7]
<i>rodents</i>			
P>0.98, adj. $R^2 = -0.33\%$			
not reported	198	200 (58)	26.8 [24.9, 28.7]
yes	185	144 (42)	26.8 [24.9, 28.7]
<i>non-rodents</i>			
P>0.10, adj. $R^2 = 0.80\%$			
not reported	60	220 (50)	23.9 [22.0, 25.8]
yes	60	221 (50)	21.7 [19.8, 23.6]
reported blinding			
P>0.69, adj. $R^2 = -0.15\%$			
not reported	447	707 (90)	24.5 [23.5, 25.5]
yes	56	78 (10)	25.2 [21.9, 28.5]
<i>rodents</i>			
P>0.43, adj. $R^2 = -0.03\%$			
not reported	345	315 (92)	27.0 [25.4, 28.5]
yes	38	29 (8)	24.9 [23.3, 26.4]
<i>non-rodents</i>			
P>0.17, adj. $R^2 = 0.21\%$			
not reported	102	392 (89)	22.4 [21.0, 23.8]
yes	18	49 (11)	25.3 [23.9, 26.7]
random group allocation (selection bias)			
P>0.92, adj. $R^2 = -0.28\%$			
high	11	14 (2)	23.2 [16.0, 30.3]
low	10	11 (1)	25.0 [13.9, 36.0]
unclear	482	760 (97)	24.6 [17.4, 31.8]
groups similar at baseline (selection bias)			
P>0.01, adj. $R^2 = 1.24\%$			
high	5	8 (1)	27.1 [17.4, 36.8]
low	207	344 (44)	26.2 [16.4, 36.0]
unclear	291	433 (55)	23.2 [13.5, 33.0]
blinded group allocation (selection bias)			
not analyzed			
high	2	2 (0.3)	30.5 [11.6, 49.4]
low	1	1 (0.1)	16.2 [-18.1, 50.5]
unclear	500	782 (99)	24.6 [5.6, 43.5]

Supplemental table C (continued) - Meta-analysis study quality

	# pub	# comp (%)	MD [95%CI]
random housing (performance bias)			
not analyzed			
high	1	1 (0.1)	31.0 [4.8, 57.2]
low	0	0 (0)	NA [NA]
unclear	502	784 (99)	24.6 [-1.6, 50.8]
blind intervention (performance bias)			
not analyzed			
high	2	2 (0.3)	30.4 [10.6, 50.3]
low	3	3 (0.4)	27.1 [0.8, 53.3]
unclear	498	780 (99)	24.5 [4.7, 44.4]
random outcome assessment (detection bias)			
not analyzed			
high	1	1 (0.1)	31.0 [4.8, 57.2]
low	1	1 (0.1)	17.1 [-21.3, 55.5]
unclear	501	783 (99)	24.6 [-1.7, 50.8]
blind outcome assessment (detection bias)			
P>0.87, adj. R ² = -0.28%			
high	2	2 (0.3)	29.5 [10.9, 48.1]
low	40	52 (7)	24.6 [5.6, 43.6]
unclear	461	731 (93)	24.5 [6.0, 43.1]
reporting of drop-outs (attrition bias)			
P>0.01, adj. R ² = 1.29%			
high	27	42 (5)	24.4 [20.3, 28.5]
low	226	340 (43)	22.9 [18.5, 27.3]
unclear	250	403 (51)	26.0 [21.7, 30.4]

Total # comparisons = 8, corrected P<0.006; pub = publications, comp = comparisons, NA = not applicable, adj. = adjusted, MD = weighted difference in means, RoB = risk of bias, ass. = assessment.

Supplemental Text C - included studies reference list - page 1 of 24

1. Alcindor D, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR. Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. *Anesthesiology*. 2004;100:547-554
2. Alizadeh AM, Faghihi M, Sadeghipour HR, Mohammadghasemi F, Khori V. Role of endogenous oxytocin in cardiac ischemic preconditioning. *Regul Pept.* 2011;167:86-90
3. Alkhulaifi AM, Pugsley WB, Yellon DM. The influence of the time period between preconditioning ischemia and prolonged ischemia on myocardial protection. *Cardioscience*. 1993;4:163-169
4. Amour J, Brzezinska AK, Weihrauch D, Billstrom AR, Zielonka J, Krolikowski JG, Bienengraeber MW, Warltier DC, Pratt PF, Jr., Kersten JR. Role of heat shock protein 90 and endothelial nitric oxide synthase during early anesthetic and ischemic preconditioning. *Anesthesiology*. 2009;110:317-325
5. Andreadou I, Iliodromitis EK, Mikros E, Bofilis E, Zoga A, Constantinou M, Tsantili-Kakoulidou A, Kremastinos DT. Melatonin does not prevent the protection of ischemic preconditioning in vivo despite its antioxidant effect against oxidative stress. *Free Radic Biol Med.* 2004;37:500-510
6. Andreadou I, Iliodromitis EK, Tsvolias K, Aggeli IK, Zoga A, Gaitanaki C, Paraskevaidis IA, Markantonis SL, Beis I, Kremastinos DT. Acute administration of vitamin e triggers preconditioning via k(atp) channels and cyclic-gmp without inhibiting lipid peroxidation. *Free Radic Biol Med.* 2006;41:1092-1099
7. Andreadou I, Iliodromitis EK, Souridis V, Prokotas E, Kostidis S, Zoga A, Dagres N, Tsantili-Kakoulidou A, Kremastinos DT, Mikros E, Anastasiou-Nana M. Investigating the effect of antioxidant treatment on the protective effect of preconditioning in anesthetized rabbits. *Journal of cardiovascular pharmacology*. 2011;58:609-616
8. Aouam K, Tissier R, Bruneval P, Mandet C, Berdeaux A, Ghaleh B. Preconditioning of salvaged myocardium in conscious rabbits with postinfarction dysfunction. *American journal of physiology. Heart and circulatory physiology*. 2005;288:21
9. Argaud L, Gateau-Roesch O, Chalabreysse L, Gomez L, Loufouat J, Thivolet-Bejui F, Robert D, Ovize M. Preconditioning delays ca₂₊-induced mitochondrial permeability transition. *Cardiovascular research*. 2004;61:115-122
10. Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D, Ovize M. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. *Journal of molecular and cellular cardiology*. 2005;38:367-374
11. Argaud L, Gateau-Roesch O, Raissy O, Loufouat J, Robert D, Ovize M. Postconditioning inhibits mitochondrial permeability transition. *Circulation*. 2005;111:194-197
12. Argaud L, Gomez L, Gateau-Roesch O, Couture-Lepetit E, Loufouat J, Robert D, Ovize M. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. *Journal of molecular and cellular cardiology*. 2005;39:893-899
13. Argaud L, Gateau-Roesch O, Augeul L, Couture-Lepetit E, Loufouat J, Gomez L, Robert D, Ovize M. Increased mitochondrial calcium coexists with decreased reperfusion injury in postconditioned (but not preconditioned) hearts. *American journal of physiology. Heart and circulatory physiology*. 2008;294:19
14. Auchampach JA, Grover GJ, Gross GJ. Blockade of ischaemic preconditioning in dogs by the novel atp dependent potassium channel antagonist sodium 5-hydroxydecanoate. *Cardiovascular research*. 1992;26:1054-1062
15. Auchampach JA, Gross GJ. Adenosine a1 receptors, katp channels, and ischemic preconditioning in dogs. *The American journal of physiology*. 1993;264:H1327-1336
16. Auchampach JA, Jin X, Moore J, Wan TC, Kreckler LM, Ge ZD, Narayanan J, Whalley E, Kiesman W, Ticho B, Smits G, Gross GJ. Comparison of three different a1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. *J Pharmacol Exp Ther*. 2004;308:846-856
17. Aye NN, Komori S, Hashimoto K. Effects and interaction, of cariporide and preconditioning on cardiac arrhythmias and infarction in rat in vivo. *British journal of pharmacology*. 1999;127:1048-1055
18. Baines CP, Goto M, Downey JM. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. *Journal of molecular and cellular cardiology*. 1997;29:207-216
19. Baines CP, Liu GS, Birincioglu M, Critz SD, Cohen MV, Downey JM. Ischemic preconditioning depends on interaction between mitochondrial k(atp) channels and actin cytoskeleton. *American Journal of Physiology - Heart and Circulatory Physiology*. 1999;276:H1361-H1368
20. Barbosa V, Sievers RE, Zaugg CE, Wolfe CL. Preconditioning ischemia time determines the degree of glycogen depletion and infarct size reduction in rat hearts. *Am Heart J*. 1996;131:224-230
21. Basalay M, Barsukevich V, Mastitskaya S, Mrochek A, Pernow J, Sjoquist PO, Ackland GL, Gourine AV, Gourine A. Remote ischaemic pre- and delayed postconditioning - similar degree of cardioprotection but distinct mechanisms. *Exp Physiol*. 2012;16:16
22. Baumert JH, Hein M, Gerets C, Baltus T, Hecker KE, Rossaint R. The effect of xenon anesthesia on the size of experimental myocardial infarction. *Anesth Analg*. 2007;105:1200-1206

Supplemental Text C - included studies reference list - page 2 of 24

23. Baxter GF, Marber MS, Patel VC, Yellon DM. Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning. *Circulation*. 1994;90:2993-3000
24. Baxter GF, Goma FM, Yellon DM. Involvement of protein kinase c in the delayed cytoprotection following sublethal ischaemia in rabbit myocardium. *British journal of pharmacology*. 1995;115:222-224
25. Baxter GF, Goma FM, Yellon DM. Characterisation of the infarct-limiting effect of delayed preconditioning: Timecourse and dose-dependency studies in rabbit myocardium. *Basic research in cardiology*. 1997;92:159-167
26. Belosjorow S, Schulz R, Borge H, Schade FU, Heusch G. Endotoxin and ischemic preconditioning: Tnf-alpha concentration and myocardial infarct development in rabbits. *American Journal of Physiology - Heart and Circulatory Physiology*. 1999;277:H2470-H2475
27. Belosjorow S, Bolle I, Duschin A, Heusch G, Schulz R. Tnf-alpha antibodies are as effective as ischemic preconditioning in reducing infarct size in rabbits. *American journal of physiology. Heart and circulatory physiology*. 2003;284:5
28. Bencsik P, Kupai K, Gericz Z, Gorbe A, Pipis J, Murlasits Z, Kocsis GF, Varga-Orvos Z, Puskas LG, Csonka C, Csont T, Ferdinand P. Role of inos and peroxynitrite-matrix metalloproteinase-2 signaling in myocardial late preconditioning in rats. *American journal of physiology. Heart and circulatory physiology*. 2010;299:11
29. Bernardo NL, D'Angelo M, Okubo S, Joy A, Kukreja RC. Delayed ischemic preconditioning is mediated by opening of atp-sensitive potassium channels in the rabbit heart. *The American journal of physiology*. 1999;276:H1323-1330
30. Bibli SI, Andreadou I, Lazaris E, Zoga A, Varnavas V, Andreou CC, Dages N, Iliodromitis EK, Kyriakides ZS. Myocardial protection provided by chronic skeletal muscle ischemia is not further enhanced by ischemic pre- or postconditioning: Comparative effects on intracellular signaling. *Journal of cardiovascular pharmacology and therapeutics*. 2014;19:220-227
31. Blokhin IO, Galagudza MM, Vlasov TD, Nifontov EM, Petrishchev NN. [the relationship between ischemic preconditioning-induced infarction size limitation and duration of test myocardial ischemia]. *Ross Fiziol Zh Im I M Sechenova*. 2008;94:785-789
32. Blokhin IO, Vlasov TD, Galagudza MM, Nifontov EM, Petrishchev NN. [role of sodium-calcium exchanger in the myocardial protection against ischemia-reperfusion injury]. *Ross Fiziol Zh Im I M Sechenova*. 2008;94:284-292
33. Boengler K, Konietzka I, Buechert A, Heinen Y, Garcia-Dorado D, Heusch G, Schulz R. Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43. *American journal of physiology. Heart and circulatory physiology*. 2007;292:1
34. Brandenburger T, Galas A, Huhn R, Pannen B, Bauer I, Heinen A. Remote ischemic preconditioning influences the protein expression of connexin 43 in the rat heart in vivo. *Applied Cardiopulmonary Pathophysiology*. 2012;16:328-329
35. Bukhari EA, Krukenkamp IB, Burns PG, Gaudette GR, Schulman JJ, al-Fagih MR, Levitsky S. Does aprotinin increase the myocardial damage in the setting of ischemia and preconditioning? *Ann Thorac Surg*. 1995;60:307-310
36. Burckhardt B, Yang XM, Tsuchida A, Mullane KM, Downey JM, Cohen MV. Acadesine extends the window of protection afforded by ischaemic preconditioning in conscious rabbits. *Cardiovascular research*. 1995;29:653-657
37. Burns PG, Krunkenkamp IB, Calderone CA, Kirvaitis RJ, Gaudette GR, Levitsky S. Is the preconditioning response conserved in senescent myocardium? *Ann Thorac Surg*. 1996;61:925-929
38. Cai ZP, Shen Z, Van Kaer L, Becker LC. Ischemic preconditioning-induced cardioprotection is lost in mice with immunoproteasome subunit low molecular mass polypeptide-2 deficiency. *Faseb J*. 2008;22:4248-4257
39. Cai Z, Luo W, Zhan H, Semenza GL. Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart. *Proc Natl Acad Sci U S A*. 2013;110:17462-17467
40. Canyon SJ, Dobson GP. Pretreatment with an adenosine a1 receptor agonist and lidocaine: A possible alternative to myocardial ischemic preconditioning. *J Thorac Cardiovasc Surg*. 2005;130:371-377
41. Cason BA, Gamperl AK, Slocum RE, Hickey RF. Anesthetic-induced preconditioning: Previous administration of isoflurane decreases myocardial infarct size in rabbits. *Anesthesiology*. 1997;87:1182-1190
42. Chazov EI, Kalenikova EI, Gorodetskaya EA. In vivo monitoring of hydroxyl radical generation in the rat myocardium in ischemia and reperfusion: The effect of ischemic preconditioning. *Dokl Biol Sci*. 2001;380:441-444
43. Chen K, Zhang J, Ye C. [metallothionein involvement in the delayed protection after ischemic or anoxic preconditioning in myocardium or cultured cardiomyocytes]. *Zhonghua Yi Xue Za Zhi*. 1997;77:106-110

Supplemental Text C - included studies reference list - page 3 of 24

44. Chen XG, Wu BY, Wang JK, Bai T. [mechanism of the protective effects of noninvasive limbs preconditioning on myocardial ischemia-reperfusion injury]. *Chin Med J.* 2005;118:1723-1727
45. Chen CH, Liu K, Chan JY. Anesthetic preconditioning confers acute cardioprotection via up-regulation of manganese superoxide dismutase and preservation of mitochondrial respiratory enzyme activity. *Shock.* 2008;29:300-308
46. Cheng XQ, Zhang Y, Lu Y, Li R, Weng LJ, Chen ZW. The role of beta-endorphin in protective effect of intracerebroventricular morphine preconditioning against myocardial post-ischemic injury in rats. [chinese]. *Chinese Pharmacological Bulletin.* 2009;25:1152+1153-1156
47. Cheng Y, Tan N, Yang J, Liu X, Cao X, He P, Dong X, Qin S, Zhang C. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. *Clin Sci.* 2010;119:87-95
48. Cheng Y, Zhu P, Yang J, Liu X, Dong S, Wang X, Chun B, Zhuang J, Zhang C. Ischaemic preconditioning-regulated mir-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target pcd4. *Cardiovascular research.* 2010;87:431-439
49. Chiari P, Piriou V, Hadour G, Rodriguez C, Loufouat J, Lehot JJ, Ovize M, Ferrera R. Preservation of ischemia and isoflurane-induced preconditioning after brain death in rabbit hearts. *American journal of physiology. Heart and circulatory physiology.* 2002;283:H1769-1774
50. Chien GL, Van Winkle DM. Naloxone blockade of myocardial ischemic preconditioning is stereoselective. *Journal of molecular and cellular cardiology.* 1996;28:1895-1900
51. Chien GL, Mohtadi K, Wolff RA, Van Winkle DM. Naloxone blockade of myocardial ischemic preconditioning does not require central nervous system participation. *Basic research in cardiology.* 1999;94:136-143
52. Cohen MV, Liu GS, Downey JM. Preconditioning causes improved wall motion as well as smaller infarcts after transient coronary occlusion in rabbits. *Circulation.* 1991;84:341-349
53. Cohen MV, Yang XM, Downey JM. Conscious rabbits become tolerant to multiple episodes of ischemic preconditioning. *Circulation research.* 1994;74:998-1004
54. Cohen MV, Yang XM, Downey JM. Smaller infarct after preconditioning does not predict extent of early functional improvement of reperfused heart. *The American journal of physiology.* 1999;277:H1754-1761
55. Cohen MV, Yang XM, Neumann T, Heusch G, Downey JM. Favorable remodeling enhances recovery of regional myocardial function in the weeks after infarction in ischemically preconditioned hearts. *Circulation.* 2000;102:579-583
56. Colantonio DA, Van Eyk JE, Przyklenk K. Stunned peri-infarct canine myocardium is characterized by degradation of troponin t, not troponin i. *Cardiovascular research.* 2004;63:217-225
57. Dai W, Kloner RA. Effects of acetaminophen on myocardial infarct size in rats. *Journal of cardiovascular pharmacology and therapeutics.* 2003;8:277-284
58. Dai W, Simkhovich BZ, Kloner RA. Ischemic preconditioning maintains cardioprotection in aging normotensive and spontaneously hypertensive rats. *Experimental gerontology.* 2009;44:344-349
59. Dairaku Y, Miura T, Harada N, Kimura M, Okamura T, Iwamoto H, Kametani R, Yamada M, Ikeda Y, Iwatake M, Kawamura S, Matsuzaki M. Effect of ischemic preconditioning and mitochondrial katp channel openers on chronic left ventricular remodeling in the ischemic-reperfused rat heart. *Circ J.* 2002;66:411-415
60. Daleau P, Boudrau S, Michaud M, Jolicoeur C, Kingma JG, Jr. Preconditioning in the absence or presence of sustained ischemia modulates myocardial cx43 protein levels and gap junction distribution. *Can J Physiol Pharmacol.* 2001;79:371-378
61. Das B, Sarkar C. Similarities between ischemic preconditioning and 17beta-estradiol mediated cardiomyocyte katp channel activation leading to cardioprotective and antiarrhythmic effects during ischemia/reperfusion in the intact rabbit heart. *Journal of cardiovascular pharmacology.* 2006;47:277-286
62. Das B, Sarkar C. Pharmacological preconditioning by levosimendan is mediated by inducible nitric oxide synthase and mitochondrial katp channel activation in the in vivo anesthetized rabbit heart model. *Vascul Pharmacol.* 2007;47:248-256
63. Das B, Sarkar C. Is preconditioning by oxytocin administration mediated by inos and/or mitochondrial k(atp) channel activation in the in vivo anesthetized rabbit heart? *Life Sci.* 2012;90:763-769
64. Dawn B, Takano H, Tang XL, Kodani E, Banerjee S, Rezazadeh A, Qiu Y, Bolli R. Role of src protein tyrosine kinases in late preconditioning against myocardial infarction. *American journal of physiology. Heart and circulatory physiology.* 2002;283:H549-556
65. Dawn B, Guo Y, Rezazadeh A, Wang OL, Stein AB, Hunt G, Varma J, Xuan YT, Wu WJ, Tan W, Zhu X, Bolli R. Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naive myocardium but is essential for the development of late preconditioning. *Journal of molecular and cellular cardiology.* 2004;37:51-61

Supplemental Text C - included studies reference list - page 4 of 24

66. Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, Hunt G, Wu WJ, Tan W, Bolli R. IL-6 plays an obligatory role in late preconditioning via Jak-stat signaling and upregulation of iNOS and COX-2. *Cardiovascular research*. 2004;64:61-71
67. Demiryurek S, Kara AF, Celik A, Babul A, Tarakcioglu M, Demiryurek AT. Effects of fasudil, a rho-kinase inhibitor, on myocardial preconditioning in anesthetized rats. *European journal of pharmacology*. 2005;527:129-140
68. Demiryurek S, Kara AF, Celik A, Tarakcioglu M, Bagci C, Demiryurek AT. Effects of y-27632, a selective rho-kinase inhibitor, on myocardial preconditioning in anesthetized rats. *Biochem Pharmacol*. 2005;69:49-58
69. De Paulis D, Chiari P, Teixeira G, Couture-Lepetit E, Abrial M, Argaud L, Gharib A, Ovize M. Cyclosporine A at reperfusion fails to reduce infarct size in the in vivo rat heart. *Basic research in cardiology*. 2013;108:379
70. Depre C, Park JY, Shen YT, Zhao X, Qiu H, Yan L, Tian B, Vatner SF, Vatner DE. Molecular mechanisms mediating preconditioning following chronic ischemia differ from those in classical second window. *American journal of physiology. Heart and circulatory physiology*. 2010;299:25
71. Deuchar GA, Opie LH, Lecour S. TNFalpha is required to confer protection in an in vivo model of classical ischaemic preconditioning. *Life Sci*. 2007;80:1686-1691
72. de Zeeuw S, Lameris TW, Duncker DJ, Hasan D, Boomsma F, van den Meiracker AH, Verdouw PD. Cardioprotection in pigs by exogenous norepinephrine but not by cerebral ischemia-induced release of endogenous norepinephrine. *Stroke; a journal of cerebral circulation*. 2001;32:767-774
73. Ding YF, Zhang MM, He RR. [Ischemic preconditioning reduces cardiomyocytic apoptosis in rabbit heart in vivo]. *Sheng Li Xue Bao*. 2000;52:220-224
74. Ding YF, Zhang MM, He RR. Role of renal nerve in cardioprotection provided by renal ischemic preconditioning in anesthetized rabbits. *Sheng Li Xue Bao*. 2001;53:7-12
75. Dong JH, Liu YX, Ji ES, He RR. [Limb ischemic preconditioning reduces infarct size following myocardial ischemia-reperfusion in rats]. *Sheng Li Xue Bao*. 2004;56:41-46
76. Ebel D, Mullenheim J, Frassdorf J, Heinen A, Huhn R, Bohlen T, Ferrari J, Sudkamp H, Preckel B, Schlack W, Thamer V. Effect of acute hyperglycaemia and diabetes mellitus with and without short-term insulin treatment on myocardial ischaemic late preconditioning in the rabbit heart in vivo. *Pflugers Arch*. 2003;446:175-182
77. Ebel D, Toma O, Appler S, Baumann K, Frassdorf J, Preckel B, Rosen P, Schlack W, Weber NC. Ischemic preconditioning phosphorylates mitogen-activated kinases and heat shock protein 27 in the diabetic rat heart. *Horm Metab Res*. 2009;41:10-15
78. Eckle T, Grenz A, Kohler D, Redel A, Falk M, Rolauffs B, Osswald H, Kehl F, Eltzschig HK. Systematic evaluation of a novel model for cardiac ischemic preconditioning in mice. *American journal of physiology. Heart and circulatory physiology*. 2006;291:9
79. Eckle T, Hartmann K, Bonney S, Reithel S, Mittelbronn M, Walker LA, Lowes BD, Han J, Borchers CH, Buttrick PM, Kominsky DJ, Colgan SP, Eltzschig HK. Adora2b-elicited p2 stabilization promotes a hif-dependent metabolic switch crucial for myocardial adaptation to ischemia. *Nature medicine*. 2012;18:774-782
80. Erikson JM, Velasco CE. Endothelin-1 and myocardial preconditioning. *Am Heart J*. 1996;132:84-90
81. Fang J, Wu L, Chen L. Postconditioning attenuates cardiocyte ultrastructure injury and apoptosis by blocking mitochondrial permeability transition in rats. *Acta Cardiol*. 2008;63:377-387
82. Farhat F, Loisance D, Garnier JP, Kirsch M. Norepinephrine release after acute brain death abolishes the cardioprotective effects of ischemic preconditioning in rabbit. *Eur J Cardiothorac Surg*. 2001;19:313-320
83. Fisher SG, Marber MS. An in vivo model of ischaemia-reperfusion injury and ischaemic preconditioning in the mouse heart. *J Pharmacol Toxicol Methods*. 2002;48:161-169
84. Flack 3rd JE, Kimura Y, Engelman RM, Rousou JA, Iyengar J, Jones R, Das DK. Preconditioning the heart by repeated stunning improves myocardial salvage. *Circulation*. 1991;84:III369-374
85. Flaherty MP, Guo Y, Tiwari S, Rezazadeh A, Hunt G, Sanganalmath SK, Tang XL, Bolli R, Dawn B. The role of TNF-alpha receptors p55 and p75 in acute myocardial ischemia/reperfusion injury and late preconditioning. *Journal of molecular and cellular cardiology*. 2008;45:735-741
86. Flynn DM, Smith AH, Treadway JL, Levy CB, Soeller WC, Boettner WA, Wisniecki P, Plowchalk DR, Gernhardt SS, Tracey WR, Knight DR. The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits. *Cardiovasc Drugs Ther*. 2005;19:337-346
87. Fryer RM, Schultz JE, Hsu AK, Gross GJ. Pretreatment with tyrosine kinase inhibitors partially attenuates ischemic preconditioning in rat hearts. *The American journal of physiology*. 1998;275:H2009-2015
88. Fryer RM, Schultz JE, Hsu AK, Gross GJ. Importance of PKC and tyrosine kinase in single or multiple cycles of preconditioning in rat hearts. *American Journal of Physiology - Heart and Circulatory Physiology*. 1999;276:H1229-H1235

Supplemental Text C - included studies reference list - page 5 of 24

89. Fryer RM, Eells JT, Hsu AK, Henry MM, Gross GJ. Ischemic preconditioning in rats: Role of mitochondrial k(atp) channel in preservation of mitochondrial function. *American journal of physiology. Heart and circulatory physiology.* 2000;278:H305-312
90. Fryer RM, Hsu AK, Gross GJ. Mitochondrial k(atp) channel opening is important during index ischemia and following myocardial reperfusion in ischemic preconditioned rat hearts. *Journal of molecular and cellular cardiology.* 2001;33:831-834
91. Fryer RM, Patel HH, Hsu AK, Gross GJ. Stress-activated protein kinase phosphorylation during cardioprotection in the ischemic myocardium. *American journal of physiology. Heart and circulatory physiology.* 2001;281:H1184-1192
92. Fryer RM, Pratt PF, Hsu AK, Gross GJ. Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid-induced cardioprotection. *J Pharmacol Exp Ther.* 2001;296:642-649
93. Fryer RM, Hsu AK, Wang Y, Henry M, Eells J, Gross GJ. Pkc- inhibition does not block preconditioning-induced preservation in mitochondrial atp synthesis and infarct size reduction in rats. *Basic research in cardiology.* 2002;97:47-54
94. Fukuma T, Miura T, Suzuki K, Tsuchida A, Nozawa Y, Shimamoto K. Relationship between free radicals and adenosine in the mechanism of preconditioning: Are they interrelated or independent triggers? *Mol Cell Biochem.* 2000;211:51-59
95. Galagudza MM, Nekrasova MK, Syrenskii AV, Nifontov EM. Resistance of the myocardium to ischemia and the efficacy of ischemic preconditioning in experimental diabetes mellitus. *Neurosci Behav Physiol.* 2007;37:489-493
96. Galagudza MM. [the influence of local and remote myocardial preconditioning on the incidence and severity of experimentally induced ischemic tachyarrhythmias]. *Vestn Ross Akad Med Nauk.* 2007;4:12-17
97. Galagudza MM, Syrenskii AV, Vlasov TD, Morozova LI, Egorova EI, Polumiskov VI. Effects of individual and combined administration of ethylmethylhydroxypyridine succinate and ischemic preconditioning on ischemic-reperfusion myocardial injury in rats. [russian]. *Eksperimental'naia i klinicheskaia farmakologija.* 2009;72:22-26
98. Gao XM, Wang BH, Woodcock E, Du XJ. Expression of active alpha(1b)-adrenergic receptors in the heart does not alleviate ischemia reperfusion injury. *Journal of molecular and cellular cardiology.* 2000;32:1679-1686
99. Gao X, A., Zhang B, Shang H, Wang Y, Guo L, Zhang M, Shi H, Liu M. Protective effect of fufangdanshenfang pretreatment on myocardial ischemical reperfusion injury. [chinese]. *Chinese Journal of Clinical Rehabilitation.* 2003;7:1754-1756
100. Gao J, Kang Y, Lou J. The optimal strategy of noninvasive limb ischemic preconditioning for protecting heart against ischemia-reperfusion injury in rats. *J Surg Res.* 2012;8:8
101. Ge ZD, Ionova IA, Vladic N, Pravdic D, Hirata N, Vasquez-Vivar J, Pratt PF, Jr., Warltier DC, Pieper GM, Kersten JR. Cardiac-specific overexpression of gtp cyclohydrolase 1 restores ischaemic preconditioning during hyperglycaemia. *Cardiovascular research.* 2011;91:340-349
102. Gerczuk PZ, Breckenridge DG, Liles JT, Budas GR, Shryock JC, Belardinelli L, Kloner RA, Dai W. An apoptosis signal-regulating kinase 1 inhibitor reduces cardiomyocyte apoptosis and infarct size in a rat ischemia-reperfusion model. *Journal of cardiovascular pharmacology.* 2012;60:276-282
103. Gho BCG, Schoemaker RG, Van den Doel MA, Duncker DJ, Verdouw PD. Myocardial protection by brief ischemia in noncardiac tissue. *Circulation.* 1996;94:2193-2200
104. Gomez L, Paillard M, Price M, Chen Q, Teixeira G, Spiegel S, Lesnefsky EJ. A novel role for mitochondrial sphingosine-1-phosphate produced by sphingosine kinase-2 in ptp-mediated cell survival during cardioprotection. *Basic research in cardiology.* 2011;106:1341-1353
105. Gomoll AW. Cardioprotection associated with preconditioning in the anesthetized ferret. *Basic research in cardiology.* 1996;91:433-443
106. Goto M, Miura T, Itoya M, Sakamoto J, Iimura O. Reduction of regional contractile function by preconditioning ischemia does not play a permissive role in the infarct size-limitation by the preconditioning. *Basic research in cardiology.* 1993;88:594-606
107. Gourine AV, Molosh AI, Poputnikov D, Bulhak A, Sjoquist PO, Pernow J. Endothelin-1 exerts a preconditioning-like cardioprotective effect against ischaemia/reperfusion injury via the et(a) receptor and the mitochondrial k(atp) channel in the rat *in vivo*. *British journal of pharmacology.* 2005;144:331-337
108. Gozal Y, Raphael J, Rivo J, Berenshtein E, Chevion M, Drenger B. Isoflurane does not mimic ischaemic preconditioning in decreasing hydroxyl radical production in the rabbit. *Br J Anaesth.* 2005;95:442-447
109. Griol-Charhbili V, Messadi-Laribi E, Bascands JL, Heudes D, Meneton P, Giudicelli JF, Alhenc-Gelas F, Richer C. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. *Faseb J.* 2005;19:1172-1174

Supplemental Text C - included studies reference list - page 6 of 24

110. Gross GJ, Auchampach JA. Blockade of atp-sensitive potassium channels prevents myocardial preconditioning in dogs. *Circulation research*. 1992;70:223-233
111. Gross GJ, Gauthier KM, Moore J, Campbell WB, Falck JR, Nithipatikom K. Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in dog. *American journal of physiology. Heart and circulatory physiology*. 2009;297:15
112. Grover GJ, Slep P, Dzwonczyk S. Role of myocardial atp-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine a1-receptors. *Circulation*. 1992;86:1310-1316
113. Grover GJ, D'Alonzo AJ, Dzwonczyk S, Parham CS, Darbenzio RB. Preconditioning is not abolished by the delayed rectifier k⁺ blocker dofetilide. *The American journal of physiology*. 1996;271:H1207-1214
114. Grund F, Sommerschild HT, Kirkeboen KA, Illebekk A. Preconditioning with ischaemia reduces both myocardial oxygen consumption and infarct size in a graded pattern. *Journal of molecular and cellular cardiology*. 1997;29:3067-3079
115. Gu W, Kehl F, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR. Simvastatin restores ischemic preconditioning in the presence of hyperglycemia through a nitric oxide-mediated mechanism. *Anesthesiology*. 2008;108:634-642
116. Gumina RJ, Buerger E, Eickmeier C, Moore J, Daemmggen J, Gross GJ. Inhibition of the na(+)/h(+) exchanger confers greater cardioprotection against 90 minutes of myocardial ischemia than ischemic preconditioning in dogs. *Circulation*. 1999;100:2519-2526
117. Gumina RJ, Moore J, Schelling P, Beier N, Gross GJ. Na(+)/h(+) exchange inhibition prevents endothelial dysfunction after i/r injury. *American journal of physiology. Heart and circulatory physiology*. 2001;281:H1260-1266
118. Gumina RJ, El Schultz J, Moore J, Beier N, Schelling P, Gross GJ. Cardioprotective-mimetics reduce myocardial infarct size in animals resistant to ischemic preconditioning. *Cardiovasc Drugs Ther*. 2005;19:315-322
119. Guo Y, Wu WJ, Qiu Y, Tang XL, Yang Z, Bolli R. Demonstration of an early and a late phase of ischemic preconditioning in mice. *The American journal of physiology*. 1998;275:H1375-1387
120. Guo Y, Jones WK, Xuan YT, Tang XL, Bao W, Wu WJ, Han H, Laubach VE, Ping P, Yang Z, Qiu Y, Bolli R. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible no synthase gene. *Proc Natl Acad Sci U S A*. 1999;96:11507-11512
121. Guo Y, Bolli R, Bao W, Wu WJ, Black RG, Jr., Murphree SS, Salvatore CA, Jacobson MA, Auchampach JA. Targeted deletion of the a3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. *Journal of molecular and cellular cardiology*. 2001;33:825-830
122. Guo D, Nguyen T, Ogbu M, Tawfik H, Ma G, Yu Q, Caldwell RW, Johnson JA. Protein kinase c-epsilon coimmunoprecipitates with cytochrome oxidase subunit iv and is associated with improved cytochrome-c oxidase activity and cardioprotection. *American journal of physiology. Heart and circulatory physiology*. 2007;293:27
123. Guo Y, Tukaye DN, Wu WJ, Zhu X, Book M, Tan W, Jones SP, Rokosh G, Narumiya S, Li Q, Bolli R. The cox-2/pgi2 receptor axis plays an obligatory role in mediating the cardioprotection conferred by the late phase of ischemic preconditioning. *PloS one*. 2012;7:e41178
124. Gysembergh A, Margonari H, Loufoua J, Ovize A, Andre-Fouet X, Minaire Y, Ovize M. Stretch-induced protection shares a common mechanism with ischemic preconditioning in rabbit heart. *The American journal of physiology*. 1998;274:H955-964
125. Haessler R, Kuzume K, Chien GL, Wolff RA, Davis RF, Van Winkle DM. Anaesthetics alter the magnitude of infarct limitation by ischaemic preconditioning. *Cardiovascular research*. 1994;28:1574-1580
126. Haessler R, Wolff RA, Chien GL, Davis RF, Van Winkle DM. High spinal anesthesia does not alter experimental myocardial Infarction size or ischemic preconditioning. *Journal of Cardiothoracic and Vascular Anesthesia*. 1997;11:72-79
127. Hale SL, Kloner RA. Effect of ischemic preconditioning on regional myocardial flow in the rabbit heart. *Coronary Artery Disease*. 1992;3:133-140
128. Hale SL, Kloner RA. Ischemic preconditioning and myocardial hypothermia in rabbits with prolonged coronary artery occlusion. *The American journal of physiology*. 1999;276:H2029-2034
129. Halkos ME, Kerendi F, Corvera JS, Wang NP, Kin H, Payne CS, Sun HY, Guyton RA, Vinten-Johansen J, Zhao ZQ. Myocardial protection with postconditioning is not enhanced by ischemic preconditioning. *Ann Thorac Surg*. 2004;78:961-969
130. Hampton CR, Shimamoto A, Rothnie CL, Griscavage-Ennis J, Chong A, Dix DJ, Verrier ED, Pohlman TH. Hsp70.1 and -70.3 are required for late-phase protection induced by ischemic preconditioning of mouse hearts. *American journal of physiology. Heart and circulatory physiology*. 2003;285:24

Supplemental Text C - included studies reference list - page 7 of 24

131. Haruna T, Horie M, Kouchi I, Nawada R, Tsuchiya K, Akao M, Otani H, Murakami T, Sasayama S. Coordinate interaction between atp-sensitive k+ channel and na+, k+-atpase modulates ischemic preconditioning. *Circulation*. 1998;98:2905-2910
132. Hatori N, Segawa D, Hinokiyama K, Kimura T, Iizuka Y, Ochi M, Tanaka S. Effects of ischemic preconditioning and synchronized coronary venous retroperfusion in an off-pump coronary artery bypass grafting model. *Artif Organs*. 2001;25:47-52
133. Hausenloy DJ, Iliodromitis EK, Andreadou I, Papalois A, Gritsopoulos G, Anastasiou-Nana M, Kremastinos DT, Yellon DM. Investigating the signal transduction pathways underlying remote ischemic conditioning in the porcine heart. *Cardiovasc Drugs Ther*. 2012;30:30
134. He Y, Zeng ZY, Zhong GQ, Li JY, Li WK, Li W. Cx43 in mitochondria participates in the protection for heptanol preconditioning on myocardial ischemia/reperfusion injury of rabbits. [chinese]. *Chinese Pharmacological Bulletin*. 2009;25:1660-1665
135. Heinen NM, Putz VE, Gorgens JL, Huhn R, Gruber Y, Barthuber C, Preckel B, Pannen BH, Bauer I. Cardioprotection by remote ischemic preconditioning exhibits a signaling pattern different from local ischemic preconditioning. *Shock*. 2011;36:45-53
136. Hemetsberger H, Steiner S, Farhan S, Kvakan H, Hemetsberger R, Pavo N, Kopp C, Garamvolgyi R, Petrasz I, Petnehazy O, Manczur F, Huber K, Wojta J, Glogar D, Gyongyosi M. Ischemic preconditioning leads to reduction of circulating mesenchymal stem cells in a porcine ischaemia/reperfusion model. *Journal fur Kardiologie*. 2008;15:348-352
137. Hemetsberger R, Posa A, Pavo N, Farhan S, Csonka C, Csont T, Ferdinand P, Garamvolgyi R, Petrasz I, Petnehazy O, Varga C, Pavo Jr I, Laszlo Jr F, Huber K, Wojta J, Glogar D, Gyongyosi M. Involvement of nitric oxide in the cardioprotective effect of early ischemic preconditioning in the reperfusion phase in pigs. *Journal fur Kardiologie*. 2008;15:119-122
138. Hiasa G, Hamada M, Ikeda S, Hiwada K. Ischemic preconditioning and lipopolysaccharide attenuate nuclear factor-kappab activation and gene expression of inflammatory cytokines in the ischemia-reperfused rat heart. *Jpn Circ J*. 2001;65:984-990
139. Hibert P, Prunier-Mirebeau D, Beseme O, Chwastyniak M, Tamareille S, Lamon D, Furber A, Pinet F, Prunier F. Apolipoprotein a-i is a potential mediator of remote ischemic preconditioning. *PloS one*. 2013;8:e77211
140. Hide EJ, Thiemermann C. Limitation of myocardial infarct size in the rabbit by ischaemic preconditioning is abolished by sodium 5-hydroxydecanoate. *Cardiovascular research*. 1996;31:941-946
141. Hinokiyama K, Hatori N, Ochi M, Maehara T, Tanaka S. Myocardial protective effect of lidocaine during experimental off-pump coronary artery bypass grafting. *Ann Thorac Cardiovasc Surg*. 2003;9:36-42
142. Hiroi T, Wajima T, Kaneko Y, Kiuchi Y, Shimizu S. An important role of increase in tetrahydrobiopterin via h2o2-jak2 signalling pathway in late phase of ischaemic preconditioning. *Exp Physiol*. 2010;95:609-621
143. Hoshida S, Kuzuya T, Nishida M, Yamashita N, Oe H, Hori M, Kamada T, Tada M. Adenosine blockade during reperfusion reverses the infarct limiting effect in preconditioned canine hearts. *Cardiovascular research*. 1994;28:1083-1088
144. Htun P, Ito WD, Hoefer IE, Schaper J, Schaper W. Intramyocardial infusion of fgf-1 mimics ischemic preconditioning in pig myocardium. *Journal of molecular and cellular cardiology*. 1998;30:867-877
145. Hu CP, Peng J, Xiao L, Ye F, Deng HW, Li YJ. Effect of age on alpha-calcitonin gene-related peptide-mediated delayed cardioprotection induced by intestinal preconditioning in rats. *Regul Pept*. 2002;107:137-143
146. Huang CH, Kim SJ, Ghaleh B, Kudej RK, Shen YT, Bishop SP, Vatner SF. An adenosine agonist and preconditioning shift the distribution of myocardial blood flow in conscious pigs. *The American journal of physiology*. 1999;276:H368-375
147. Huang CH, Wang JS, Chiang SC, Wang YY, Lai ST, Weng ZC. Brief pressure overload of the left ventricle preconditions rabbit myocardium against infarction. *Ann Thorac Surg*. 2004;78:628-633
148. Huang CH, Tsai SK, Chiang SC, Wang YY, Chih CL, Weng ZC, Lai ST. Brief pressure overload preconditions rabbit myocardium independent of adenosine receptor activation. *Ann Thorac Surg*. 2011;92:1727-1732
149. Huang CH, Tsai SK, Chiang SC, Lai CC, Weng ZC. The role of adenosine in preconditioning by brief pressure overload in rats. *Journal of the Formosan Medical Association = Taiwan yi zhi*. 2013
150. Iliodromitis EK, Kremastinos Th D, Bouris I, Papadopoulos C, Paraskevaidis IA, Yellon DM. The re-introduction of ischemic preconditioning is able to protect myocardium after repeated long reperfusion intervals. *Cardioscience*. 1994;5:277-281
151. Iliodromitis EK, Papadopoulos CC, Markianos M, Paraskevaidis IA, Kyriakides ZS, Kremastinos DT. Alterations in circulating cyclic guanosine monophosphate (c-gmp) during short and long ischemia in preconditioning. *Basic research in cardiology*. 1996;91:234-239
152. Iliodromitis EK, Papadopoulos C, Paraskevaidis IA, Kyriakides ZS, Flessa C, Kremastinos DT. Protection from preconditioning can be reinstated at various reperfusion intervals. *Cardiovasc Drugs Ther*. 1996;10:341-346

Supplemental Text C - included studies reference list - page 8 of 24

153. Iliodromitis EK, Kremastinos DT, Katritsis DG, Papadopoulos CC, Hearse DJ. Multiple cycles of preconditioning cause loss of protection in open-chest rabbits. *Journal of molecular and cellular cardiology*. 1997;29:915-920
154. Iliodromitis EK, Gaitanaki C, Lazou A, Bofilis E, Karavolias GK, Beis I, Kremastinos DT. Dissociation of stress-activated protein kinase (p38-mapk and jnks) phosphorylation from the protective effect of preconditioning in vivo. *Journal of molecular and cellular cardiology*. 2002;34:1019-1028
155. Iliodromitis EK, Vlahakos DV, Bofilis E, Karavolias GK, Tasouli A, Kremastinos DT. Angiotensin ii fails to induce preconditioning in vivo--the protective role of myocardial stretch due to pressure overload. *Can J Cardiol*. 2002;18:34-42
156. Iliodromitis EK, Cokkinos P, Zoga A, Steliou I, Vrettou AR, Kremastinos DT. Oral nicorandil recaptures the waned protection from preconditioning in vivo. *British journal of pharmacology*. 2003;138:1101-1106
157. Iliodromitis EK, Tasouli A, Andreadou I, Bofilis E, Zoga A, Cokkinos P, Kremastinos DT. Intravenous atenolol and esmolol maintain the protective effect of ischemic preconditioning in vivo. *European journal of pharmacology*. 2004;499:163-169
158. Iliodromitis EK, Gaitanaki C, Lazou A, Aggeli IK, Gizas V, Bofilis E, Zoga A, Beis I, Kremastinos DT. Differential activation of mitogen-activated protein kinases in ischemic and nitroglycerin-induced preconditioning. *Basic research in cardiology*. 2006;101:327-335
159. Iliodromitis EK, Zoga A, Vrettou A, Andreadou I, Paraskevaidis IA, Kaklamanis L, Kremastinos DT. The effectiveness of postconditioning and preconditioning on infarct size in hypercholesterolemic and normal anesthetized rabbits. *Atherosclerosis*. 2006;188:356-362
160. Iliodromitis EK, Aggeli IK, Gaitanaki C, Tsiafoutis I, Zoga A, Beis I, Kremastinos DT. P38-mapk is involved in restoration of the lost protection of preconditioning by nicorandil in vivo. *European journal of pharmacology*. 2008;579:289-297
161. Iliodromitis K, Farmakis D, Andreadou I, Zoga A, Bibli SI, Manolaki T, Dages N, Iliodromitis EK, Anastasiou-Nana M, Kremastinos DT. Various models of cardiac conditioning in single or sequential periods of ischemia: Comparative effects on infarct size and intracellular signaling. *Int J Cardiol*. 2013;168:1336-1341
162. Imagawa J, Baxter GF, Yellon DM. Genistein, a tyrosine kinase inhibitor, blocks the "second window of protection" 48 h after ischemic preconditioning in the rabbit. *Journal of molecular and cellular cardiology*. 1997;29:1885-1893
163. Imagawa J, Baxter GF, Yellon DM. Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo. *Journal of cardiovascular pharmacology*. 1998;31:74-79
164. Imagawa J, Yellon DM, Baxter GF. Pharmacological evidence that inducible nitric oxide synthase is a mediator of delayed preconditioning. *British journal of pharmacology*. 1999;126:701-708
165. Ismaeil MS, Tkachenko I, Gamperl AK, Hickey RF, Cason BA. Mechanisms of isoflurane-induced myocardial preconditioning in rabbits. *Anesthesiology*. 1999;90:812-821
166. Iwamoto T, Miura T, Adachi T, Noto T, Ogawa T, Tsuchida A, Iimura O. Myocardial infarct size-limiting effect of ischemic preconditioning was not attenuated by oxygen free-radical scavengers in the rabbit. *Circulation*. 1991;83:1015-1022
167. Jaberansari MT, Baxter GF, Muller CA, Latouf SE, Roth E, Opie LH, Yellon DM. Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium. *J Am Coll Cardiol*. 2001;37:1996-2001
168. Jancso G, Gasz B, Szanto Z, Cserepes B, Roth E. Bradykinin and angiotensin-converting enzyme inhibition in cardioprotection. *Experimental and Clinical Cardiology*. 2004;9:21-25
169. Jancso G, Cserepes B, Gasz B, Benko L, Ferencz A, Borsiczky B, Lantos J, Dureja A, Kiss K, Szeberenyi J, Roth E. Effect of acetylsalicylic acid on nuclear factor-kappab activation and on late preconditioning against infarction in the myocardium. *Journal of cardiovascular pharmacology*. 2005;46:295-301
170. Ji L, Zhang X, Liu W, Huang Q, Yang W, Fu F, Ma H, Su H, Wang H, Wang J, Zhang H, Gao F. Ampk-regulated and akt-dependent enhancement of glucose uptake is essential in ischemic preconditioning-alleviated reperfusion injury. *PloS one*. 2013;8:e69910
171. Jiao XY, Luo N, Zhi JM, Zhao RR. Effects of exogenous platelet activating factor and its antagonist ginkgolide b on ischemia-reperfusion injury of myocardium in rats. *Chinese Journal of Pharmacology and Toxicology*. 2002;16:81-87
172. Jung O, Jung W, Malinski T, Wiemer G, Schoelkens BA, Linz W. Ischemic preconditioning and infarct mass: The effect of hypercholesterolemia and endothelial dysfunction. *Clin Exp Hypertens*. 2000;22:165-179
173. Junhua Z, Kui C, Jian C. Mitogen-activated protein kinase involvement in the delayed protection after ischemic or anoxic preconditioning in myocardium or cultured cardiomyocytes. [chinese]. *Chinese Journal of Cardiology*. 1997;25:215-218

Supplemental Text C - included studies reference list - page 9 of 24

174. Kalakech H, Tamareille S, Pons S, Godin-Ribuot D, Carmeliet P, Furber A, Martin V, Berdeaux A, Ghaleh B, Prunier F. Role of hypoxia inducible factor-1alpha in remote limb ischemic preconditioning. *Journal of molecular and cellular cardiology*. 2013;65:98-104
175. Kapadia SJ, Terlato JS, Most AS. Presence of a critical coronary artery stenosis does not abolish the protective effect of ischemic preconditioning. *Circulation*. 1997;95:1286-1292
176. Kara AF, Demiryurek S, Celik A, Tarakcioglu M, Demiryurek AT. Effects of trimetazidine on myocardial preconditioning in anesthetized rats. *European journal of pharmacology*. 2004;503:135-145
177. Kara AF, Demiryurek S, Celik A, Tarakcioglu M, Demiryurek AT. Effects of chronic trimetazidine treatment on myocardial preconditioning in anesthetized rats. *Fundam Clin Pharmacol*. 2006;20:449-459
178. Kariya T, Minatoguchi S, Ohno T, Yamashita K, Uno Y, Arai M, Koshiji M, Fujiwara T, Fujiwara H. Infarct size-reducing effect of ischemic preconditioning is related to alpha1b-adrenoceptors but not to alpha1a-adrenoceptors in rabbits. *Journal of cardiovascular pharmacology*. 1997;30:437-445
179. Katakam PV, Jordan JE, Snipes JA, Tulbert CD, Miller AW, Busija DW. Myocardial preconditioning against ischemia-reperfusion injury is abolished in zucker obese rats with insulin resistance. *Am J Physiol Regul Integr Comp Physiol*. 2007;292:28
180. Kersten JR, Schmeling TJ, Pagel PS, Gross GJ, Warltier DC. Isoflurane mimics ischemic preconditioning via activation of k(atp) channels: Reduction of myocardial infarct size with an acute memory phase. *Anesthesiology*. 1997;87:361-370
181. Kersten JR, Schmeling TJ, Orth KG, Pagel PS, Warltier DC. Acute hyperglycemia abolishes ischemic preconditioning in vivo. *The American journal of physiology*. 1998;275:H721-725
182. Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC. Diabetes abolishes ischemic preconditioning: Role of glucose, insulin, and osmolality. *American journal of physiology. Heart and circulatory physiology*. 2000;278:H1218-1224
183. Kingma JG, Jr. Cardiac adaptation to ischemia-reperfusion injury. *Ann N Y Acad Sci*. 1999;874:83-99
184. Kingma Jr JG, Simard D, Voisine P, Rouleau JR. Role of the autonomic nervous system in cardioprotection by remote preconditioning in isoflurane-anaesthetized dogs. *Cardiovascular research*. 2011;89:384-391
185. Kingma JG, Simard D, Voisine P, Rouleau JR. Influence of cardiac decentralization on cardioprotection. *PloS one*. 2013;8:e79190
186. Kirsch M, Farhat F, Garnier JP, Loisance D. Acute brain death abolishes the cardioprotective effects of ischemic preconditioning in the rabbit. *Transplantation*. 2000;69:2013-2019
187. Kis A, Yellon DM, Baxter GF. Second window of protection following myocardial preconditioning: An essential role for pi3 kinase and p70s6 kinase. *Journal of molecular and cellular cardiology*. 2003;35:1063-1071
188. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, et al. Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5'-nucleotidase activity and attenuation of adenosine release. *Circulation*. 1994;89:1237-1246
189. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, Kamada T. Alpha1-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5'-nucleotidase activity. *Journal of Clinical Investigation*. 1994;93:2197-2205
190. Kitakaze M, Node K, Minamino T, Komamura K, Funaya H, Shinozaki Y, Chujo M, Mori H, Inoue M, Hori M, Kamada T. Role of activation of protein kinase c in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5'-nucleotidase. *Circulation*. 1996;93:781-791
191. Kitakaze M, Minamino T, Node K, Komamura K, Shinozaki Y, Chujo M, Mori H, Inoue M, Hori M, Kamada T. Role of activation of ectosolic 5'-nucleotidase in the cardioprotection mediated by opening of k+c channels. *The American journal of physiology*. 1996;270:H1744-1756
192. Kitakaze M, Node K, Asanuma H, Takashima S, Sakata Y, Asakura M, Sanada S, Shinozaki Y, Mori H, Kuzuya T, Hori M. Protein tyrosine kinase is not involved in the infarct size-limiting effect of ischemic preconditioning in canine hearts. *Circulation research*. 2000;87:303-308
193. Kocoglu H, Karaaslan K, Gonca E, Bozdogan O, Gulcu N. Preconditionin effects of dexmedetomidine on myocardial ischemia/reperfusion injury in rats. *Current Therapeutic Research - Clinical and Experimental*. 2008;69:150-158
194. Kohler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, Laucher S, Hart ML, Robson SC, Muller CE, Eltzschig HK. Cd39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. *Circulation*. 2007;116:1784-1794
195. Kojima M, Kusumoto K, Fujiwara S, Watanabe T, Fujino M. Role of endogenous endothelin in the extension of myocardial infarct size studied with the endothelin receptor antagonist, tak-044. *Journal of cardiovascular pharmacology*. 1995;26:S365-368

Supplemental Text C - included studies reference list - page 10 of 24

196. Kolettis TM, Vilaeti AD, Tsalikakis DG, Zoga A, Valenti M, Tzallas AT, Papalois A, Iliodromitis EK. Effects of pre- and postconditioning on arrhythmogenesis in the in vivo rat model. *Journal of cardiovascular pharmacology and therapeutics*. 2013;18:376-385
197. Koneru S, Penumathsa SV, Thirunavukkarasu M, Samuel SM, Zhan L, Han Z, Maulik G, Das DK, Maulik N. Redox regulation of ischemic preconditioning is mediated by the differential activation of caveolins and their association with enos and glut-4. *American journal of physiology. Heart and circulatory physiology*. 2007;292:2
198. Koning MM, De Zeeuw S, Niekuop S, De Jong JW, Verdouw PD. Is myocardial infarct size limitation by ischemic preconditioning an "all or nothing" phenomenon? *Ann N Y Acad Sci*. 1994;723:333-336
199. Koning MM, Simonis LA, de Zeeuw S, Niekuop S, Post S, Verdouw PD. Ischaemic preconditioning by partial occlusion without intermittent reperfusion. *Cardiovascular research*. 1994;28:1146-1151
200. Kositprapa C, Ockaili RA, Kukreja RC. Bradykinin b2 receptor is involved in the late phase of preconditioning in rabbit heart. *Journal of molecular and cellular cardiology*. 2001;33:1355-1362
201. Kouchi I, Murakami T, Nawada R, Akao M, Sasayama S. Katp channels are common mediators of ischemic and calcium preconditioning in rabbits. *The American journal of physiology*. 1998;274:H1106-1112
202. Kremastinos DT, Bofilis E, Karavolias GK, Papalois A, Kaklamani L, Iliodromitis EK. Preconditioning limits myocardial infarct size in hypercholesterolemic rabbits. *Atherosclerosis*. 2000;150:81-89
203. Kristensen J, Mortensen UM, Nielsen SS, Maeng M, Kaltoft A, Nielsen TT, Rehling M. Myocardial perfusion imaging with 99mtc sestamibi early after reperfusion reliably reflects infarct size reduction by ischaemic preconditioning in an experimental porcine model. *Nucl Med Commun*. 2004;25:495-500
204. Kudej RK, Shen YT, Peppas AP, Huang CH, Chen W, Yan L, Vatner DE, Vatner SF. Obligatory role of cardiac nerves and alpha1-adrenergic receptors for the second window of ischemic preconditioning in conscious pigs. *Circulation research*. 2006;99:1270-1276
205. Kunuthur SP, Mocanu MM, Hemmings BA, Hausenloy DJ, Yellon DM. The akt1 isoform is an essential mediator of ischemic preconditioning. *Journal of cellular and molecular medicine*. 2012;28:1582-4934
206. Kuzmin AI, Gourine AV, Molosh AI, Lakomkin VL, Vassort G. Effects of preconditioning on myocardial interstitial levels of atp and its catabolites during regional ischemia and reperfusion in the rat. *Basic research in cardiology*. 2000;95:127-136
207. Kuzume K, Wolff RA, Chien GL, Van Winkle DM. Remifentanil limits infarct size but attenuates preconditioning-induced infarct limitation. *Coron Artery Dis*. 2004;15:449-455
208. Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M, Kamada T, Tada M. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. *Circulation research*. 1993;72:1293-1299
209. Landim MB, Dourado PM, Casella-Filho A, Chagas AC, da-Luz PL. High plasma concentrations of asymmetric dimethylarginine inhibit ischemic cardioprotection in hypercholesterolemic rats. *Brazilian journal of medical and biological research*. 2013;46:454-459
210. Lang SC, Elsasser A, Scheler C, Vetter S, Tiefenbacher CP, Kubler W, Katus HA, Vogt AM. Myocardial preconditioning and remote renal preconditioning--identifying a protective factor using proteomic methods? *Basic research in cardiology*. 2006;101:149-158
211. Lange M, Smul TM, Blomeyer CA, Redel A, Klotz KN, Roewer N, Kehl F. Role of the beta1-adrenergic pathway in anesthetic and ischemic preconditioning against myocardial infarction in the rabbit heart in vivo. *Anesthesiology*. 2006;105:503-510
212. Lankford AR, Yang JN, Rose'Meyer R, French BA, Matherne GP, Fredholm BB, Yang Z. Effect of modulating cardiac a1 adenosine receptor expression on protection with ischemic preconditioning. *American journal of physiology. Heart and circulatory physiology*. 2006;290:18
213. Larsen JR, Aagaard SR, Hasenkam JM, Sloth E. Pre-occlusion ischaemia, not sevoflurane, successfully preconditions the myocardium against further damage in porcine in vivo hearts. *Acta Anaesthesiol Scand*. 2007;51:402-409
214. Lasley RD, Kony PJ, Hegge JO, Mentzer RM, Jr. Effects of ischemic and adenosine preconditioning on interstitial fluid adenosine and myocardial infarct size. *The American journal of physiology*. 1995;269:H1460-1466
215. Lazou A, Iliodromitis EK, Cieslak D, Voskarides K, Mousikos S, Bofilis E, Kremastinos DT. Ischemic but not mechanical preconditioning attenuates ischemia/reperfusion induced myocardial apoptosis in anaesthetized rabbits: The role of bcl-2 family proteins and erk1/2. *Apoptosis*. 2006;11:2195-2204
216. Lee TM, Su SF, Tsai CC, Lee YT, Tsai CH. Cardioprotective effects of 17 beta-estradiol produced by activation of mitochondrial atp-sensitive k(+)channels in canine hearts. *Journal of molecular and cellular cardiology*. 2000;32:1147-1158
217. Lee BH, Choi MJ, Kim WG. Effect of ischemic preconditioning based on different epicardial branching patterns of the left coronary artery in the rabbit heart. *J Invest Surg*. 2004;17:71-79

Supplemental Text C - included studies reference list - page 11 of 24

218. Li GC, Vasquez JA, Gallagher KP, Lucchesi BR. Myocardial protection with preconditioning. *Circulation*. 1990;82:609-619
219. Li Q, Guo Y, Xuan YT, Lowenstein CJ, Stevenson SC, Prabhu SD, Wu WJ, Zhu Y, Bolli R. Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. *Circulation research*. 2003;92:741-748
220. Li R, Wong GT, Wong TM, Zhang Y, Xia Z, Irwin MG. Intrathecal morphine preconditioning induces cardioprotection via activation of delta, kappa, and mu opioid receptors in rats. *Anesth Analg*. 2009;108:23-29
221. Li SJ, Wu YN, Kang Y, Yin YQ, Gao WZ, Liu YX, Lou JS. Influence of limb atraumatic ischemic preconditioning on fibrolysis factors in myocardial ischemia/reperfusion injury in rats. [chinese]. *Chinese Pharmacological Bulletin*. 2008;24:1344-1347
222. Li SJ, Wu YN, Kang Y, Yin YQ, Gao WZ, Liu YX, Lou JS. Effects of limb atraumatic ischemic preconditioning on apoptosis induced by myocardial ischemia-reperfusion injury in rats. [chinese]. *Chinese Pharmacological Bulletin*. 2009;25:100-104
223. Li SJ, Wu YN, Kang Y, Yin YQ, Gao WZ, Liu YX, Lou JS. Noninvasive limb ischemic preconditioning protects against myocardial i/r injury in rats. *J Surg Res*. 2010;164:162-168
224. Li W, Jia G, Guo W, Wang H. Nitric oxide opens second window of protection in ischemic preconditioning via induction of heat-shock protein 72. *Chin Med J*. 2003;116:258-262
225. Li XD, Cheng YT, Yang YJ, Meng XM, Zhao JL, Zhang HT, Wu YJ, You SJ, Wu YL. Pka-mediated enos phosphorylation in the protection of ischemic preconditioning against no-reflow. *Microvascular research*. 2012;84:44-54
226. Li XD, Yang YJ, Zhao JL, Zhang HT, Cheng YT, Tian Y, Meng XM, Cui HH, Wang TJ. [ischemic preconditioning attenuates myocardial no-reflow and reperfusion injury after revascularization of acute myocardial infarction by reducing myocardial edema via the protein kinase a pathway]. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2012;40:945-951
227. Li YW, Whittaker P, Kloner RA. The transient nature of the effect of ischemic preconditioning on myocardial infarct size and ventricular arrhythmia. *Am Heart J*. 1992;123:346-353
228. Li Y, Kloner RA. Cardioprotective effects of ischaemic preconditioning are not mediated by prostanoids. *Cardiovascular research*. 1992;26:226-231
229. Li Y, Kloner RA. Adenosine deaminase inhibition is not cardioprotective in the rat. *Am Heart J*. 1993;126:1293-1298
230. Li Y, Kloner RA. The cardioprotective effects of ischemic 'preconditioning' are not mediated by adenosine receptors in rat hearts. *Circulation*. 1993;87:1642-1648
231. Li Y, Kloner RA. Cardioprotective effects of ischemic preconditioning can be recaptured after they are lost. *J Am Coll Cardiol*. 1994;23:470-474
232. Li Y, Kloner RA. Does protein kinase c play a role in ischemic preconditioning in rat hearts? *The American journal of physiology*. 1995;268:H426-431
233. Li Y, Cai M, Xu Y, Swartz HM, He G. Late phase ischemic preconditioning preserves mitochondrial oxygen metabolism and attenuates post-ischemic myocardial tissue hyperoxygenation. *Life Sci*. 2011;88:57-64
234. Liao XL, Hu XX, Chang FJ, Yuan HY, Ci HB, Wu JY, Xu Z, Wang ZP, Zhang X, Xia Z, Ou JS. A simple modification results in greater success in the model of coronary artery ligation and myocardial ischemia in mice. *Journal of cardiovascular pharmacology*. 2013;61:430-436
235. Liaudet L, Yang Z, Al-Affar EB, Szabo C. Myocardial ischemic preconditioning in rodents is dependent on poly (adp-ribose) synthetase. *Mol Med*. 2001;7:406-417
236. Lie RH, Stoestrup N, Sloth E, Hasenham JM, Kroyer R, Nielsen TT. Post-conditioning with cyclosporine a fails to reduce the infarct size in an *in vivo* porcine model. *Acta Anaesthesiol Scand*. 2010;54:804-813
237. Liem DA, van den Doel MA, de Zeeuw S, Verdouw PD, Duncker DJ. Role of adenosine in ischemic preconditioning in rats depends critically on the duration of the stimulus and involves both a(1) and a(3) receptors. *Cardiovascular research*. 2001;51:701-708
238. Liem DA, te Lintel Hekkert M, Manintveld OC, Boomsma F, Verdouw PD, Duncker DJ. Myocardium tolerant to an adenosine-dependent ischemic preconditioning stimulus can still be protected by stimuli that employ alternative signaling pathways. *American journal of physiology. Heart and circulatory physiology*. 2005;288:14
239. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: The essential role of the mitochondrial permeability transition pore. *Cardiovascular research*. 2007;75:530-535
240. Lim SY, Yellon DM, Hausenloy DJ. The neural and humoral pathways in remote limb ischemic preconditioning. *Basic research in cardiology*. 2010;105:651-655

Supplemental Text C - included studies reference list - page 12 of 24

241. Liu Y, Thornton JD, Cohen MV, Downey JM, Schaffer SW. Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction. *Circulation*. 1993;88:1273-1278
242. Liu Y, Downey JM. Preconditioning against infarction in the rat heart does not involve a pertussis toxin sensitive g protein. *Cardiovascular research*. 1993;27:608-611
243. Liu Y, Ytrehus K, Downey JM. Evidence that translocation of protein kinase c is a key event during ischemic preconditioning of rabbit myocardium. *Journal of molecular and cellular cardiology*. 1994;26:661-668
244. Liu Y, Wu WK, Chen C, Liu KX. [role of nf-kappab in the induction of delayed preconditioning in rat heart by pretreatment with sini decoction]. *Zhongguo Zhong Yao Za Zhi*. 2005;30:453-456
245. Liu Z, Barrett HH, Stevenson GD, Furenlid LR, Pak KY, Woolfenden JM. Evaluating the protective role of ischaemic preconditioning in rat hearts using a stationary small-animal spect imager and 99mtc-glucarate. *Nucl Med Commun*. 2008;29:120-128
246. Liu GS, Stanley AW, Downey J. Cyclooxygenase products are not involved in the protection against myocardial infarction afforded by preconditioning in rabbit. Cyclooxygenase pathway's involvement in preconditioning. *Am J Cardiovasc Pathol*. 1992;4:157-164
247. Liu GS, Stanley AW, Downey JM. Ischaemic preconditioning is not dependent on neutrophils or glycolytic substrate at reperfusion in rabbit heart. *Cardiovascular research*. 1992;26:1195-1198
248. Liu Y, Downey JM. Ischemic preconditioning protects against infarction in rat heart. *The American journal of physiology*. 1992;263:H1107-1112
249. Loke KE, Woodman OL. Preconditioning improves myocardial function and reflow, but not vasodilator reactivity, after ischaemia and reperfusion in anaesthetized dogs. *Clin Exp Pharmacol Physiol*. 1998;25:552-558
250. Lott FD, Guo P, Toombs CF. Reduction in infarct size by ischemic preconditioning persists in a chronic rat model of myocardial ischemia-reperfusion injury. *Pharmacology*. 1996;52:113-118
251. Lotz C, Lazariotto M, Redel A, Smul TM, Stumpner J, Blomeyer C, Tischer-Zeitz T, Schmidt J, Pociej J, Roewer N, Kehl F, Lange M. Activation of peroxisome-proliferator-activated receptors alpha and gamma mediates remote ischemic preconditioning against myocardial infarction in vivo. *Exp Biol Med*. 2011;236:113-122
252. Lou JS, Liang HX, Liu YX. The pharmacological preconditioning of nitroglycerin and buprenorphine used in combination against myocardial ischemia in rats: Early cardioprotection. [chinese]. *Chinese Pharmacological Bulletin*. 2003;19:1119-1125
253. Lu XM, Zhang GX, Yu YQ, Kimura S, Nishiyama A, Matsuyoshi H, Shimizu J, Takaki M. The opposite roles of nnos in cardiac ischemia-reperfusion-induced injury and in ischemia preconditioning-induced cardioprotection in mice. *J Physiol Sci*. 2009;59:253-262
254. Lu Y, Dong C, Yu J, Li L. Role of central and peripheral opioid receptors in the cardioprotection of intravenous morphine preconditioning. *Ir J Med Sci*. 2011;180:881-885
255. Lu Y, Dong CS, Yu JM, Li H. Morphine reduces the threshold of remote ischemic preconditioning against myocardial ischemia and reperfusion injury in rats: The role of opioid receptors. *J Cardiothorac Vasc Anesth*. 2012;26:403-406
256. Luo D, Deng PY, Ye F, Peng WJ, Deng HW, Li YJ. Delayed preconditioning by cardiac ischemia involves endogenous calcitonin gene-related peptide via the nitric oxide pathway. *European journal of pharmacology*. 2004;502:135-141
257. Manintveld OC, te Lintel Hekkert M, Keijzer E, Verdouw PD, Duncker DJ. Intravenous adenosine protects the myocardium primarily by activation of a neurogenic pathway. *British journal of pharmacology*. 2005;145:703-711
258. Manintveld OC, Sluiter W, Dekkers DH, te Lintel Hekkert M, Lamers JM, Verdouw PD, Duncker DJ. Involvement of reperfusion injury salvage kinases in preconditioning depends critically on the preconditioning stimulus. *Exp Biol Med*. 2011;236:874-882
259. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. *Circulation*. 1993;88:1264-1272
260. Martin BJ, McClanahan TB, Van Wylen DG, Gallagher KP. Effects of ischemia, preconditioning, and adenosine deaminase inhibition on interstitial adenosine levels and infarct size. *Basic research in cardiology*. 1997;92:240-251
261. Matsuda M, Catena TG, Vander Heide RS, Jennings RB, Reimer KA. Cardiac protection by ischaemic preconditioning is not mediated by myocardial stunning. *Cardiovascular research*. 1993;27:585-592
262. Matsumura K, Komori S, Takusagawa M, Osada M, Tanabe F, Itoh M, Tamura K. Protein kinase c is involved in cardioprotective effects of ischemic preconditioning on infarct size and ventricular arrhythmia in rats in vivo. *Mol Cell Biochem*. 2000;214:39-45

Supplemental Text C - included studies reference list - page 13 of 24

263. McVey M, Perrone MH, Clark KL. Does tumor necrosis factor-alpha (tnf-alpha) contribute to myocardial reperfusion injury in anesthetized rats? *Gen Pharmacol.* 1999;32:41-45
264. McVey MJ, Smits GJ, Cox BF, Kitzen JM, Clark KL, Perrone MH. Cardiovascular pharmacology of the adenosine a1/a2-receptor agonist amp 579: Coronary hemodynamic and cardioprotective effects in the canine myocardium. *Journal of cardiovascular pharmacology.* 1999;33:703-710
265. Mei DA, Nithipatikom K, Lasley RD, Gross GJ. Myocardial preconditioning produced by ischemia, hypoxia, and a katp channel opener: Effects on interstitial adenosine in dogs. *Journal of molecular and cellular cardiology.* 1998;30:1225-1236
266. Miki T, Miura T, Ura N, Ogawa T, Suzuki K, Shimamoto K, Iimura O. Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin b2 receptor activation. *J Am Coll Cardiol.* 1996;28:1616-1622
267. Miki T, Cohen MV, Downey JM. Opioid receptor contributes to ischemic preconditioning through protein kinase c activation in rabbits. *Mol Cell Biochem.* 1998;186:3-12
268. Miki T, Miura T, Bunger R, Suzuki K, Sakamoto J, Shimamoto K. Ecto-5'-nucleotidase is not required for ischemic preconditioning in rabbit myocardium in situ. *The American journal of physiology.* 1998;275:H1329-1337
269. Miki T, Swafford AN, Cohen MV, Downey JM. Second window of protection against infarction in conscious rabbits: Real or artifactual. *Journal of molecular and cellular cardiology.* 1999;31:809-816
270. Miller DL, Van Winkle DM. Ischemic preconditioning limits infarct size following regional ischemia-reperfusion in in situ mouse hearts. *Cardiovascular research.* 1999;42:680-684
271. Minamino T, Kitakaze M, Morioka T, Node K, Komamura K, Takeda H, Inoue M, Hori M, Kamada T. Cardioprotection due to preconditioning correlates with increased ecto-5'-nucleotidase activity. *The American journal of physiology.* 1996;270:H238-244
272. Miura T, Goto M, Urabe K, Endoh A, Shimamoto K, Iimura O. Does myocardial stunning contribute to infarct size limitation by ischemic preconditioning? *Circulation.* 1991;84:2504-2512
273. Miura T, Ogawa T, Iwamoto T, Shimamoto K, Iimura O. Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning. *Circulation.* 1992;86:979-985
274. Miura T, Kawamura S, Goto M, Sakamoto J, Tsuchida A, Matsuzaki M, Shimamoto K. Effect of protein kinase c inhibitors on cardioprotection by ischemic preconditioning depends on the number of preconditioning episodes. *Cardiovascular research.* 1998;37:700-709
275. Mizumura T, Nithipatikom K, Gross GJ. Bimakalim, an atp-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs. *Circulation.* 1995;92:1236-1245
276. Mizumura T, Auchampach JA, Linden J, Bruns RF, Gross GJ. Pd 81,723, an allosteric enhancer of the a1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. *Circulation research.* 1996;79:415-423
277. Mizumura T, Saito S, Ozawa Y, Kanmatsuse K, Gross GJ. An atp-sensitive potassium (katp) channel opener, nicorandil, lowers the threshold for ischemic preconditioning in barbital-anesthetized dogs. *Heart Vessels.* 1997;12:175-177
278. Morgan EN, Boyle EM, Jr., Yun W, Griscavage-Ennis JM, Farr AL, Carty TG, Jr., Pohlman TH, Verrier ED. An essential role for nf-kappab in the cardioadaptive response to ischemia. *Ann Thorac Surg.* 1999;68:377-382
279. Mortensen UM, Norgaard BL, Nielsen-Kudsk JE, Kristensen J, Maeng M, Nielsen TT. A phase of increased st elevation during coronary occlusion following ischemic preconditioning. *Basic research in cardiology.* 2006;101:140-148
280. Mullenheim J, Frassdorf J, Preckel B, Thamer V, Schlack W. Ketamine, but not s(+)-ketamine, blocks ischemic preconditioning in rabbit hearts in vivo. *Anesthesiology.* 2001;94:630-636
281. Mullenheim J, Rulands R, Wietschorke T, Frassdorf J, Preckel B, Schlack W. Late preconditioning is blocked by racemic ketamine, but not by s(+)-ketamine. *Anesth Analg.* 2001;93:265-270
282. Mullenheim J, Schlack W, Frassdorf J, Heinen A, Preckel B, Thamer V. Additive protective effects of late and early ischaemic preconditioning are mediated by the opening of katp channels in vivo. *Pflugers Arch.* 2001;442:178-187
283. Mullenheim J, Ebel D, Bauer M, Otto F, Heinen A, Frassdorf J, Preckel B, Schlack W. Sevoflurane confers additional cardioprotection after ischemic late preconditioning in rabbits. *Anesthesiology.* 2003;99:624-631
284. Munch-Ellingsen J, Bugge E, Lokebo JE, Ytrehus K. Potassium channel blocker dofetilide does not abolish ischaemic preconditioning. *Scand J Clin Lab Invest.* 1997;57:13-20
285. Munch-Ellingsen J, Lokebo JE, Bugge B, Ytrehus K. Equal reduction in infarct size by ethylisopropyl amiloride pretreatment and ischemic preconditioning in the in situ rabbit heart. *Molecular and Cellular Biochemistry.* 1998;186:13-18

Supplemental Text C - included studies reference list - page 14 of 24

286. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. *Circulation*. 1986;74:1124-1136
287. Murry CE, Richard VJ, Jennings RB, Reimer KA. Myocardial protection is lost before contractile function recovers from ischemic preconditioning. *The American journal of physiology*. 1991;260:H796-804
288. Nadtochiy SM, Burwell LS, Ingraham CA, Spencer CM, Friedman AE, Pinkert CA, Brookes PS. In vivo cardioprotection by s-nitroso-2-mercaptopropionyl glycine. *Journal of molecular and cellular cardiology*. 2009;46:960-968
289. Nakae I, Takaoka A, Mitsunami K, Yabe T, Ito M, Masayuki, Takahashi, Matsumoto T, Omura T, Yokohama H, Kinoshita M. Cardioprotective effects of nicorandil in rabbits anaesthetized with halothane: Potentiation of ischaemic preconditioning via katp channels. *Clin Exp Pharmacol Physiol*. 2000;27:810-817
290. Nakano A, Miura T, Ura N, Suzuki K, Shimamoto K. Role of the angiotensin ii type 1 receptor in preconditioning against infarction. *Coron Artery Dis*. 1997;8:343-350
291. Naumenko SE, Latysheva TV, Gilinskii MA. Inhibition of norepinephrine reuptake and size of myocardial infarction during focal ischemia and after preconditioning. *Bull Exp Biol Med*. 2010;150:15-17
292. Nawada R, Murakami T, Iwase T, Nagai K, Morita Y, Kouchi I, Akao M, Sasayama S. Inhibition of sarcolemmal na⁺,k⁺-atpase activity reduces the infarct size-limiting effect of preconditioning in rabbit hearts. *Circulation*. 1997;96:599-604
293. Neckar J, Papousek F, Novakova O, Ost'adal B, Kolar F. Cardioprotective effects of chronic hypoxia and ischaemic preconditioning are not additive. *Basic research in cardiology*. 2002;97:161-167
294. Nieszner E, Posa I, Kocsis E, Pogatsa G, Preda I, Koltai MZ. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits. *Exp Clin Endocrinol Diabetes*. 2002;110:212-218
295. Nishihara M, Miura T, Miki T, Sakamoto J, Tanno M, Kobayashi H, Ikeda Y, Ohori K, Takahashi A, Shimamoto K. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. *American journal of physiology. Heart and circulatory physiology*. 2006;291:24
296. Nithipatikom K, Endsley MP, Moore JM, Isbell MA, Falck JR, Campbell WB, Gross GJ. Effects of selective inhibition of cytochrome p-450 omega-hydroxylases and ischemic preconditioning in myocardial protection. *American journal of physiology. Heart and circulatory physiology*. 2006;290:7
297. Nithipatikom K, Moore JM, Isbell MA, Falck JR, Gross GJ. Epoxyeicosatrienoic acids in cardioprotection: Ischemic versus reperfusion injury. *American journal of physiology. Heart and circulatory physiology*. 2006;291:10
298. Node K, Kitakaze M, Minamino T, Tada M, Inoue M, Hori M, Kamada T. Activation of ecto-5'-nucleotidase by protein kinase c and its role in ischaemic tolerance in the canine heart. *British journal of pharmacology*. 1997;120:273-281
299. Nozawa Y, Miura T, Tsuchida A, Kita H, Fukuma T, Shimamoto K. Chronic treatment with an ace inhibitor, temocapril, lowers the threshold for the infarct size-limiting effect of ischemic preconditioning. *Cardiovasc Drugs Ther*. 1999;13:151-157
300. Nozawa Y, Miura T, Miki T, Ohnuma Y, Yano T, Shimamoto K. Mitochondrial katp channel-dependent and -independent phases of ischemic preconditioning against myocardial infarction in the rat. *Basic research in cardiology*. 2003;98:50-58
301. Okamura T, Miura T, Iwamoto H, Shirakawa K, Kawamura S, Ikeda Y, Iwatate M, Matsuzaki M. Ischemic preconditioning attenuates apoptosis through protein kinase c in rat hearts. *The American journal of physiology*. 1999;277:H1997-2001
302. Okubo S, Bernardo NL, Elliott GT, Hess ML, Kukreja RC. Tyrosine kinase signaling in action potential shortening and expression of hsp72 in late preconditioning. *American journal of physiology. Heart and circulatory physiology*. 2000;279:H2269-2276
303. Okubo S, Tanabe Y, Takeda K, Kitayama M, Kanemitsu S, Kukreja RC, Takekoshi N. Ischemic preconditioning and morphine attenuate myocardial apoptosis and infarction after ischemia-reperfusion in rabbits: Role of delta-opioid receptor. *American journal of physiology. Heart and circulatory physiology*. 2004;287:1
304. Okubo S, Tanabe Y, Takeda K, Kitayama M, Kanemitsu S, Kukreja RC, Takekoshi N. Pretreatment with tyrosine kinase inhibitor attenuates the reduction of apoptosis 24 h after ischemic preconditioning. *Jpn J Physiol*. 2004;54:143-151
305. Ovize M, Kloner RA, Hale SL, Przyklenk K. Coronary cyclic flow variations "precondition" ischemic myocardium. *Circulation*. 1992;85:779-789
306. Ovize M, Aupetit JF, Rioufol G, Loufoua J, Andre-Fouet X, Minaire Y, Faucon G. Preconditioning reduces infarct size but accelerates time to ventricular fibrillation in ischemic pig heart. *The American journal of physiology*. 1995;269:H72-79

Supplemental Text C - included studies reference list - page 15 of 24

307. Pagel PS, Krolikowski JG, Shim YH, Venkatapuram S, Kersten JR, Weihrauch D, Warltier DC, Pratt PF, Jr. Noble gases without anesthetic properties protect myocardium against infarction by activating prosurvival signaling kinases and inhibiting mitochondrial permeability transition in vivo. *Anesth Analg.* 2007;105:562-569
308. Patel HH, Hsu A, Moore J, Gross GJ. Bw373u86, a delta opioid agonist, partially mediates delayed cardioprotection via a free radical mechanism that is independent of opioid receptor stimulation. *Journal of molecular and cellular cardiology.* 2001;33:1455-1465
309. Patel HH, Moore J, Hsu AK, Gross GJ. Cardioprotection at a distance: Mesenteric artery occlusion protects the myocardium via an opioid sensitive mechanism. *Journal of molecular and cellular cardiology.* 2002;34:1317-1323
310. Patel HH, Gross ER, Peart JN, Hsu AK, Gross GJ. Sarcolemmal katp channel triggers delayed ischemic preconditioning in rats. *American journal of physiology. Heart and circulatory physiology.* 2005;288:24
311. Peart JN, Patel HH, Gross GJ. Delta-opioid receptor activation mimics ischemic preconditioning in the canine heart. *Journal of cardiovascular pharmacology.* 2003;42:78-81
312. Pell TJ, Baxter GF, Yellon DM, Drew GM. Renal ischemia preconditions myocardium: Role of adenosine receptors and atp-sensitive potassium channels. *The American journal of physiology.* 1998;275:H1542-1547
313. Perricone AJ, Bivona BJ, Jackson FR, Vander Heide RS. Conditional knockout of myocyte focal adhesion kinase abrogates ischemic preconditioning in adult murine hearts. *Journal of the American Heart Association.* 2013;2:e000457
314. Petrischev NN, Shlyakhto Ye V, Tsyrin VA, Vlasov TD, Syrensky AV, Galagudza MM. The role of oxygen free radicals in the mechanisms of local and distant ischemic myocardial preconditioning. [russian]. *Vestnik Rossiiskoi Akademii Meditsinskikh Nauk.* 2006:10-15
315. Ping P, Takano H, Zhang J, Tang XL, Qiu Y, Li RC, Banerjee S, Dawn B, Balafonova Z, Bolli R. Isoform-selective activation of protein kinase c by nitric oxide in the heart of conscious rabbits: A signaling mechanism for both nitric oxide-induced and ischemia-induced preconditioning. *Circulation research.* 1999;84:587-604
316. Ping P, Song C, Zhang J, Guo Y, Cao X, Li RC, Wu W, Vondriska TM, Pass JM, Tang XL, Pierce WM, Bolli R. Formation of protein kinase c(epsilon)-lck signaling modules confers cardioprotection. *The Journal of clinical investigation.* 2002;109:499-507
317. Piot CA, Padmanaban D, Ursell PC, Sievers RE, Wolfe CL. Ischemic preconditioning decreases apoptosis in rat hearts in vivo. *Circulation.* 1997;96:1598-1604
318. Poulsen RH, Rasmussen JT, Botker HE, Waehrens LS, Falborg L, Heegaard CW, Rehling M. Imaging the myocardium at risk with (9)(9)mct-lactadherin administered after reperfusion in a porcine model. *Nuclear medicine and biology.* 2014;41:114-119
319. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. *Circulation.* 1993;87:893-899
320. Przyklenk K, Sussman MA, Simkhovich BZ, Kloner RA. Does ischemic preconditioning trigger translocation of protein kinase c in the canine model? *Circulation.* 1995;92:1546-1557
321. Przyklenk K, Zhao L, Kloner RA, Elliott GT. Cardioprotection with ischemic preconditioning and mla: Role of adenosine-regulating enzymes? *The American journal of physiology.* 1996;271:H1004-1014
322. Przyklenk K, Hata K, Kloner RA. Is calcium a mediator of infarct size reduction with preconditioning in canine myocardium? *Circulation.* 1997;96:1305-1312
323. Przyklenk K, Li G, Whittaker P. No loss in the in vivo efficacy of ischemic preconditioning in middle-aged and old rabbits. *J Am Coll Cardiol.* 2001;38:1741-1747
324. Przyklenk K, Li G, Simkhovich BZ, Kloner RA. Mechanisms of myocardial ischemic preconditioning are age related: Pkc-epsilon does not play a requisite role in old rabbits. *J Appl Physiol.* 2003;95:2563-2569
325. Qian YZ, Levasseur JE, Yoshida KI, Kukreja RC. K(atp) channels in rat heart: Blockade of ischemic and acetylcholine- mediated preconditioning by glibenclamide. *American Journal of Physiology - Heart and Circulatory Physiology.* 1996;271:H23-H28
326. Qian YZ, Bernardo NL, Nayeem MA, Chelliah J, Kukreja RC. Induction of 72-kda heat shock protein does not produce second window of ischemic preconditioning in rat heart. *The American journal of physiology.* 1999;276:H224-234
327. Qiu Y, Rizvi A, Tang XL, Manchikalapudi S, Takano H, Jadoon AK, Wu WJ, Bolli R. Nitric oxide triggers late preconditioning against myocardial infarction in conscious rabbits. *The American journal of physiology.* 1997;273:H2931-2936
328. Qiu Y, Tang XL, Park SW, Sun JZ, Kalya A, Bolli R. The early and late phases of ischemic preconditioning: A comparative analysis of their effects on infarct size, myocardial stunning, and arrhythmias in conscious pigs undergoing a 40-minute coronary occlusion. *Circulation research.* 1997;80:730-742

Supplemental Text C - included studies reference list - page 16 of 24

329. Rajesh KG, Sasaguri S, Zhitian Z, Suzuki R, Asakai R, Maeda H. Second window of ischemic preconditioning regulates mitochondrial permeability transition pore by enhancing bcl-2 expression. *Cardiovascular research*. 2003;59:297-307
330. Rajesh KG, Sasaguri S, Suzuki R, Xing Y, Maeda H. Ischemic preconditioning prevents reperfusion heart injury in cardiac hypertrophy by activation of mitochondrial katp channels. *Int J Cardiol*. 2004;96:41-49
331. Raphael J, Drenger B, Rivo J, Berenshtein E, Chevion M, Gozal Y. Ischemic preconditioning decreases the reperfusion-related formation of hydroxyl radicals in a rabbit model of regional myocardial ischemia and reperfusion: The role of k(atp) channels. *Free Radic Res*. 2005;39:747-754
332. Redel A, Stumpner J, Tischer-Zeitz T, Lange M, Smul TM, Lotz C, Roewer N, Kehl F. Comparison of isoflurane-, sevoflurane-, and desflurane-induced pre- and postconditioning against myocardial infarction in mice in vivo. *Exp Biol Med*. 2009;234:1186-1191
333. Reffelmann T, Kloner RA. Is microvascular protection by cariporide and ischemic preconditioning causally linked to myocardial salvage? *American journal of physiology. Heart and circulatory physiology*. 2003;284:10
334. Ren X, Wang Y, Jones WK. Tnf-alpha is required for late ischemic preconditioning but not for remote preconditioning of trauma. *J Surg Res*. 2004;121:120-129
335. Richard V, Tron C, Thuillez C. Ischaemic preconditioning is not mediated by oxygen derived free radicals in rats. *Cardiovascular research*. 1993;27:2016-2021
336. Richard V, Kaeffer N, Tron C, Thuillez C. Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion. *Circulation*. 1994;89:1254-1261
337. Rioufol G, Ovize M, Loufoua J, Pop C, Andre-Fouat X, Minaire Y. Ventricular fibrillation in preconditioned pig hearts: Role of k+atp channels. *The American journal of physiology*. 1997;273:H2804-2810
338. Rivo J, Raphael J, Drenger B, Berenshtein E, Chevion M, Gozal Y. Flumazenil mimics whereas midazolam abolishes ischemic preconditioning in a rabbit heart model of ischemia-reperfusion. *Anesthesiology*. 2006;105:65-71
339. Roesner JP, Petzelbauer P, Koch A, Mersmann J, Zacharowski PA, Boehm O, Reingruber S, Pasteiner W, Mascher D, Wolzt M, Barthuber C, Noldge-Schomburg GE, Scheeren TW, Zacharowski K. The fibrin-derived peptide bbeta15-42 is cardioprotective in a pig model of myocardial ischemia-reperfusion injury. *Crit Care Med*. 2007;35:1730-1735
340. Roesner JP, Mersmann J, Bergt S, Bohnenberg K, Barthuber C, Szabo C, Noldge-Schomburg GE, Zacharowski K. Therapeutic injection of parp inhibitor ino-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. *Shock*. 2010;33:507-512
341. Rohmann S, Weygandt H, Schelling P, Kie Soei L, Verdouw PD, Lues I. Involvement of atp-sensitive potassium channels in preconditioning protection. *Basic research in cardiology*. 1994;89:563-576
342. Sack S, Mohri M, Arras M, Schwarz ER, Schaper W. Ischaemic preconditioning--time course of renewal in the pig. *Cardiovascular research*. 1993;27:551-555
343. Sanada S, Kitakaze M, Asanuma H, Harada K, Ogita H, Node K, Takashima S, Sakata Y, Asakura M, Shinozaki Y, Mori H, Kuzuya T, Hori M. Role of mitochondrial and sarcolemmal k(atp) channels in ischemic preconditioning of the canine heart. *American journal of physiology. Heart and circulatory physiology*. 2001;280:H256-263
344. Sanada S, Kitakaze M, Papst PJ, Hatanaka K, Asanuma H, Aki T, Shinozaki Y, Ogita H, Node K, Takashima S, Asakura M, Yamada J, Fukushima T, Ogai A, Kuzuya T, Mori H, Terada N, Yoshida K, Hori M. Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart. *Circulation research*. 2001;88:175-180
345. Sanada S, Asanuma H, Tsukamoto O, Minamino T, Node K, Takashima S, Fukushima T, Ogai A, Shinozaki Y, Fujita M, Hirata A, Okuda H, Shimokawa H, Tomoike H, Hori M, Kitakaze M. Protein kinase a as another mediator of ischemic preconditioning independent of protein kinase c. *Circulation*. 2004;110:51-57
346. Sandhu R, Diaz RJ, Mao GD, Wilson GJ. Ischemic preconditioning: Differences in protection and susceptibility to blockade with single-cycle versus multicycle transient ischemia. *Circulation*. 1997;96:984-995
347. Sanz E, Garcia Dorado D, Oliveras J, Barrabes JA, Gonzalez MA, Ruiz-Meana M, Solares J, Carreras MJ, Garcia-Lafuente A, Desco M, et al. Dissociation between anti-infarct effect and anti-edema effect of ischemic preconditioning. *The American journal of physiology*. 1995;268:H233-241
348. Sarkar K, Cai Z, Gupta R, Parajuli N, Fox-Talbot K, Darshan MS, Gonzalez FJ, Semenza GL. Hypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning. *Proc Natl Acad Sci U S A*. 2012;109:10504-10509
349. Sasamori J, Aihara K, Yoneyama F, Sato I, Kogi K, Takeo S. Amelioration of ischemia/reperfusion-induced myocardial infarction by the 2-alkynyladenosine derivative 2-octynyladenosine (yt-146). *Journal of cardiovascular pharmacology*. 2006;47:614-620

Supplemental Text C - included studies reference list - page 17 of 24

350. Sato H, Bolli R, Rokosh GD, Bi Q, Dai S, Shirk G, Tang XL. The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a cox-2-mediated mechanism in conscious rats. *American journal of physiology. Heart and circulatory physiology.* 2007;293:17
351. Sbarouni E, Iliodromitis EK, Zoga A, Vlachou G, Andreadou I, Kremastinos DT. The effect of the phytoestrogen genistein on myocardial protection, preconditioning and oxidative stress. *Cardiovasc Drugs Ther.* 2006;20:253-258
352. Schmidt MR, Stotrup NB, Contractor H, Hyldebrandt JA, Johannsen M, Pedersen CM, Birkler R, Ashrafian H, Sorensen KE, Kharbanda RK, Redington AN, Botker HE. Remote ischemic preconditioning with--but not without--metabolic support protects the neonatal porcine heart against ischemia-reperfusion injury. *Int J Cardiol.* 2014;170:388-393
353. Schoemaker RG, van Heijningen CL. Bradykinin mediates cardiac preconditioning at a distance. *American journal of physiology. Heart and circulatory physiology.* 2000;278:H1571-1576
354. Schott RJ, Schaper W. Ischemic preconditioning and myocardial stunning: Related consequences of brief coronary occlusion and reperfusion? *Adv Cardiol.* 1990;37:32-41
355. Schultz JEJ, Rose E, Yao Z, Gross GJ. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. *American Journal of Physiology - Heart and Circulatory Physiology.* 1995;268:H2157-H2161
356. Schultz JEJ, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effects of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. *Circulation research.* 1996;78:1100-1104
357. Schultz JE, Qian YZ, Gross GJ, Kukreja RC. The ischemia-selective katp channel antagonist, 5-hydroxydecanoate, blocks ischemic preconditioning in the rat heart. *Journal of molecular and cellular cardiology.* 1997;29:1055-1060
358. Schultz JE, Yao Z, Cavero I, Gross GJ. Glibenclamide-induced blockade of ischemic preconditioning is time dependent in intact rat heart. *The American journal of physiology.* 1997;272:H2607-2615
359. Schultz JJ, Hsu AK, Gross GJ. Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart. *Journal of molecular and cellular cardiology.* 1997;29:1355-1362
360. Schultz JJ, Hsu AK, Gross GJ. Ischemic preconditioning and morphine-induced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart. *Journal of molecular and cellular cardiology.* 1997;29:2187-2195
361. Schultz JE, Hsu AK, Barbieri JT, Li PL, Gross GJ. Pertussis toxin abolishes the cardioprotective effect of ischemic preconditioning in intact rat heart. *The American journal of physiology.* 1998;275:H495-500
362. Schultz JE, Hsu AK, Gross GJ. Ischemic preconditioning in the intact rat heart is mediated by delta1- but not mu- or kappa-opioid receptors. *Circulation.* 1998;97:1282-1289
363. Schultz JE, Kwok WM, Hsu AK, Gross GJ. Terikalant, an inward-rectifier potassium channel blocker, does not abolish the cardioprotection induced by ischemic preconditioning in the rat. *Journal of molecular and cellular cardiology.* 1998;30:1817-1825
364. Schulz R, Rose J, Heusch G. Involvement of activation of atp-dependent potassium channels in ischemic preconditioning in swine. *The American journal of physiology.* 1994;267:H1341-1352
365. Schwartz LM, Jennings RB, Reimer KA. Premedication with the opioid analgesic butorphanol raises the threshold for ischemic preconditioning in dogs. *Basic research in cardiology.* 1997;92:106-114
366. Schwartz LM, Sebbag L, Jennings RB, Reimer KA. Duration and reinstatement of myocardial protection against infarction by ischemic preconditioning in open chest dogs. *Journal of molecular and cellular cardiology.* 2001;33:1561-1570
367. Schwartz LM, Welch TS, Crago MS. Cardioprotection by multiple preconditioning cycles does not require mitochondrial k(atp) channels in pigs. *American journal of physiology. Heart and circulatory physiology.* 2002;283:27
368. Schwarz ER, Montino H, Fleischhauer J, Klues HG, vom Dahl J, Hanrath P. Angiotensin ii receptor antagonist exp 3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart. *Cardiovasc Drugs Ther.* 1997;11:687-695
369. Schwarz ER, Fleischhauer J, Montino H, Chakupurakal R, Foresti M, Schuetz T, Sack S, Mohri M, Arras M, Schaper W, Hanrath P. Infarct size reduction by ischemic preconditioning is a monophasic, short-lived phenomenon in anesthetized pigs. *Journal of cardiovascular pharmacology and therapeutics.* 1998;3:63-70
370. Sebbag L, Katsuragawa M, Verbinski S, Jennings RB, Reimer KA. Intracoronary administration of the alpha 1-receptor agonist, methoxamine, does not reproduce the infarct-limiting effect of ischemic preconditioning in dogs. *Cardiovascular research.* 1996;32:830-838
371. Shahid M, Tauseef M, Sharma KK, Fahim M. Brief femoral artery ischaemia provides protection against myocardial ischaemia-reperfusion injury in rats: The possible mechanisms. *Exp Physiol.* 2008;93:954-968

Supplemental Text C - included studies reference list - page 18 of 24

372. Shattock MJ, Lawson CS, Hearse DJ, Downey JM. Electrophysiological characteristics of repetitive ischemic preconditioning in the pig heart. *Journal of molecular and cellular cardiology*. 1996;28:1339-1347
373. Shekarforoush S, Noroozzadeh A, Safari F, Golmanesh L, Khoshbaten A. Acute effect of burn trauma to small skin areas on myocardial ischemiareperfusion injury in rat. *Physiology and Pharmacology*. 2011;15:241-248
374. Sheldrick A, Gray KM, Drew GM, Louttit JB. The effect of body temperature on myocardial protection conferred by ischaemic preconditioning or the selective adenosine a1 receptor agonist gr79236, in an anaesthetized rabbit model of myocardial ischaemia and reperfusion. *British journal of pharmacology*. 1999;128:385-395
375. Shen YT, Depre C, Yan L, Park JY, Tian B, Jain K, Chen L, Zhang Y, Kudej RK, Zhao X, Sadoshima J, Vatner DE, Vatner SF. Repetitive ischemia by coronary stenosis induces a novel window of ischemic preconditioning. *Circulation*. 2008;118:1961-1969
376. Shen B, Li J, Gao L, Zhang J, Yang B. Role of cc-chemokine receptor 5 on myocardial ischemia-reperfusion injury in rats. *Mol Cell Biochem*. 2013;378:137-144
377. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A, Bolli R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. *Proc Natl Acad Sci U S A*. 2000;97:10197-10202
378. Shinmura K, Bolli R, Liu SQ, Tang XL, Kodani E, Xuan YT, Srivastava S, Bhatnagar A. Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. *Circulation research*. 2002;91:240-246
379. Shintani Y, Node K, Asanuma H, Sanada S, Takashima S, Asano Y, Liao Y, Fujita M, Hirata A, Shinozaki Y, Fukushima T, Nagamachi Y, Okuda H, Kim J, Tomoike H, Hori M, Kitakaze M. Opening of ca²⁺-activated k⁺ channels is involved in ischemic preconditioning in canine hearts. *Journal of molecular and cellular cardiology*. 2004;37:1213-1218
380. Singh D, Sharma A, Singh M. Effect of actinomycin d and cycloheximide on ischemic preconditioning-induced delayed cardioprotective effect in rats. *Indian J Exp Biol*. 2000;38:982-987
381. Singh D, Chopra K. Evidence of the role of angiotensin at(1) receptors in remote renal preconditioning of myocardium. *Methods Find Exp Clin Pharmacol*. 2004;26:117-122
382. Sivarajah A, McDonald MC, Thiemermann C. The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist. *J Pharmacol Exp Ther*. 2005;313:896-901
383. Sivarajah A, McDonald MC, Thiemermann C. The production of hydrogen sulfide limits myocardial ischemia and reperfusion injury and contributes to the cardioprotective effects of preconditioning with endotoxin, but not ischemia in the rat. *Shock*. 2006;26:154-161
384. Smits GJ, McVey M, Cox BF, Perrone MH, Clark KL. Cardioprotective effects of the novel adenosine a1/a2 receptor agonist amp 579 in a porcine model of myocardial infarction. *J Pharmacol Exp Ther*. 1998;286:611-618
385. Smul TM, Stumpner J, Blomeyer C, Lotz C, Redel A, Lange M, Roewer N, Kehl F. Propofol inhibits desflurane-induced preconditioning in rabbits. *J Cardiothorac Vasc Anesth*. 2011;25:276-281
386. Speechley-Dick ME, Mocanu MM, Yellon DM. Protein kinase c. Its role in ischemic preconditioning in the rat. *Circulation research*. 1994;75:586-590
387. Speechley-Dick ME, Baxter GF, Yellon DM. Ischaemic preconditioning protects hypertrophied myocardium. *Cardiovascular research*. 1994;28:1025-1029
388. Strohm C, Barancik T, Bruhl ML, Kilian SA, Schaper W. Inhibition of the er-kinase cascade by pd98059 and uo126 counteracts ischemic preconditioning in pig myocardium. *Journal of cardiovascular pharmacology*. 2000;36:218-229
389. Su DC, Chang ZW, Fan SY. [role of gap junction in ischemic preconditioning]. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2006;34:690-694
390. Suzuki K, Miura T, Miki T, Tsuchida A, Shimamoto K. Infarct-size limitation by preconditioning is enhanced by dipyridamole administered before but not after preconditioning: Evidence for the role of interstitial adenosine level during preconditioning as a primary determinant of cardioprotection. *Journal of cardiovascular pharmacology*. 1998;31:1-9
391. Takano H, Manchikalapudi S, Tang XL, Qiu Y, Rizvi A, Jadoon AK, Zhang Q, Bolli R. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. *Circulation*. 1998;98:441-449
392. Takano H, Tang XL, Qiu Y, Guo Y, French BA, Bolli R. Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism. *Circulation research*. 1998;83:73-84

Supplemental Text C - included studies reference list - page 19 of 24

393. Takano H, Tang XL, Bolli R. Differential role of k_(ATP) channels in late preconditioning against myocardial stunning and infarction in rabbits. *American journal of physiology. Heart and circulatory physiology.* 2000;279:H2350-2359
394. Takano H, Tang XL, Kodani E, Bolli R. Late preconditioning enhances recovery of myocardial function after infarction in conscious rabbits. *American journal of physiology. Heart and circulatory physiology.* 2000;279:H2372-2381
395. Takaoka A, Nakae I, Mitsunami K, Yabe T, Morikawa S, Inubushi T, Kinoshita M. Renal ischemia/reperfusion remotely improves myocardial energy metabolism during myocardial ischemia via adenosine receptors in rabbits: Effects of "remote preconditioning". *J Am Coll Cardiol.* 1999;33:556-564
396. Takasaki Y, Adachi N, Dote K, Tsubota S, Yorozuya T, Arai T. Ischemic preconditioning suppresses the noradrenaline turnover in the rat heart. *Cardiovascular research.* 1998;39:373-380
397. Talukder MA, Yang F, Shimokawa H, Zweier JL. Enos is required for acute *in vivo* ischemic preconditioning of the heart: Effects of ischemic duration and sex. *American journal of physiology. Heart and circulatory physiology.* 2010;299:4
398. Tanaka M, Fujiwara H, Yamasaki K, Miyamae M, Yokota R, Hasegawa K, Fujiwara T, Sasayama S. Ischemic preconditioning elevates cardiac stress protein but does not limit infarct size 24 or 48 h later in rabbits. *The American journal of physiology.* 1994;267:H1476-1482
399. Tanaka M, Fujiwara H, Yamasaki K, Sasayama S. Superoxide dismutase and n-2-mercaptopropionyl glycine attenuate infarct size limitation effect of ischaemic preconditioning in the rabbit. *Cardiovascular research.* 1994;28:980-986
400. Tang XL, Xuan YT, Zhu Y, Shirk G, Bolli R. Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits. *American journal of physiology. Heart and circulatory physiology.* 2004;286:18
401. Tang XL, Takano H, Xuan YT, Sato H, Kodani E, Dawn B, Zhu Y, Shirk G, Wu WJ, Bolli R. Hypercholesterolemia abrogates late preconditioning via a tetrahydrobiopterin-dependent mechanism in conscious rabbits. *Circulation.* 2005;112:2149-2156
402. Tang XL, Sato H, Tiwari S, Dawn B, Bi Q, Li Q, Shirk G, Bolli R. Cardioprotection by postconditioning in conscious rats is limited to coronary occlusions <45 min. *American journal of physiology. Heart and circulatory physiology.* 2006;291:30
403. Tanhehco EJ, Yasojima K, McGeer PL, McGeer EG, Lucchesi BR. Preconditioning reduces myocardial complement gene expression *in vivo*. *American journal of physiology. Heart and circulatory physiology.* 2000;279:H1157-1165
404. Tanno M, Tsuchida A, Nozawa Y, Matsumoto T, Hasegawa T, Miura T, Shimamoto K. Roles of tyrosine kinase and protein kinase c in infarct size limitation by repetitive ischemic preconditioning in the rat. *Journal of cardiovascular pharmacology.* 2000;35:345-352
405. Thornton J, Striplin S, Liu GS, Swafford A, Stanley AW, Van Winkle DM, Downey JM. Inhibition of protein synthesis does not block myocardial protection afforded by preconditioning. *The American journal of physiology.* 1990;259:H1822-1825
406. Thornton JD, Liu GS, Olsson RA, Downey JM. Intravenous pretreatment with a1-selective adenosine analogues protects the heart against infarction. *Circulation.* 1992;85:659-665
407. Thornton JD, Daly JF, Cohen MV, Yang XM, Downey JM. Catecholamines can induce adenosine receptor-mediated protection of the myocardium but do not participate in ischemic preconditioning in the rabbit. *Circulation research.* 1993;73:649-655
408. Thornton JD, Liu GS, Downey JM. Pretreatment with pertussis toxin blocks the protective effects of preconditioning: Evidence for a g-protein mechanism. *Journal of molecular and cellular cardiology.* 1993;25:311-320
409. Thornton JD, Thornton CS, Downey JM. Effect of adenosine receptor blockade: Preventing protective preconditioning depends on time of initiation. *The American journal of physiology.* 1993;265:H504-508
410. Tissier R, Souktani R, Parent de Curzon O, Lellouche N, Henry P, Giudicelli JF, Berdeaux A, Ghaleh B. Pharmacological delayed preconditioning against ischaemia-induced ventricular arrhythmias: Effect of an adenosine a(1)-receptor agonist. *British journal of pharmacology.* 2001;134:1532-1538
411. Tissier R, Souktani R, Bruneval P, Giudicelli JF, Berdeaux A, Ghaleh B. Adenosine a(1)-receptor induced late preconditioning and myocardial infarction: Reperfusion duration is critical. *American journal of physiology. Heart and circulatory physiology.* 2002;283:H38-43
412. Toller WG, Kersten JR, Pagel PS, Hetrick DA, Warltier DC. Sevoflurane reduces myocardial infarct size and decreases the time threshold for ischemic preconditioning in dogs. *Anesthesiology.* 1999;91:1437-1446

Supplemental Text C - included studies reference list - page 20 of 24

413. Toombs CF, Wiltse AL, Shebuski RJ. Ischemic preconditioning fails to limit infarct size in reserpinized rabbit myocardium. Implication of norepinephrine release in the preconditioning effect. *Circulation*. 1993;88:2351-2358
414. Toufektsian MC, Morel S, Tanguy S, Jeunet A, de Leiris J, Boucher F. Involvement of reactive oxygen species in cardiac preconditioning in rats. *Antioxidants & redox signaling*. 2003;5:115-122
415. Toyoda Y, Di Gregorio V, Parker RA, Levitsky S, McCully JD. Anti-stunning and anti-infarct effects of adenosine-enhanced ischemic preconditioning. *Circulation*. 2000;102:III326-331
416. Tranter M, Ren X, Forde T, Wilhude ME, Chen J, Sartor MA, Medvedovic M, Jones WK. Nf-kb driven cardioprotective gene programs; hsp70.3 and cardioprotection after late ischemic preconditioning. *Journal of molecular and cellular cardiology*. 2010;49:664-672
417. Tsovolas K, Iliodromitis EK, Andreadou I, Zoga A, Demopoulou M, Iliodromitis KE, Manolaki T, Markantonis SL, Kremastinos DT. Acute administration of vitamin c abrogates protection from ischemic preconditioning in rabbits. *Pharmacol Res*. 2008;57:283-289
418. Tsuchida A, Miura T, Miki T, Shimamoto K, Iimura O. Role of adenosine receptor activation in myocardial infarct size limitation by ischaemic preconditioning. *Cardiovascular research*. 1992;26:456-461
419. Tsuchida A, Thompson R, Olsson RA, Downey JM. The anti-infarct effect of an adenosine a1-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of ischaemic preconditioning in rabbit heart. *Journal of molecular and cellular cardiology*. 1994;26:303-311
420. Tsuchida A, Yang XM, Burckhardt B, Mullane KM, Cohen MV, Downey JM. Acadesine extends the window of protection afforded by ischaemic preconditioning. *Cardiovascular research*. 1994;28:379-383
421. Tsuchida A, Miura T, Tanno M, Nozawa Y, Kita H, Shimamoto K. Time window for the contribution of the delta-opioid receptor to cardioprotection by ischemic preconditioning in the rat heart. *Cardiovasc Drugs Ther*. 1998;12:365-373
422. Turan NN, Basgut B, Aypar E, Ark M, Iskit AB, Cakici I. Chemical preconditioning effect of 3-nitropropionic acid in anesthetized rat heart. *Life Sci*. 2008;82:928-933
423. Ueda Y, Kitakaze M, Komamura K, Minamino T, Asanuma H, Sato H, Kuzuya T, Takeda H, Hori M. Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. *J Am Coll Cardiol*. 1999;34:2120-2125
424. Uematsu M, Gaudette GR, Laurikka JO, Levitsky S, McCully JD. Adenosine-enhanced ischemic preconditioning decreases infarct in the regional ischemic sheep heart. *Ann Thorac Surg*. 1998;66:382-387
425. Valtchanova-Matchouganska A, Gondwe M, Nadar A. The role of c-reactive protein in ischemia/reperfusion injury and preconditioning in a rat model of myocardial infarction. *Life Sci*. 2004;75:901-910
426. Valtchanova-Matchouganska A, Ojewole JA. Mechanisms of opioid delta (delta) and kappa (kappa) receptors' cardioprotection in ischaemic preconditioning in a rat model of myocardial infarction. *Cardiovasc JS Afr*. 2003;14:73-80
427. Van Den Doel MA, Gho BCG, Duval SY, Schoemaker RG, Duncker DJ, Verdouw PD. Hypothermia extends the cardioprotection by ischaemic preconditioning to coronary artery occlusions of longer duration. *Cardiovascular research*. 1998;37:76-81
428. Vander Heide RS, Schwartz LM, Reimer KA. The novel calcium antagonist ro 40-5967 limits myocardial infarct size in the dog. *Cardiovascular research*. 1994;28:1526-1532
429. Van Winkle DM, Chien GL, Wolff RA, Soifer BE, Kuzume K, Davis RF. Cardioprotection provided by adenosine receptor activation is abolished by blockade of the katp channel. *The American journal of physiology*. 1994;266:H829-839
430. Van Wylen DG. Effect of ischemic preconditioning on interstitial purine metabolite and lactate accumulation during myocardial ischemia. *Circulation*. 1994;89:2283-2289
431. Vetterlein F, Muhlfeld C, Cetegen C, Volkmann R, Schrader C, Hellige G. Redistribution of connexin43 in regional acute ischemic myocardium: Influence of ischemic preconditioning. *American journal of physiology. Heart and circulatory physiology*. 2006;291:24
432. Vincent A, Gahide G, Sportouch-Dukhan C, Covinhes A, Franck-Miclo A, Roubille F, Barrere C, Adda J, Dantec C, Redt-Clouet C, Piot C, Nargeot J, Barrere-Lemaire S. Down-regulation of the transcription factor zac1 upon pre- and postconditioning protects against i/r injury in the mouse myocardium. *Cardiovascular research*. 2012;16:16
433. Virag JA, Anderson EJ, Kent SD, Blanton HD, Johnson TL, Moukdar F, DeAntonio JH, Thayne K, Ding JM, Lust RM. Cardioprotection via preserved mitochondrial structure and function in the mper2-mutant mouse myocardium. *American journal of physiology. Heart and circulatory physiology*. 2013;305:H477-483
434. Vladic N, Ge ZD, Leucker T, Brzezinska AK, Du JH, Shi Y, Warltier DC, Pratt PF, Jr., Kersten JR. Decreased tetrahydrobiopterin and disrupted association of hsp90 with enos by hyperglycemia impair myocardial ischemic preconditioning. *American journal of physiology. Heart and circulatory physiology*. 2011;301:9

Supplemental Text C - included studies reference list - page 21 of 24

435. Vogt AM, Ando H, Arras M, Elsasser A. Lack of adenosine causes myocardial refractoriness. *J Am Coll Cardiol.* 1998;31:1134-1141
436. Vogt AM, Ackermann C, Yildiz M, Schoels W, Kubler W. Lactate accumulation rather than atp depletion predicts ischemic myocardial necrosis: Implications for the development of lethal myocardial injury. *Biochim Biophys Acta.* 2001;16:219-226
437. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. *J Pharmacol Exp Ther.* 1994;270:681-689
438. Walsh RS, Tsuchida A, Daly JJ, Thornton JD, Cohen MV, Downey JM. Ketamine-xylazine anaesthesia permits a katp channel antagonist to attenuate preconditioning in rabbit myocardium. *Cardiovascular research.* 1994;28:1337-1341
439. Wang Y, Xu H, Mizoguchi K, Oe M, Maeta H. Intestinal ischemia induces late preconditioning against myocardial infarction: A role for inducible nitric oxide synthase. *Cardiovascular research.* 2001;49:391-398
440. Wang YP, Maeta H, Mizoguchi K, Suzuki T, Yamashita Y, Oe M. Intestinal ischemia preconditions myocardium: Role of protein kinase c and mitochondrial k(atp) channel. *Cardiovascular research.* 2002;55:576-582
441. Wang NF, Xu J, Xia Q, Gao Q, Shi XX, Zhou ZL, Wang LL, Tong GX, Li H, Li PZ, Zhang X, Ling F, Pan H, Yang JM. [mechanism of cardioprotection induced by noninvasive limb ischemic preconditioning]. *Zhonghua Yi Xue Za Zhi.* 2009;89:1999-2002
442. Wang S, Dusting GJ, May CN, Woodman OL. 3',4'-dihydroxyflavonol reduces infarct size and injury associated with myocardial ischaemia and reperfusion in sheep. *British journal of pharmacology.* 2004;142:443-452
443. Wang Y, Kodani E, Wang J, Zhang SX, Takano H, Tang XL, Bolli R. Cardioprotection during the final stage of the late phase of ischemic preconditioning is mediated by neuronal no synthase in concert with cyclooxygenase-2. *Circulation research.* 2004;95:84-91
444. Watanabe K, Yaoita H, Ogawa K, Oikawa M, Maehara K, Maruyama Y. Attenuated cardioprotection by ischemic preconditioning in coronary stenosed heart and its restoration by carvedilol. *Cardiovascular research.* 2006;71:537-547
445. Weber NC, Toma O, Wolter JI, Obal D, Mullenheim J, Preckel B, Schlack W. The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of pkc- and p38 mapk. *British journal of pharmacology.* 2005;144:123-132
446. Weber NC, Frassdorf J, Ratajczak C, Grueber Y, Schlack W, Hollmann MW, Preckel B. Xenon induces late cardiac preconditioning in vivo: A role for cyclooxygenase 2? *Anesth Analg.* 2008;107:1807-1813
447. Weinbrenner C, Nelles M, Herzog N, Sarvary L, Strasser RH. Remote preconditioning by infrarenal occlusion of the aorta protects the heart from infarction: A newly identified non-neuronal but pkc-dependent pathway. *Cardiovascular research.* 2002;55:590-601
448. Weinbrenner C, Schulze F, Sarvary L, Strasser RH. Remote preconditioning by infrarenal aortic occlusion is operative via delta1-opioid receptors and free radicals in vivo in the rat heart. *Cardiovascular research.* 2004;61:591-599
449. Wolfe CL, Sievers RE, Visseren FL, Donnelly TJ. Loss of myocardial protection after preconditioning correlates with the time course of glycogen recovery within the preconditioned segment. *Circulation.* 1993;87:881-892
450. Wolfrum S, Schneider K, Heidbreder M, Nienstedt J, Dominiak P, Dendorfer A. Remote preconditioning protects the heart by activating myocardial pkcepsilon-isoform. *Cardiovascular research.* 2002;55:583-589
451. Wolfrum S, Nienstedt J, Heidbreder M, Schneider K, Dominiak P, Dendorfer A. Calcitonin gene related peptide mediates cardioprotection by remote preconditioning. *Regul Pept.* 2005;127:217-224
452. Wong GT, Ling Ling J, Irwin MG. Activation of central opioid receptors induces cardioprotection against ischemia-reperfusion injury. *Anesth Analg.* 2010;111:24-28
453. Wong GT, Lu Y, Mei B, Xia Z, Irwin MG. Cardioprotection from remote preconditioning involves spinal opioid receptor activation. *Life Sci.* 2012;91:860-865
454. Wu DJ, Minatoguchi S, Uno Y, Arai M, Wang N, Nishida Y, Hashimoto K, Hashimoto Y, Takemura G, Fujiwara T, Fujiwara H. Combination of n-methyl-1-deoxynojirimycin and ischemic preconditioning markedly reduces the size of myocardial infarcts in rabbits. *Jpn Circ J.* 2001;65:673-677
455. Wu YN, Zhang Z, Chen Y, Jiao JJ, Kang Y, Gao WZ, Lou JS, Liu YX. Study on cardioprotection of ramipril against ischemia/reperfusion injury in diabetic rats. [chinese]. *Chinese Pharmacological Bulletin.* 2008;24:924-928
456. Wu YN, Zhu XH, Yuan HJ, Yu H, Li SJ, Kang Y, Jiao JJ, Gao WZ, Liu YX, Lou JS. Noninvasive limb ischemic preconditioning increased antioxidative ability of myocardium after ischemia-reperfusion injury in rats. [chinese]. *Chinese Pharmacological Bulletin.* 2008;24:1049-1052

Supplemental Text C - included studies reference list - page 22 of 24

457. Wu YN, Chen Y, Zhang Z, Dong YL, Yu XK, Jiao JJ, Kang Y, Gao WZ, Lou JS, Liu YX. [study on ultrastructure of cardioprotection of ramipril against ischemia/reperfusion injury in diabetic rats]. *Zhongguo Ying Yong Sheng Li Xue Za Zhi.* 2009;25:485-489
458. Wu YN, Yu H, Zhu XH, Yuan HJ, Kang Y, Jiao JJ, Gao WZ, Liu YX, Lou JS. Noninvasive delayed limb ischemic preconditioning attenuates myocardial ischemia-reperfusion injury in rats by a mitochondrial k(atp) channel-dependent mechanism. *Physiol Res.* 2011;60:271-279
459. Wu FY, Hsiao CY, Ou-Yang CP, Lai CC, Wang YY, Weng ZC, Huang CH. Preconditioning threshold of brief pressure overload of the left ventricle. *Journal of the Chinese Medical Association : JCMA.* 2013;76:497-503
460. Xiang SY, Ye LL, Duan LL, Liu LH, Ge ZD, Auchampach JA, Gross GJ, Duan DD. Characterization of a critical role for cftr chloride channels in cardioprotection against ischemia/reperfusion injury. *Acta Pharmacol Sin.* 2011;32:824-833
461. Xiao L, Lu R, Hu CP, Deng HW, Li YJ. Delayed cardioprotection by intestinal preconditioning is mediated by calcitonin gene-related peptide. *European journal of pharmacology.* 2001;427:131-135
462. Xiong J, Wang Q, Xue FS, Yuan YJ, Li S, Liu JH, Liao X, Zhang YM. Comparison of cardioprotective and anti-inflammatory effects of ischemia pre- and postconditioning in rats with myocardial ischemia-reperfusion injury. *Inflamm Res.* 2011;60:547-554
463. Xu JM, Chang YT, Hu DX. [protective effects of sevoflurane pretreatment on myocardial ischemia-reperfusion injury in rabbits]. *Hunan Yi Ke Da Xue Xue Bao.* 2001;26:79-82
464. Xu Z, Jiao Z, Cohen MV, Downey JM. Protection from amp 579 can be added to that from either cariporide or ischemic preconditioning in ischemic rabbit heart. *Journal of cardiovascular pharmacology.* 2002;40:510-518
465. Xu HS, Chen SX, Luo WJ, Gao QA, Yang Y. [effect of cortisol on ischemic preconditioning in rabbit hearts]. *Zhong Nan Da Xue Xue Bao Yi Xue Ban.* 2006;31:667-670
466. Xu JF, Wang ZQ, Wang JP. Ferilnic nitrate produces delayed preconditioning against myocardial ischemia and reperfusion injury in rats. *Arch Pharm Res.* 2010;33:881-887
467. Xu H, Chen S, Luo W, Jiang H. [role of stress in myocardial protection of ischemic preconditioning]. *Zhong Nan Da Xue Xue Bao Yi Xue Ban.* 2013;38:804-808
468. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, Bolli R. Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase c epsilon p44/42 mitogen-activated protein kinase pser-signal transducers and activators of transcription1/3 pathway. *Circulation.* 2007;116:535-544
469. Yada T, Shimokawa H, Kajiyama F. Cardioprotective effect of hydroxyfasudil as a specific rho-kinase inhibitor, on ischemia-reperfusion injury in canine coronary microvessels in vivo. *Clin Hemorheol Microcirc.* 2006;34:177-183
470. Yamada K, Matsui K, Yamamoto S, Kitano M, Ohashi N. Effect of an na+/h+ exchange inhibitor, sm-20550, on ischemic preconditioning in rabbits. *Int J Tissue React.* 2002;24:1-10
471. Yamasaki K, Fujiwara H, Tanaka M, Yokota R, Miyamae M, Ogawa J, Fujiwara T, Sasayama S. Preconditioning with 15-minute ischemia extends myocardial infarct size after subsequent 30-minute ischemia in rabbits. *Jpn Circ J.* 1997;61:344-352
472. Yamasaki K, Tanaka M, Yokota R, Fujiwara H, Sasayama S. Dilazep dihydrochloride prolongs the infarct size-limiting effect of ischemic preconditioning in rabbits. *Heart Vessels.* 2000;15:227-232
473. Yamashita N, Hoshida S, Taniguchi N, Kuzuya T, Hori M. A "second window of protection" occurs 24 h after ischemic preconditioning in the rat heart. *Journal of molecular and cellular cardiology.* 1998;30:1181-1189
474. Yamashita N, Hoshida S, Otsu K, Taniguchi N, Kuzuya T, Hori M. The involvement of cytokines in the second window of ischaemic preconditioning. *British journal of pharmacology.* 2000;131:415-422
475. Yang XM, Arnoult S, Tsuchida A, Cope D, Thornton JD, Daly JF, Cohen MV, Downey JM. The protection of ischaemic preconditioning can be reinstated in the rabbit heart after the initial protection has waned. *Cardiovascular research.* 1993;27:556-558
476. Yang XM, Baxter GF, Heads RJ, Yellon DM, Downey JM, Cohen MV. Infarct limitation of the second window of protection in a conscious rabbit model. *Cardiovascular research.* 1996;31:777-783
477. Yang YJ, Zhao JL, You SJ, Wu YJ, Jing ZC, Yang WX, Meng L, Wang YW, Gao RL. Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. *Heart.* 2006;92:1131-1137
478. Yang XM, Liu Y, Tandon N, Kambayashi J, Downey JM, Cohen MV. Attenuation of infarction in cynomolgus monkeys: Preconditioning and postconditioning. *Basic research in cardiology.* 2010;105:119-128
479. Yang J, Li Y, Hu C. Ischemic preconditioning protects against myocardial ischemia-reperfusion injury through inhibiting toll-like receptor 4/nf-kappab signaling pathway in rats. *Zhong Nan Da Xue Xue Bao Yi Xue Ban.* 2011;36:972-978

Supplemental Text C - included studies reference list - page 23 of 24

480. Yang XM, Cui L, Alhammouri A, Downey JM, Cohen MV. Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart. *Cardiovasc Drugs Ther.* 2013;27:403-412
481. Yang Z, Tian Y, Liu Y, Hennessy S, Kron IL, French BA. Acute hyperglycemia abolishes ischemic preconditioning by inhibiting akt phosphorylation: Normalizing blood glucose before ischemia restores ischemic preconditioning. *Oxidative medicine and cellular longevity.* 2013;2013:329183
482. Yao Z, Gross GJ. Role of nitric oxide, muscarinic receptors, and the atp-sensitive k⁺ channel in mediating the effects of acetylcholine to mimic preconditioning in dogs. *Circulation research.* 1993;73:1193-1201
483. Yao Z, Gross GJ. Acetylcholine mimics ischemic preconditioning via a glibenclamide-sensitive mechanism in dogs. *The American journal of physiology.* 1993;264:H2221-2225
484. Yao Z, Gross GJ. A comparison of adenosine-induced cardioprotection and ischemic preconditioning in dogs. Efficacy, time course, and role of katp channels. *Circulation.* 1994;89:1229-1236
485. Yao Z, Gross GJ. Activation of atp-sensitive potassium channels lowers threshold for ischemic preconditioning in dogs. *The American journal of physiology.* 1994;267:H1888-1894
486. Yao Z, Mizumura T, Mei DA, Gross GJ. Katp channels and memory of ischemic preconditioning in dogs: Synergism between adenosine and katp channels. *The American journal of physiology.* 1997;272:H334-342
487. Yellon DM, Alkhulaifi AM, Browne EE, Pugsley WB. Ischaemic preconditioning limits infarct size in the rat heart. *Cardiovascular research.* 1992;26:983-987
488. Yorozuya T, Adachi N, Dote K, Nakanishi K, Takasaki Y, Arai T. Enhancement of na⁺,k(+)-atpase and ca(2+)-atpase activities in multi-cycle ischemic preconditioning in rabbit hearts. *Eur J Cardiothorac Surg.* 2004;26:981-987
489. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase c activation. *The American journal of physiology.* 1994;266:H1145-1152
490. Yu CK, Li YH, Wong GT, Wong TM, Irwin MG. Remifentanil preconditioning confers delayed cardioprotection in the rat. *Br J Anaesth.* 2007;99:632-638
491. Yu M, Wen N, Wenzhong Z, Yuanchang X, Xiaoming D, Yongjin L. Effect of repeated ischaemic preconditioning on tlr4 and proinflammatory cytokines tnf-alpha and il-1beta in myocardial ischaemia-reperfusion injury in a rat model. *Arch Med Sci.* 2010;6:843-847
492. Yu GG, Zeng XJ, Wang HX, Lu LQ, Zheng SP, Ma LQ, Chang J, Wang J, Zhang DM, Du FH, Zhang LK. Cytochrome p450 2j3/epoxyeicosatrienoic acids mediate the cardioprotection induced by ischaemic post-conditioning, but not preconditioning, in the rat. *Clin Exp Pharmacol Physiol.* 2011;38:63-70
493. Zacharowski K, Zacharowski PA, Friedl P, Mastan P, Koch A, Boehm O, Rother RP, Reingruber S, Henning R, Emeis JJ, Petzelbauer P. The effects of the fibrin-derived peptide bbeta(15-42) in acute and chronic rodent models of myocardial ischemia-reperfusion. *Shock.* 2007;27:631-637
494. Zhang Y, Irwin MG, Wong TM. Remifentanil preconditioning protects against ischemic injury in the intact rat heart. *Anesthesiology.* 2004;101:918-923
495. Zhang J, Bian HJ, Li XX, Liu XB, Sun JP, Li N, Zhang Y, Ji XP. Erk-mapk signaling opposes rho-kinase to reduce cardiomyocyte apoptosis in heart ischemic preconditioning. *Mol Med.* 2010;16:307-315
496. Zhang SZ, Wang NF, Xu J, Gao Q, Lin GH, Bruce IC, Xia Q. Kappa-opioid receptors mediate cardioprotection by remote preconditioning. *Anesthesiology.* 2006;105:550-556
497. Zhang XH, Li CM, Ma XJ, Luo M. [correlation of limb and myocardial ischemia postconditioning with acute myocardial reperfusion injury]. *Zhonghua Yi Xue Za Zhi.* 2006;86:841-845
498. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. *American journal of physiology. Heart and circulatory physiology.* 2003;285:H579-588
499. Zhao X, Park J, Ho D, Gao S, Yan L, Ge H, IIsmaa S, Lin L, Tian B, Vatner DE, Graham RM, Vatner SF. Cardiomyocyte overexpression of the alpha1a-adrenergic receptor in the rat phenocopies second but not first window preconditioning. *American journal of physiology. Heart and circulatory physiology.* 2012;3:1
500. Zhu X, Liu B, Zhou S, Chen YR, Deng Y, Zweier JL, He G. Ischemic preconditioning prevents in vivo hyperoxygenation in postischemic myocardium with preservation of mitochondrial oxygen consumption. *American journal of physiology. Heart and circulatory physiology.* 2007;293:18
501. Zhu XH, Li YM, Yuan HJ, Luo Q, Wu YN, Kang Y, Jiao JJ, Gao WZ, Liu YX, Lou JS. Noninvasive limb ischemic preconditioning increased antioxidative ability of myocardium after ischemia-reperfusion injury in diabetic rats. [chinese]. *Chinese Pharmacological Bulletin.* 2009;25:239-243
502. Zhu XH, Yuan HJ, Wu YN, Kang Y, Jiao JJ, Gao WZ, Liu YX, Lou JS, Xia Z. Non-invasive limb ischemic preconditioning reduces oxidative stress and attenuates myocardium ischemia-reperfusion injury in diabetic rats. *Free Radic Res.* 2011;45:201-210

Supplemental Text C - included studies reference list - page 24 of 24

503. Zhu SB, Liu Y, Zhu Y, Yin GL, Wang RP, Zhang Y, Zhu J, Jiang W. Remote preconditioning, perconditioning, and postconditioning: A comparative study of their cardio-protective properties in rat models. *Clinics*. 2013;68:263-268